================================================================================ 
RUNNING PUBLICATION TABLE EXTRACTION
================================================================================ 

 ================================================================================ 
EXTRACTING RESULTS FOR PUBLICATION TABLE
================================================================================ 

=== DIAGNOSTIC: AVAILABLE FILES AND RESULTS ===
Available cohort files:
   ipwt_cohort_GLP1_vs_SGLT2_ADRD.csv 
   ipwt_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
   ipwt_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
   ipwt_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
   ipwt_cohort_GLP1_vs_SGLT2_stroke.csv 
   ipwt_cohort_GLP1_vs_SU_DPP4_ADRD.csv 
   ipwt_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
   ipwt_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
   ipwt_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
   ipwt_cohort_GLP1_vs_SU_DPP4_stroke.csv 
   ipwt_cohort_SGLT2_vs_SU_DPP4_ADRD.csv 
   ipwt_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
   ipwt_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
   ipwt_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
   ipwt_cohort_SGLT2_vs_SU_DPP4_stroke.csv 
   tmle_cohort_GLP1_vs_SGLT2_ADRD.csv 
   tmle_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
   tmle_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
   tmle_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
   tmle_cohort_GLP1_vs_SGLT2_stroke.csv 
   tmle_cohort_GLP1_vs_SU_DPP4_ADRD.csv 
   tmle_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
   tmle_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
   tmle_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
   tmle_cohort_GLP1_vs_SU_DPP4_stroke.csv 
   tmle_cohort_SGLT2_vs_SU_DPP4_ADRD.csv 
   tmle_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
   tmle_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
   tmle_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
   tmle_cohort_SGLT2_vs_SU_DPP4_stroke.csv 

IPTW results summary:
# A tibble: 15 × 4
   comparison       outcome                      effect_measure n_rows
   <chr>            <chr>                        <chr>           <int>
 1 GLP1 vs SGLT2    ADRD                         Hazard Ratio        1
 2 GLP1 vs SGLT2    Early-onset Epilepsy/Seizure Hazard Ratio        1
 3 GLP1 vs SGLT2    Epilepsy/Seizure             Hazard Ratio        1
 4 GLP1 vs SGLT2    Late-onset Epilepsy/Seizure  Hazard Ratio        1
 5 GLP1 vs SGLT2    stroke                       Hazard Ratio        1
 6 GLP1 vs SU_DPP4  ADRD                         Hazard Ratio        1
 7 GLP1 vs SU_DPP4  Early-onset Epilepsy/Seizure Hazard Ratio        1
 8 GLP1 vs SU_DPP4  Epilepsy/Seizure             Hazard Ratio        1
 9 GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure  Hazard Ratio        1
10 GLP1 vs SU_DPP4  stroke                       Hazard Ratio        1
11 SGLT2 vs SU_DPP4 ADRD                         Hazard Ratio        1
12 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure Hazard Ratio        1
13 SGLT2 vs SU_DPP4 Epilepsy/Seizure             Hazard Ratio        1
14 SGLT2 vs SU_DPP4 Late-onset Epilepsy/Seizure  Hazard Ratio        1
15 SGLT2 vs SU_DPP4 stroke                       Hazard Ratio        1

TMLE results summary:
# A tibble: 30 × 4
   comparison    outcome                      effect_measure  n_rows
   <chr>         <chr>                        <chr>            <int>
 1 GLP1 vs SGLT2 ADRD                         Odds Ratio           1
 2 GLP1 vs SGLT2 ADRD                         Risk Difference      1
 3 GLP1 vs SGLT2 Early-onset Epilepsy/Seizure Odds Ratio           1
 4 GLP1 vs SGLT2 Early-onset Epilepsy/Seizure Risk Difference      1
 5 GLP1 vs SGLT2 Epilepsy/Seizure             Odds Ratio           1
 6 GLP1 vs SGLT2 Epilepsy/Seizure             Risk Difference      1
 7 GLP1 vs SGLT2 Late-onset Epilepsy/Seizure  Odds Ratio           1
 8 GLP1 vs SGLT2 Late-onset Epilepsy/Seizure  Risk Difference      1
 9 GLP1 vs SGLT2 stroke                       Odds Ratio           1
10 GLP1 vs SGLT2 stroke                       Risk Difference      1
# ℹ 20 more rows
=== END DIAGNOSTIC ===

 ------------------------------------------------------------ 
COMPARISON: GLP1 vs SGLT2 - OUTCOME: Epilepsy/Seizure 
------------------------------------------------------------ 
DEBUG: Looking for cohort files:
  IPTW: ipwt_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv - Exists: TRUE 
  TMLE: tmle_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv - Exists: TRUE 
DEBUG: IPTW outcomes available for GLP1 vs SGLT2 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 
DEBUG: TMLE outcomes available for GLP1 vs SGLT2 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 

=== NON-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5375 rows, 108 columns
DEBUG: Events by treatment: 3650 1636 75 14 
Non-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 14/1,650 
  Comparator : 75/3,725 
Follow-up, mean (SD), y:
  Semaglutide : 2.27 (1.16) 
  Comparator : 2.51 (1.32) 
Crude HR (95% CI):
  Semaglutide vs Comparator : 0.46 (0.26 to 0.82) 
  P-value: 0.009 

=== IPTW-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5375 rows, 108 columns
DEBUG: Events by treatment: 3650 1636 75 14 
IPTW-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 23/2651 
  Comparator : 54/2724 
Follow-up, mean (SD), y:
  Semaglutide : 2.44 (1.24) 
  Comparator : 2.42 (1.29) 
Incidence rate per 1000 person-years:
  Semaglutide : 3.64 (2.50 to 4.77) 
  Comparator : 8.10 (5.53 to 10.67) 
Rate difference per 1000 person-years:
  Semaglutide vs Comparator : -4.47 (-7.28 to -1.66) 
Adjusted HR (95% CI):
  Semaglutide vs Comparator : 0.45 (0.23 to 0.85) 
  P-value: 0.015 

=== TMLE RESULTS ===
DEBUG: Filtering TMLE results for comparison=' GLP1 vs SGLT2 ' and outcome=' Epilepsy/Seizure '
DEBUG: Found 10 TMLE result rows for this combination:
# A tibble: 10 × 6
   comparison    outcome                effect_measure estimate n_total n_events
   <chr>         <chr>                  <chr>             <dbl>   <dbl>    <dbl>
 1 GLP1 vs SGLT2 Epilepsy/Seizure       Risk Differen…  -0.0097    5839       96
 2 GLP1 vs SGLT2 Epilepsy/Seizure       Odds Ratio       0.49      5839       96
 3 GLP1 vs SGLT2 Early-onset Epilepsy/… Risk Differen…  -0.0008    5839       13
 4 GLP1 vs SGLT2 Early-onset Epilepsy/… Odds Ratio       0.69      5839       13
 5 GLP1 vs SGLT2 Late-onset Epilepsy/S… Risk Differen…  -0.0099    5839       83
 6 GLP1 vs SGLT2 Late-onset Epilepsy/S… Odds Ratio       0.46      5839       83
 7 GLP1 vs SGLT2 ADRD                   Risk Differen…  -0.0108    5950      159
 8 GLP1 vs SGLT2 ADRD                   Odds Ratio       0.64      5950      159
 9 GLP1 vs SGLT2 stroke                 Risk Differen…   0.0031    5577      181
10 GLP1 vs SGLT2 stroke                 Odds Ratio       1.1       5577      181
DEBUG: OR rows found: 1 
DEBUG: OR estimate: 0.49 for outcome: Epilepsy/Seizure 
DEBUG: RD rows found: 1 
DEBUG: RD estimate: -0.0097 for outcome: Epilepsy/Seizure 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5839 rows, 102 columns
DEBUG: Events by treatment: 3985 1758 81 15 
No. of events/No. of patients at risk:
  Semaglutide : 15/1,773 
  Comparator : 81/4,066 
OR (95% CI):
  Semaglutide vs Comparator : 0.49 (0.26-0.94) 
Risk difference (95% CI):
  Semaglutide vs Comparator : -9.700 (-16.800 to -2.500) 
P-value: 0.008 

 ------------------------------------------------------------ 
COMPARISON: GLP1 vs SGLT2 - OUTCOME: Early-onset Epilepsy/Seizure 
------------------------------------------------------------ 
DEBUG: Looking for cohort files:
  IPTW: ipwt_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv - Exists: TRUE 
  TMLE: tmle_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv - Exists: TRUE 
DEBUG: IPTW outcomes available for GLP1 vs SGLT2 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 
DEBUG: TMLE outcomes available for GLP1 vs SGLT2 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 

=== NON-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5375 rows, 108 columns
DEBUG: Events by treatment: 3716 1646 9 4 
Non-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 4/1,650 
  Comparator : 9/3,725 
Follow-up, mean (SD), y:
  Semaglutide : 2.27 (1.16) 
  Comparator : 2.51 (1.32) 
Crude HR (95% CI):
  Semaglutide vs Comparator : 1.14 (0.35 to 3.71) 
  P-value: 0.832 

=== IPTW-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5375 rows, 108 columns
DEBUG: Events by treatment: 3716 1646 9 4 
IPTW-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 5/2651 
  Comparator : 8/2724 
Follow-up, mean (SD), y:
  Semaglutide : 2.44 (1.24) 
  Comparator : 2.42 (1.29) 
Incidence rate per 1000 person-years:
  Semaglutide : 0.77 (0.16 to 1.37) 
  Comparator : 1.26 (0.37 to 2.15) 
Rate difference per 1000 person-years:
  Semaglutide vs Comparator : -0.49 (-1.57 to 0.59) 
Adjusted HR (95% CI):
  Semaglutide vs Comparator : 0.61 (0.16 to 2.31) 
  P-value: 0.466 

=== TMLE RESULTS ===
DEBUG: Filtering TMLE results for comparison=' GLP1 vs SGLT2 ' and outcome=' Early-onset Epilepsy/Seizure '
DEBUG: Found 10 TMLE result rows for this combination:
# A tibble: 10 × 6
   comparison    outcome                effect_measure estimate n_total n_events
   <chr>         <chr>                  <chr>             <dbl>   <dbl>    <dbl>
 1 GLP1 vs SGLT2 Epilepsy/Seizure       Risk Differen…  -0.0097    5839       96
 2 GLP1 vs SGLT2 Epilepsy/Seizure       Odds Ratio       0.49      5839       96
 3 GLP1 vs SGLT2 Early-onset Epilepsy/… Risk Differen…  -0.0008    5839       13
 4 GLP1 vs SGLT2 Early-onset Epilepsy/… Odds Ratio       0.69      5839       13
 5 GLP1 vs SGLT2 Late-onset Epilepsy/S… Risk Differen…  -0.0099    5839       83
 6 GLP1 vs SGLT2 Late-onset Epilepsy/S… Odds Ratio       0.46      5839       83
 7 GLP1 vs SGLT2 ADRD                   Risk Differen…  -0.0108    5950      159
 8 GLP1 vs SGLT2 ADRD                   Odds Ratio       0.64      5950      159
 9 GLP1 vs SGLT2 stroke                 Risk Differen…   0.0031    5577      181
10 GLP1 vs SGLT2 stroke                 Odds Ratio       1.1       5577      181
DEBUG: OR rows found: 1 
DEBUG: OR estimate: 0.69 for outcome: Early-onset Epilepsy/Seizure 
DEBUG: RD rows found: 1 
DEBUG: RD estimate: -8e-04 for outcome: Early-onset Epilepsy/Seizure 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5839 rows, 102 columns
DEBUG: Events by treatment: 4057 1769 9 4 
No. of events/No. of patients at risk:
  Semaglutide : 4/1,773 
  Comparator : 9/4,066 
OR (95% CI):
  Semaglutide vs Comparator : 0.69 (0.20-2.34) 
Risk difference (95% CI):
  Semaglutide vs Comparator : -0.800 (-3.500 to 1.800) 
P-value: 0.543 

 ------------------------------------------------------------ 
COMPARISON: GLP1 vs SGLT2 - OUTCOME: Late-onset Epilepsy/Seizure 
------------------------------------------------------------ 
DEBUG: Looking for cohort files:
  IPTW: ipwt_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv - Exists: TRUE 
  TMLE: tmle_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv - Exists: TRUE 
DEBUG: IPTW outcomes available for GLP1 vs SGLT2 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 
DEBUG: TMLE outcomes available for GLP1 vs SGLT2 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 

=== NON-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 4718 rows, 108 columns
DEBUG: Events by treatment: 3286 1357 65 10 
Non-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 10/1,367 
  Comparator : 65/3,351 
Follow-up, mean (SD), y:
  Semaglutide : 2.29 (1.16) 
  Comparator : 2.51 (1.32) 
Crude HR (95% CI):
  Semaglutide vs Comparator : 0.41 (0.21 to 0.79) 
  P-value: 0.008 

=== IPTW-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 4718 rows, 108 columns
DEBUG: Events by treatment: 3286 1357 65 10 
IPTW-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 19/2327 
  Comparator : 45/2391 
Follow-up, mean (SD), y:
  Semaglutide : 2.45 (1.24) 
  Comparator : 2.42 (1.29) 
Incidence rate per 1000 person-years:
  Semaglutide : 3.25 (2.16 to 4.34) 
  Comparator : 7.71 (4.98 to 10.43) 
Rate difference per 1000 person-years:
  Semaglutide vs Comparator : -4.46 (-7.39 to -1.52) 
Adjusted HR (95% CI):
  Semaglutide vs Comparator : 0.42 (0.20 to 0.88) 
  P-value: 0.021 

=== TMLE RESULTS ===
DEBUG: Filtering TMLE results for comparison=' GLP1 vs SGLT2 ' and outcome=' Late-onset Epilepsy/Seizure '
DEBUG: Found 10 TMLE result rows for this combination:
# A tibble: 10 × 6
   comparison    outcome                effect_measure estimate n_total n_events
   <chr>         <chr>                  <chr>             <dbl>   <dbl>    <dbl>
 1 GLP1 vs SGLT2 Epilepsy/Seizure       Risk Differen…  -0.0097    5839       96
 2 GLP1 vs SGLT2 Epilepsy/Seizure       Odds Ratio       0.49      5839       96
 3 GLP1 vs SGLT2 Early-onset Epilepsy/… Risk Differen…  -0.0008    5839       13
 4 GLP1 vs SGLT2 Early-onset Epilepsy/… Odds Ratio       0.69      5839       13
 5 GLP1 vs SGLT2 Late-onset Epilepsy/S… Risk Differen…  -0.0099    5839       83
 6 GLP1 vs SGLT2 Late-onset Epilepsy/S… Odds Ratio       0.46      5839       83
 7 GLP1 vs SGLT2 ADRD                   Risk Differen…  -0.0108    5950      159
 8 GLP1 vs SGLT2 ADRD                   Odds Ratio       0.64      5950      159
 9 GLP1 vs SGLT2 stroke                 Risk Differen…   0.0031    5577      181
10 GLP1 vs SGLT2 stroke                 Odds Ratio       1.1       5577      181
DEBUG: OR rows found: 1 
DEBUG: OR estimate: 0.46 for outcome: Late-onset Epilepsy/Seizure 
DEBUG: RD rows found: 1 
DEBUG: RD estimate: -0.0099 for outcome: Late-onset Epilepsy/Seizure 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5114 rows, 102 columns
DEBUG: Events by treatment: 3575 1457 71 11 
No. of events/No. of patients at risk:
  Semaglutide : 11/1,468 
  Comparator : 71/3,646 
OR (95% CI):
  Semaglutide vs Comparator : 0.46 (0.23-0.96) 
Risk difference (95% CI):
  Semaglutide vs Comparator : -9.900 (-17.300 to -2.500) 
P-value: 0.009 

 ------------------------------------------------------------ 
COMPARISON: GLP1 vs SU_DPP4 - OUTCOME: Epilepsy/Seizure 
------------------------------------------------------------ 
DEBUG: Looking for cohort files:
  IPTW: ipwt_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv - Exists: TRUE 
  TMLE: tmle_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv - Exists: TRUE 
DEBUG: IPTW outcomes available for GLP1 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 
DEBUG: TMLE outcomes available for GLP1 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 

=== NON-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7326 rows, 108 columns
DEBUG: Events by treatment: 5226 1940 136 24 
Non-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 24/1,964 
  Comparator : 136/5,362 
Follow-up, mean (SD), y:
  Semaglutide : 2.35 (1.17) 
  Comparator : 2.88 (1.53) 
Crude HR (95% CI):
  Semaglutide vs Comparator : 0.59 (0.38 to 0.91) 
  P-value: 0.016 

=== IPTW-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7326 rows, 108 columns
DEBUG: Events by treatment: 5226 1940 136 24 
IPTW-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 43/3442 
  Comparator : 89/3884 
Follow-up, mean (SD), y:
  Semaglutide : 2.88 (1.32) 
  Comparator : 2.69 (1.49) 
Incidence rate per 1000 person-years:
  Semaglutide : 4.34 (3.37 to 5.31) 
  Comparator : 8.53 (6.35 to 10.72) 
Rate difference per 1000 person-years:
  Semaglutide vs Comparator : -4.20 (-6.59 to -1.80) 
Adjusted HR (95% CI):
  Semaglutide vs Comparator : 0.51 (0.31 to 0.82) 
  P-value: 0.006 

=== TMLE RESULTS ===
DEBUG: Filtering TMLE results for comparison=' GLP1 vs SU_DPP4 ' and outcome=' Epilepsy/Seizure '
DEBUG: Found 10 TMLE result rows for this combination:
# A tibble: 10 × 6
   comparison      outcome              effect_measure estimate n_total n_events
   <chr>           <chr>                <chr>             <dbl>   <dbl>    <dbl>
 1 GLP1 vs SU_DPP4 Epilepsy/Seizure     Risk Differen…  -0.0102    8216      172
 2 GLP1 vs SU_DPP4 Epilepsy/Seizure     Odds Ratio       0.56      8216      172
 3 GLP1 vs SU_DPP4 Early-onset Epileps… Risk Differen…  -0.0001    8216       24
 4 GLP1 vs SU_DPP4 Early-onset Epileps… Odds Ratio       0.97      8216       24
 5 GLP1 vs SU_DPP4 Late-onset Epilepsy… Risk Differen…  -0.012     8216      148
 6 GLP1 vs SU_DPP4 Late-onset Epilepsy… Odds Ratio       0.48      8216      148
 7 GLP1 vs SU_DPP4 ADRD                 Risk Differen…  -0.0095    8389      243
 8 GLP1 vs SU_DPP4 ADRD                 Odds Ratio       0.7       8389      243
 9 GLP1 vs SU_DPP4 stroke               Risk Differen…  -0.0063    7969      315
10 GLP1 vs SU_DPP4 stroke               Odds Ratio       0.85      7969      315
DEBUG: OR rows found: 1 
DEBUG: OR estimate: 0.56 for outcome: Epilepsy/Seizure 
DEBUG: RD rows found: 1 
DEBUG: RD estimate: -0.0102 for outcome: Epilepsy/Seizure 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 8216 rows, 102 columns
DEBUG: Events by treatment: 5971 2073 147 25 
No. of events/No. of patients at risk:
  Semaglutide : 25/2,098 
  Comparator : 147/6,118 
OR (95% CI):
  Semaglutide vs Comparator : 0.56 (0.35-0.90) 
Risk difference (95% CI):
  Semaglutide vs Comparator : -10.200 (-17.400 to -3.100) 
P-value: 0.005 

 ------------------------------------------------------------ 
COMPARISON: GLP1 vs SU_DPP4 - OUTCOME: Early-onset Epilepsy/Seizure 
------------------------------------------------------------ 
DEBUG: Looking for cohort files:
  IPTW: ipwt_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv - Exists: TRUE 
  TMLE: tmle_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv - Exists: TRUE 
DEBUG: IPTW outcomes available for GLP1 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 
DEBUG: TMLE outcomes available for GLP1 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 

=== NON-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7326 rows, 108 columns
DEBUG: Events by treatment: 5345 1958 17 6 
Non-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 6/1,964 
  Comparator : 17/5,362 
Follow-up, mean (SD), y:
  Semaglutide : 2.35 (1.17) 
  Comparator : 2.88 (1.53) 
Crude HR (95% CI):
  Semaglutide vs Comparator : 1.20 (0.47 to 3.07) 
  P-value: 0.702 

=== IPTW-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7326 rows, 108 columns
DEBUG: Events by treatment: 5345 1958 17 6 
IPTW-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 14/3442 
  Comparator : 11/3884 
Follow-up, mean (SD), y:
  Semaglutide : 2.88 (1.32) 
  Comparator : 2.69 (1.49) 
Incidence rate per 1000 person-years:
  Semaglutide : 1.37 (0.88 to 1.85) 
  Comparator : 1.09 (0.32 to 1.86) 
Rate difference per 1000 person-years:
  Semaglutide vs Comparator : 0.28 (-0.63 to 1.19) 
Adjusted HR (95% CI):
  Semaglutide vs Comparator : 1.24 (0.43 to 3.59) 
  P-value: 0.697 

=== TMLE RESULTS ===
DEBUG: Filtering TMLE results for comparison=' GLP1 vs SU_DPP4 ' and outcome=' Early-onset Epilepsy/Seizure '
DEBUG: Found 10 TMLE result rows for this combination:
# A tibble: 10 × 6
   comparison      outcome              effect_measure estimate n_total n_events
   <chr>           <chr>                <chr>             <dbl>   <dbl>    <dbl>
 1 GLP1 vs SU_DPP4 Epilepsy/Seizure     Risk Differen…  -0.0102    8216      172
 2 GLP1 vs SU_DPP4 Epilepsy/Seizure     Odds Ratio       0.56      8216      172
 3 GLP1 vs SU_DPP4 Early-onset Epileps… Risk Differen…  -0.0001    8216       24
 4 GLP1 vs SU_DPP4 Early-onset Epileps… Odds Ratio       0.97      8216       24
 5 GLP1 vs SU_DPP4 Late-onset Epilepsy… Risk Differen…  -0.012     8216      148
 6 GLP1 vs SU_DPP4 Late-onset Epilepsy… Odds Ratio       0.48      8216      148
 7 GLP1 vs SU_DPP4 ADRD                 Risk Differen…  -0.0095    8389      243
 8 GLP1 vs SU_DPP4 ADRD                 Odds Ratio       0.7       8389      243
 9 GLP1 vs SU_DPP4 stroke               Risk Differen…  -0.0063    7969      315
10 GLP1 vs SU_DPP4 stroke               Odds Ratio       0.85      7969      315
DEBUG: OR rows found: 1 
DEBUG: OR estimate: 0.97 for outcome: Early-onset Epilepsy/Seizure 
DEBUG: RD rows found: 1 
DEBUG: RD estimate: -1e-04 for outcome: Early-onset Epilepsy/Seizure 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 8216 rows, 102 columns
DEBUG: Events by treatment: 6100 2092 18 6 
No. of events/No. of patients at risk:
  Semaglutide : 6/2,098 
  Comparator : 18/6,118 
OR (95% CI):
  Semaglutide vs Comparator : 0.97 (0.33-2.86) 
Risk difference (95% CI):
  Semaglutide vs Comparator : -0.100 (-3.400 to 3.300) 
P-value: 0.960 

 ------------------------------------------------------------ 
COMPARISON: GLP1 vs SU_DPP4 - OUTCOME: Late-onset Epilepsy/Seizure 
------------------------------------------------------------ 
DEBUG: Looking for cohort files:
  IPTW: ipwt_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv - Exists: TRUE 
  TMLE: tmle_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv - Exists: TRUE 
DEBUG: IPTW outcomes available for GLP1 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 
DEBUG: TMLE outcomes available for GLP1 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 

=== NON-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 6387 rows, 108 columns
DEBUG: Events by treatment: 4613 1639 117 18 
Non-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 18/1,657 
  Comparator : 117/4,730 
Follow-up, mean (SD), y:
  Semaglutide : 2.37 (1.17) 
  Comparator : 2.91 (1.53) 
Crude HR (95% CI):
  Semaglutide vs Comparator : 0.53 (0.32 to 0.87) 
  P-value: 0.013 

=== IPTW-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 6387 rows, 108 columns
DEBUG: Events by treatment: 4613 1639 117 18 
IPTW-weighted cohort:
No. of events/No. of patients at risk:
  Semaglutide : 29/2977 
  Comparator : 77/3374 
Follow-up, mean (SD), y:
  Semaglutide : 2.90 (1.32) 
  Comparator : 2.72 (1.49) 
Incidence rate per 1000 person-years:
  Semaglutide : 3.40 (2.44 to 4.37) 
  Comparator : 8.35 (6.04 to 10.66) 
Rate difference per 1000 person-years:
  Semaglutide vs Comparator : -4.95 (-7.45 to -2.44) 
Adjusted HR (95% CI):
  Semaglutide vs Comparator : 0.40 (0.24 to 0.68) 
  P-value: <0.001 

=== TMLE RESULTS ===
DEBUG: Filtering TMLE results for comparison=' GLP1 vs SU_DPP4 ' and outcome=' Late-onset Epilepsy/Seizure '
DEBUG: Found 10 TMLE result rows for this combination:
# A tibble: 10 × 6
   comparison      outcome              effect_measure estimate n_total n_events
   <chr>           <chr>                <chr>             <dbl>   <dbl>    <dbl>
 1 GLP1 vs SU_DPP4 Epilepsy/Seizure     Risk Differen…  -0.0102    8216      172
 2 GLP1 vs SU_DPP4 Epilepsy/Seizure     Odds Ratio       0.56      8216      172
 3 GLP1 vs SU_DPP4 Early-onset Epileps… Risk Differen…  -0.0001    8216       24
 4 GLP1 vs SU_DPP4 Early-onset Epileps… Odds Ratio       0.97      8216       24
 5 GLP1 vs SU_DPP4 Late-onset Epilepsy… Risk Differen…  -0.012     8216      148
 6 GLP1 vs SU_DPP4 Late-onset Epilepsy… Odds Ratio       0.48      8216      148
 7 GLP1 vs SU_DPP4 ADRD                 Risk Differen…  -0.0095    8389      243
 8 GLP1 vs SU_DPP4 ADRD                 Odds Ratio       0.7       8389      243
 9 GLP1 vs SU_DPP4 stroke               Risk Differen…  -0.0063    7969      315
10 GLP1 vs SU_DPP4 stroke               Odds Ratio       0.85      7969      315
DEBUG: OR rows found: 1 
DEBUG: OR estimate: 0.48 for outcome: Late-onset Epilepsy/Seizure 
DEBUG: RD rows found: 1 
DEBUG: RD estimate: -0.012 for outcome: Late-onset Epilepsy/Seizure 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7141 rows, 102 columns
DEBUG: Events by treatment: 5250 1745 127 19 
No. of events/No. of patients at risk:
  Semaglutide : 19/1,764 
  Comparator : 127/5,377 
OR (95% CI):
  Semaglutide vs Comparator : 0.48 (0.27-0.85) 
Risk difference (95% CI):
  Semaglutide vs Comparator : -12.000 (-19.400 to -4.600) 
P-value: 0.001 

 ------------------------------------------------------------ 
COMPARISON: SGLT2 vs SU_DPP4 - OUTCOME: Epilepsy/Seizure 
------------------------------------------------------------ 
DEBUG: Looking for cohort files:
  IPTW: ipwt_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv - Exists: TRUE 
  TMLE: tmle_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv - Exists: TRUE 
DEBUG: IPTW outcomes available for SGLT2 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 
DEBUG: TMLE outcomes available for SGLT2 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 

=== NON-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7717 rows, 108 columns
DEBUG: Events by treatment: 4390 3162 107 58 
Non-weighted cohort:
No. of events/No. of patients at risk:
  SGLT2i : 58/3,220 
  SU/DPP4i : 107/4,497 
Follow-up, mean (SD), y:
  SGLT2i : 2.59 (1.33) 
  SU/DPP4i : 2.82 (1.54) 
Crude HR (95% CI):
  SGLT2i vs SU/DPP4i : 0.83 (0.60 to 1.14) 
  P-value: 0.252 

=== IPTW-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded weighted cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7717 rows, 108 columns
DEBUG: Events by treatment: 4390 3162 107 58 
IPTW-weighted cohort:
No. of events/No. of patients at risk:
  SGLT2i : 73/3853 
  SU/DPP4i : 89/3864 
Follow-up, mean (SD), y:
  SGLT2i : 2.90 (1.43) 
  SU/DPP4i : 2.64 (1.49) 
Incidence rate per 1000 person-years:
  SGLT2i : 6.54 (5.20 to 7.88) 
  SU/DPP4i : 8.72 (6.74 to 10.71) 
Rate difference per 1000 person-years:
  SGLT2i vs SU/DPP4i : -2.18 (-4.58 to 0.21) 
Adjusted HR (95% CI):
  SGLT2i vs SU/DPP4i : 0.75 (0.53 to 1.06) 
  P-value: 0.100 

=== TMLE RESULTS ===
DEBUG: Filtering TMLE results for comparison=' SGLT2 vs SU_DPP4 ' and outcome=' Epilepsy/Seizure '
DEBUG: Found 10 TMLE result rows for this combination:
# A tibble: 10 × 6
   comparison       outcome             effect_measure estimate n_total n_events
   <chr>            <chr>               <chr>             <dbl>   <dbl>    <dbl>
 1 SGLT2 vs SU_DPP4 Epilepsy/Seizure    Risk Differen…  -0.0035    8615      180
 2 SGLT2 vs SU_DPP4 Epilepsy/Seizure    Odds Ratio       0.84      8615      180
 3 SGLT2 vs SU_DPP4 Early-onset Epilep… Risk Differen…   0.0002    8615       21
 4 SGLT2 vs SU_DPP4 Early-onset Epilep… Odds Ratio       1.07      8615       21
 5 SGLT2 vs SU_DPP4 Late-onset Epileps… Risk Differen…  -0.0043    8615      159
 6 SGLT2 vs SU_DPP4 Late-onset Epileps… Odds Ratio       0.81      8615      159
 7 SGLT2 vs SU_DPP4 ADRD                Risk Differen…  -0.001     8816      286
 8 SGLT2 vs SU_DPP4 ADRD                Odds Ratio       0.97      8816      286
 9 SGLT2 vs SU_DPP4 stroke              Risk Differen…  -0.0116    8312      334
10 SGLT2 vs SU_DPP4 stroke              Odds Ratio       0.75      8312      334
DEBUG: OR rows found: 1 
DEBUG: OR estimate: 0.84 for outcome: Epilepsy/Seizure 
DEBUG: RD rows found: 1 
DEBUG: RD estimate: -0.0035 for outcome: Epilepsy/Seizure 
DEBUG: Loaded cohort file: tmle_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 8615 rows, 102 columns
DEBUG: Events by treatment: 5027 3408 117 63 
No. of events/No. of patients at risk:
  SGLT2i : 63/3,471 
  SU/DPP4i : 117/5,144 
OR (95% CI):
  SGLT2i vs SU/DPP4i : 0.84 (0.61-1.17) 
Risk difference (95% CI):
  SGLT2i vs SU/DPP4i : -3.500 (-10.300 to 3.200) 
P-value: 0.306 

 ------------------------------------------------------------ 
COMPARISON: SGLT2 vs SU_DPP4 - OUTCOME: Early-onset Epilepsy/Seizure 
------------------------------------------------------------ 
DEBUG: Looking for cohort files:
  IPTW: ipwt_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv - Exists: TRUE 
  TMLE: tmle_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv - Exists: TRUE 
DEBUG: IPTW outcomes available for SGLT2 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 
DEBUG: TMLE outcomes available for SGLT2 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 

=== NON-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7717 rows, 108 columns
DEBUG: Events by treatment: 4484 3213 13 7 
Non-weighted cohort:
No. of events/No. of patients at risk:
  SGLT2i : 7/3,220 
  SU/DPP4i : 13/4,497 
Follow-up, mean (SD), y:
  SGLT2i : 2.59 (1.33) 
  SU/DPP4i : 2.82 (1.54) 
Crude HR (95% CI):
  SGLT2i vs SU/DPP4i : 0.81 (0.32 to 2.04) 
  P-value: 0.654 

=== IPTW-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded weighted cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7717 rows, 108 columns
DEBUG: Events by treatment: 4484 3213 13 7 
IPTW-weighted cohort:
No. of events/No. of patients at risk:
  SGLT2i : 10/3853 
  SU/DPP4i : 10/3864 
Follow-up, mean (SD), y:
  SGLT2i : 2.90 (1.43) 
  SU/DPP4i : 2.64 (1.49) 
Incidence rate per 1000 person-years:
  SGLT2i : 0.90 (0.43 to 1.36) 
  SU/DPP4i : 0.97 (0.27 to 1.66) 
Rate difference per 1000 person-years:
  SGLT2i vs SU/DPP4i : -0.07 (-0.90 to 0.76) 
Adjusted HR (95% CI):
  SGLT2i vs SU/DPP4i : 0.93 (0.34 to 2.56) 
  P-value: 0.891 

=== TMLE RESULTS ===
DEBUG: Filtering TMLE results for comparison=' SGLT2 vs SU_DPP4 ' and outcome=' Early-onset Epilepsy/Seizure '
DEBUG: Found 10 TMLE result rows for this combination:
# A tibble: 10 × 6
   comparison       outcome             effect_measure estimate n_total n_events
   <chr>            <chr>               <chr>             <dbl>   <dbl>    <dbl>
 1 SGLT2 vs SU_DPP4 Epilepsy/Seizure    Risk Differen…  -0.0035    8615      180
 2 SGLT2 vs SU_DPP4 Epilepsy/Seizure    Odds Ratio       0.84      8615      180
 3 SGLT2 vs SU_DPP4 Early-onset Epilep… Risk Differen…   0.0002    8615       21
 4 SGLT2 vs SU_DPP4 Early-onset Epilep… Odds Ratio       1.07      8615       21
 5 SGLT2 vs SU_DPP4 Late-onset Epileps… Risk Differen…  -0.0043    8615      159
 6 SGLT2 vs SU_DPP4 Late-onset Epileps… Odds Ratio       0.81      8615      159
 7 SGLT2 vs SU_DPP4 ADRD                Risk Differen…  -0.001     8816      286
 8 SGLT2 vs SU_DPP4 ADRD                Odds Ratio       0.97      8816      286
 9 SGLT2 vs SU_DPP4 stroke              Risk Differen…  -0.0116    8312      334
10 SGLT2 vs SU_DPP4 stroke              Odds Ratio       0.75      8312      334
DEBUG: OR rows found: 1 
DEBUG: OR estimate: 1.07 for outcome: Early-onset Epilepsy/Seizure 
DEBUG: RD rows found: 1 
DEBUG: RD estimate: 2e-04 for outcome: Early-onset Epilepsy/Seizure 
DEBUG: Loaded cohort file: tmle_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 8615 rows, 102 columns
DEBUG: Events by treatment: 5130 3464 14 7 
No. of events/No. of patients at risk:
  SGLT2i : 7/3,471 
  SU/DPP4i : 14/5,144 
OR (95% CI):
  SGLT2i vs SU/DPP4i : 1.07 (0.44-2.58) 
Risk difference (95% CI):
  SGLT2i vs SU/DPP4i : 0.200 (-2.000 to 2.400) 
P-value: 0.884 

 ------------------------------------------------------------ 
COMPARISON: SGLT2 vs SU_DPP4 - OUTCOME: Late-onset Epilepsy/Seizure 
------------------------------------------------------------ 
DEBUG: Looking for cohort files:
  IPTW: ipwt_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv - Exists: TRUE 
  TMLE: tmle_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv - Exists: TRUE 
DEBUG: IPTW outcomes available for SGLT2 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 
DEBUG: TMLE outcomes available for SGLT2 vs SU_DPP4 : Epilepsy/Seizure, Early-onset Epilepsy/Seizure, Late-onset Epilepsy/Seizure, ADRD, stroke 

=== NON-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 6823 rows, 108 columns
DEBUG: Events by treatment: 3842 2839 92 50 
Non-weighted cohort:
No. of events/No. of patients at risk:
  SGLT2i : 50/2,889 
  SU/DPP4i : 92/3,934 
Follow-up, mean (SD), y:
  SGLT2i : 2.59 (1.33) 
  SU/DPP4i : 2.85 (1.53) 
Crude HR (95% CI):
  SGLT2i vs SU/DPP4i : 0.82 (0.58 to 1.15) 
  P-value: 0.250 

=== IPTW-WEIGHTED COHORT RESULTS ===
DEBUG: Loaded weighted cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 6823 rows, 108 columns
DEBUG: Events by treatment: 3842 2839 92 50 
IPTW-weighted cohort:
No. of events/No. of patients at risk:
  SGLT2i : 60/3409 
  SU/DPP4i : 78/3404 
Follow-up, mean (SD), y:
  SGLT2i : 2.90 (1.42) 
  SU/DPP4i : 2.66 (1.49) 
Incidence rate per 1000 person-years:
  SGLT2i : 6.09 (4.69 to 7.49) 
  SU/DPP4i : 8.57 (6.49 to 10.64) 
Rate difference per 1000 person-years:
  SGLT2i vs SU/DPP4i : -2.48 (-4.98 to 0.02) 
Adjusted HR (95% CI):
  SGLT2i vs SU/DPP4i : 0.72 (0.50 to 1.05) 
  P-value: 0.087 

=== TMLE RESULTS ===
DEBUG: Filtering TMLE results for comparison=' SGLT2 vs SU_DPP4 ' and outcome=' Late-onset Epilepsy/Seizure '
DEBUG: Found 10 TMLE result rows for this combination:
# A tibble: 10 × 6
   comparison       outcome             effect_measure estimate n_total n_events
   <chr>            <chr>               <chr>             <dbl>   <dbl>    <dbl>
 1 SGLT2 vs SU_DPP4 Epilepsy/Seizure    Risk Differen…  -0.0035    8615      180
 2 SGLT2 vs SU_DPP4 Epilepsy/Seizure    Odds Ratio       0.84      8615      180
 3 SGLT2 vs SU_DPP4 Early-onset Epilep… Risk Differen…   0.0002    8615       21
 4 SGLT2 vs SU_DPP4 Early-onset Epilep… Odds Ratio       1.07      8615       21
 5 SGLT2 vs SU_DPP4 Late-onset Epileps… Risk Differen…  -0.0043    8615      159
 6 SGLT2 vs SU_DPP4 Late-onset Epileps… Odds Ratio       0.81      8615      159
 7 SGLT2 vs SU_DPP4 ADRD                Risk Differen…  -0.001     8816      286
 8 SGLT2 vs SU_DPP4 ADRD                Odds Ratio       0.97      8816      286
 9 SGLT2 vs SU_DPP4 stroke              Risk Differen…  -0.0116    8312      334
10 SGLT2 vs SU_DPP4 stroke              Odds Ratio       0.75      8312      334
DEBUG: OR rows found: 1 
DEBUG: OR estimate: 0.81 for outcome: Late-onset Epilepsy/Seizure 
DEBUG: RD rows found: 1 
DEBUG: RD estimate: -0.0043 for outcome: Late-onset Epilepsy/Seizure 
DEBUG: Loaded cohort file: tmle_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7577 rows, 102 columns
DEBUG: Events by treatment: 4379 3042 101 55 
No. of events/No. of patients at risk:
  SGLT2i : 55/3,097 
  SU/DPP4i : 101/4,480 
OR (95% CI):
  SGLT2i vs SU/DPP4i : 0.81 (0.57-1.16) 
Risk difference (95% CI):
  SGLT2i vs SU/DPP4i : -4.300 (-11.400 to 2.800) 
P-value: 0.236 

 ================================================================================ 
FORMATTED FOR DIRECT TABLE ENTRY
================================================================================ 

>>> COMPARISON: GLP1 vs SGLT2 <<<

 Epilepsy/Seizure :
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5375 rows, 108 columns
DEBUG: Events by treatment: 3650 1636 75 14 
Non-weighted cohort
  N/Events - Sema : 14/1,650   Comp : 75/3,725 
  Follow-up - Sema : 2.27 (1.16)   Comp : 2.51 (1.32) 
  Crude HR: 0.46 (0.26 to 0.82) 
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5375 rows, 108 columns
DEBUG: Events by treatment: 3650 1636 75 14 
IPTW-weighted cohort
  N/Events - Sema : 23/2651   Comp : 54/2724 
  Follow-up - Sema : 2.44 (1.24)   Comp : 2.42 (1.29) 
  Rate/1000PY - Sema : 3.64   Comp : 8.10 
  Rate diff: -4.47 (-7.28 to -1.66) 
  Adj HR: 0.45 (0.23 to 0.85) 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5839 rows, 102 columns
DEBUG: Events by treatment: 3985 1758 81 15 
TMLE analysis
  N/Events - Sema : 15/1,773   Comp : 81/4,066 
  OR: 0.49 (0.26-0.94) 
  Risk diff: -9.700 (-16.800 to -2.500) 
  P-value: 0.008 

 Early-onset Epilepsy/Seizure :
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5375 rows, 108 columns
DEBUG: Events by treatment: 3716 1646 9 4 
Non-weighted cohort
  N/Events - Sema : 4/1,650   Comp : 9/3,725 
  Follow-up - Sema : 2.27 (1.16)   Comp : 2.51 (1.32) 
  Crude HR: 1.14 (0.35 to 3.71) 
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5375 rows, 108 columns
DEBUG: Events by treatment: 3716 1646 9 4 
IPTW-weighted cohort
  N/Events - Sema : 5/2651   Comp : 8/2724 
  Follow-up - Sema : 2.44 (1.24)   Comp : 2.42 (1.29) 
  Rate/1000PY - Sema : 0.77   Comp : 1.26 
  Rate diff: -0.49 (-1.57 to 0.59) 
  Adj HR: 0.61 (0.16 to 2.31) 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5839 rows, 102 columns
DEBUG: Events by treatment: 4057 1769 9 4 
TMLE analysis
  N/Events - Sema : 4/1,773   Comp : 9/4,066 
  OR: 0.69 (0.20-2.34) 
  Risk diff: -0.800 (-3.500 to 1.800) 
  P-value: 0.543 

 Late-onset Epilepsy/Seizure :
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 4718 rows, 108 columns
DEBUG: Events by treatment: 3286 1357 65 10 
Non-weighted cohort
  N/Events - Sema : 10/1,367   Comp : 65/3,351 
  Follow-up - Sema : 2.29 (1.16)   Comp : 2.51 (1.32) 
  Crude HR: 0.41 (0.21 to 0.79) 
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 4718 rows, 108 columns
DEBUG: Events by treatment: 3286 1357 65 10 
IPTW-weighted cohort
  N/Events - Sema : 19/2327   Comp : 45/2391 
  Follow-up - Sema : 2.45 (1.24)   Comp : 2.42 (1.29) 
  Rate/1000PY - Sema : 3.25   Comp : 7.71 
  Rate diff: -4.46 (-7.39 to -1.52) 
  Adj HR: 0.42 (0.20 to 0.88) 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 5114 rows, 102 columns
DEBUG: Events by treatment: 3575 1457 71 11 
TMLE analysis
  N/Events - Sema : 11/1,468   Comp : 71/3,646 
  OR: 0.46 (0.23-0.96) 
  Risk diff: -9.900 (-17.300 to -2.500) 
  P-value: 0.009 

>>> COMPARISON: GLP1 vs SU_DPP4 <<<

 Epilepsy/Seizure :
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7326 rows, 108 columns
DEBUG: Events by treatment: 5226 1940 136 24 
Non-weighted cohort
  N/Events - Sema : 24/1,964   Comp : 136/5,362 
  Follow-up - Sema : 2.35 (1.17)   Comp : 2.88 (1.53) 
  Crude HR: 0.59 (0.38 to 0.91) 
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7326 rows, 108 columns
DEBUG: Events by treatment: 5226 1940 136 24 
IPTW-weighted cohort
  N/Events - Sema : 43/3442   Comp : 89/3884 
  Follow-up - Sema : 2.88 (1.32)   Comp : 2.69 (1.49) 
  Rate/1000PY - Sema : 4.34   Comp : 8.53 
  Rate diff: -4.20 (-6.59 to -1.80) 
  Adj HR: 0.51 (0.31 to 0.82) 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 8216 rows, 102 columns
DEBUG: Events by treatment: 5971 2073 147 25 
TMLE analysis
  N/Events - Sema : 25/2,098   Comp : 147/6,118 
  OR: 0.56 (0.35-0.90) 
  Risk diff: -10.200 (-17.400 to -3.100) 
  P-value: 0.005 

 Early-onset Epilepsy/Seizure :
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7326 rows, 108 columns
DEBUG: Events by treatment: 5345 1958 17 6 
Non-weighted cohort
  N/Events - Sema : 6/1,964   Comp : 17/5,362 
  Follow-up - Sema : 2.35 (1.17)   Comp : 2.88 (1.53) 
  Crude HR: 1.20 (0.47 to 3.07) 
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7326 rows, 108 columns
DEBUG: Events by treatment: 5345 1958 17 6 
IPTW-weighted cohort
  N/Events - Sema : 14/3442   Comp : 11/3884 
  Follow-up - Sema : 2.88 (1.32)   Comp : 2.69 (1.49) 
  Rate/1000PY - Sema : 1.37   Comp : 1.09 
  Rate diff: 0.28 (-0.63 to 1.19) 
  Adj HR: 1.24 (0.43 to 3.59) 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 8216 rows, 102 columns
DEBUG: Events by treatment: 6100 2092 18 6 
TMLE analysis
  N/Events - Sema : 6/2,098   Comp : 18/6,118 
  OR: 0.97 (0.33-2.86) 
  Risk diff: -0.100 (-3.400 to 3.300) 
  P-value: 0.960 

 Late-onset Epilepsy/Seizure :
DEBUG: Loaded cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 6387 rows, 108 columns
DEBUG: Events by treatment: 4613 1639 117 18 
Non-weighted cohort
  N/Events - Sema : 18/1,657   Comp : 117/4,730 
  Follow-up - Sema : 2.37 (1.17)   Comp : 2.91 (1.53) 
  Crude HR: 0.53 (0.32 to 0.87) 
DEBUG: Loaded weighted cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 6387 rows, 108 columns
DEBUG: Events by treatment: 4613 1639 117 18 
IPTW-weighted cohort
  N/Events - Sema : 29/2977   Comp : 77/3374 
  Follow-up - Sema : 2.90 (1.32)   Comp : 2.72 (1.49) 
  Rate/1000PY - Sema : 3.40   Comp : 8.35 
  Rate diff: -4.95 (-7.45 to -2.44) 
  Adj HR: 0.40 (0.24 to 0.68) 
DEBUG: Loaded cohort file: tmle_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7141 rows, 102 columns
DEBUG: Events by treatment: 5250 1745 127 19 
TMLE analysis
  N/Events - Sema : 19/1,764   Comp : 127/5,377 
  OR: 0.48 (0.27-0.85) 
  Risk diff: -12.000 (-19.400 to -4.600) 
  P-value: 0.001 

>>> COMPARISON: SGLT2 vs SU_DPP4 <<<

 Epilepsy/Seizure :
DEBUG: Loaded cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7717 rows, 108 columns
DEBUG: Events by treatment: 4390 3162 107 58 
Non-weighted cohort
  N/Events - SGLT2 : 58/3,220   SU_DPP4 : 107/4,497 
  Follow-up - SGLT2 : 2.59 (1.33)   SU_DPP4 : 2.82 (1.54) 
  Crude HR: 0.83 (0.60 to 1.14) 
DEBUG: Loaded weighted cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7717 rows, 108 columns
DEBUG: Events by treatment: 4390 3162 107 58 
IPTW-weighted cohort
  N/Events - SGLT2 : 73/3853   SU_DPP4 : 89/3864 
  Follow-up - SGLT2 : 2.90 (1.43)   SU_DPP4 : 2.64 (1.49) 
  Rate/1000PY - SGLT2 : 6.54   SU_DPP4 : 8.72 
  Rate diff: -2.18 (-4.58 to 0.21) 
  Adj HR: 0.75 (0.53 to 1.06) 
DEBUG: Loaded cohort file: tmle_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 8615 rows, 102 columns
DEBUG: Events by treatment: 5027 3408 117 63 
TMLE analysis
  N/Events - SGLT2 : 63/3,471   SU_DPP4 : 117/5,144 
  OR: 0.84 (0.61-1.17) 
  Risk diff: -3.500 (-10.300 to 3.200) 
  P-value: 0.306 

 Early-onset Epilepsy/Seizure :
DEBUG: Loaded cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7717 rows, 108 columns
DEBUG: Events by treatment: 4484 3213 13 7 
Non-weighted cohort
  N/Events - SGLT2 : 7/3,220   SU_DPP4 : 13/4,497 
  Follow-up - SGLT2 : 2.59 (1.33)   SU_DPP4 : 2.82 (1.54) 
  Crude HR: 0.81 (0.32 to 2.04) 
DEBUG: Loaded weighted cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7717 rows, 108 columns
DEBUG: Events by treatment: 4484 3213 13 7 
IPTW-weighted cohort
  N/Events - SGLT2 : 10/3853   SU_DPP4 : 10/3864 
  Follow-up - SGLT2 : 2.90 (1.43)   SU_DPP4 : 2.64 (1.49) 
  Rate/1000PY - SGLT2 : 0.90   SU_DPP4 : 0.97 
  Rate diff: -0.07 (-0.90 to 0.76) 
  Adj HR: 0.93 (0.34 to 2.56) 
DEBUG: Loaded cohort file: tmle_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 8615 rows, 102 columns
DEBUG: Events by treatment: 5130 3464 14 7 
TMLE analysis
  N/Events - SGLT2 : 7/3,471   SU_DPP4 : 14/5,144 
  OR: 1.07 (0.44-2.58) 
  Risk diff: 0.200 (-2.000 to 2.400) 
  P-value: 0.884 

 Late-onset Epilepsy/Seizure :
DEBUG: Loaded cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 6823 rows, 108 columns
DEBUG: Events by treatment: 3842 2839 92 50 
Non-weighted cohort
  N/Events - SGLT2 : 50/2,889   SU_DPP4 : 92/3,934 
  Follow-up - SGLT2 : 2.59 (1.33)   SU_DPP4 : 2.85 (1.53) 
  Crude HR: 0.82 (0.58 to 1.15) 
DEBUG: Loaded weighted cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 6823 rows, 108 columns
DEBUG: Events by treatment: 3842 2839 92 50 
IPTW-weighted cohort
  N/Events - SGLT2 : 60/3409   SU_DPP4 : 78/3404 
  Follow-up - SGLT2 : 2.90 (1.42)   SU_DPP4 : 2.66 (1.49) 
  Rate/1000PY - SGLT2 : 6.09   SU_DPP4 : 8.57 
  Rate diff: -2.48 (-4.98 to 0.02) 
  Adj HR: 0.72 (0.50 to 1.05) 
DEBUG: Loaded cohort file: tmle_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
DEBUG: Cohort dimensions: 7577 rows, 102 columns
DEBUG: Events by treatment: 4379 3042 101 55 
TMLE analysis
  N/Events - SGLT2 : 55/3,097   SU_DPP4 : 101/4,480 
  OR: 0.81 (0.57-1.16) 
  Risk diff: -4.300 (-11.400 to 2.800) 
  P-value: 0.236 

 ================================================================================ 
CREATING PUBLICATION-READY SUMMARY TABLE
================================================================================ 

SUMMARY TABLE:
         Comparison                      Outcome Method Treatment_N_Events
1     GLP1 vs SGLT2             Epilepsy/Seizure   IPTW            14/1650
2     GLP1 vs SGLT2             Epilepsy/Seizure   IPTW            14/1650
3     GLP1 vs SGLT2             Epilepsy/Seizure   IPTW            14/1650
4     GLP1 vs SGLT2             Epilepsy/Seizure   IPTW            14/1650
5     GLP1 vs SGLT2             Epilepsy/Seizure   IPTW            14/1650
6     GLP1 vs SGLT2             Epilepsy/Seizure   TMLE            15/1773
7     GLP1 vs SGLT2             Epilepsy/Seizure   TMLE            15/1773
8     GLP1 vs SGLT2             Epilepsy/Seizure   TMLE            15/1773
9     GLP1 vs SGLT2             Epilepsy/Seizure   TMLE            15/1773
10    GLP1 vs SGLT2             Epilepsy/Seizure   TMLE            15/1773
11    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   IPTW             4/1650
12    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   IPTW             4/1650
13    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   IPTW             4/1650
14    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   IPTW             4/1650
15    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   IPTW             4/1650
16    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   TMLE             4/1773
17    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   TMLE             4/1773
18    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   TMLE             4/1773
19    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   TMLE             4/1773
20    GLP1 vs SGLT2 Early-onset Epilepsy/Seizure   TMLE             4/1773
21    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   IPTW            10/1367
22    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   IPTW            10/1367
23    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   IPTW            10/1367
24    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   IPTW            10/1367
25    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   IPTW            10/1367
26    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   TMLE            11/1468
27    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   TMLE            11/1468
28    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   TMLE            11/1468
29    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   TMLE            11/1468
30    GLP1 vs SGLT2  Late-onset Epilepsy/Seizure   TMLE            11/1468
31  GLP1 vs SU_DPP4             Epilepsy/Seizure   IPTW            24/1964
32  GLP1 vs SU_DPP4             Epilepsy/Seizure   IPTW            24/1964
33  GLP1 vs SU_DPP4             Epilepsy/Seizure   IPTW            24/1964
34  GLP1 vs SU_DPP4             Epilepsy/Seizure   IPTW            24/1964
35  GLP1 vs SU_DPP4             Epilepsy/Seizure   IPTW            24/1964
36  GLP1 vs SU_DPP4             Epilepsy/Seizure   TMLE            25/2098
37  GLP1 vs SU_DPP4             Epilepsy/Seizure   TMLE            25/2098
38  GLP1 vs SU_DPP4             Epilepsy/Seizure   TMLE            25/2098
39  GLP1 vs SU_DPP4             Epilepsy/Seizure   TMLE            25/2098
40  GLP1 vs SU_DPP4             Epilepsy/Seizure   TMLE            25/2098
41  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             6/1964
42  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             6/1964
43  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             6/1964
44  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             6/1964
45  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             6/1964
46  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             6/2098
47  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             6/2098
48  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             6/2098
49  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             6/2098
50  GLP1 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             6/2098
51  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            18/1657
52  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            18/1657
53  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            18/1657
54  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            18/1657
55  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            18/1657
56  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            19/1764
57  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            19/1764
58  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            19/1764
59  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            19/1764
60  GLP1 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            19/1764
61 SGLT2 vs SU_DPP4             Epilepsy/Seizure   IPTW            58/3220
62 SGLT2 vs SU_DPP4             Epilepsy/Seizure   IPTW            58/3220
63 SGLT2 vs SU_DPP4             Epilepsy/Seizure   IPTW            58/3220
64 SGLT2 vs SU_DPP4             Epilepsy/Seizure   IPTW            58/3220
65 SGLT2 vs SU_DPP4             Epilepsy/Seizure   IPTW            58/3220
66 SGLT2 vs SU_DPP4             Epilepsy/Seizure   TMLE            63/3471
67 SGLT2 vs SU_DPP4             Epilepsy/Seizure   TMLE            63/3471
68 SGLT2 vs SU_DPP4             Epilepsy/Seizure   TMLE            63/3471
69 SGLT2 vs SU_DPP4             Epilepsy/Seizure   TMLE            63/3471
70 SGLT2 vs SU_DPP4             Epilepsy/Seizure   TMLE            63/3471
71 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             7/3220
72 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             7/3220
73 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             7/3220
74 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             7/3220
75 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   IPTW             7/3220
76 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             7/3471
77 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             7/3471
78 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             7/3471
79 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             7/3471
80 SGLT2 vs SU_DPP4 Early-onset Epilepsy/Seizure   TMLE             7/3471
81 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            50/2889
82 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            50/2889
83 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            50/2889
84 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            50/2889
85 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   IPTW            50/2889
86 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            55/3097
87 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            55/3097
88 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            55/3097
89 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            55/3097
90 SGLT2 vs SU_DPP4  Late-onset Epilepsy/Seizure   TMLE            55/3097
   Comparator_N_Events Treatment_Followup Comparator_Followup
1              75/3725        2.27 (1.16)         2.51 (1.32)
2              75/3725        2.27 (1.16)         2.51 (1.32)
3              75/3725        2.27 (1.16)         2.51 (1.32)
4              75/3725        2.27 (1.16)         2.51 (1.32)
5              75/3725        2.27 (1.16)         2.51 (1.32)
6              81/4066                N/A                 N/A
7              81/4066                N/A                 N/A
8              81/4066                N/A                 N/A
9              81/4066                N/A                 N/A
10             81/4066                N/A                 N/A
11              9/3725        2.27 (1.16)         2.51 (1.32)
12              9/3725        2.27 (1.16)         2.51 (1.32)
13              9/3725        2.27 (1.16)         2.51 (1.32)
14              9/3725        2.27 (1.16)         2.51 (1.32)
15              9/3725        2.27 (1.16)         2.51 (1.32)
16              9/4066                N/A                 N/A
17              9/4066                N/A                 N/A
18              9/4066                N/A                 N/A
19              9/4066                N/A                 N/A
20              9/4066                N/A                 N/A
21             65/3351        2.29 (1.16)         2.51 (1.32)
22             65/3351        2.29 (1.16)         2.51 (1.32)
23             65/3351        2.29 (1.16)         2.51 (1.32)
24             65/3351        2.29 (1.16)         2.51 (1.32)
25             65/3351        2.29 (1.16)         2.51 (1.32)
26             71/3646                N/A                 N/A
27             71/3646                N/A                 N/A
28             71/3646                N/A                 N/A
29             71/3646                N/A                 N/A
30             71/3646                N/A                 N/A
31            136/5362        2.35 (1.17)         2.88 (1.53)
32            136/5362        2.35 (1.17)         2.88 (1.53)
33            136/5362        2.35 (1.17)         2.88 (1.53)
34            136/5362        2.35 (1.17)         2.88 (1.53)
35            136/5362        2.35 (1.17)         2.88 (1.53)
36            147/6118                N/A                 N/A
37            147/6118                N/A                 N/A
38            147/6118                N/A                 N/A
39            147/6118                N/A                 N/A
40            147/6118                N/A                 N/A
41             17/5362        2.35 (1.17)         2.88 (1.53)
42             17/5362        2.35 (1.17)         2.88 (1.53)
43             17/5362        2.35 (1.17)         2.88 (1.53)
44             17/5362        2.35 (1.17)         2.88 (1.53)
45             17/5362        2.35 (1.17)         2.88 (1.53)
46             18/6118                N/A                 N/A
47             18/6118                N/A                 N/A
48             18/6118                N/A                 N/A
49             18/6118                N/A                 N/A
50             18/6118                N/A                 N/A
51            117/4730        2.37 (1.17)         2.91 (1.53)
52            117/4730        2.37 (1.17)         2.91 (1.53)
53            117/4730        2.37 (1.17)         2.91 (1.53)
54            117/4730        2.37 (1.17)         2.91 (1.53)
55            117/4730        2.37 (1.17)         2.91 (1.53)
56            127/5377                N/A                 N/A
57            127/5377                N/A                 N/A
58            127/5377                N/A                 N/A
59            127/5377                N/A                 N/A
60            127/5377                N/A                 N/A
61            107/4497        2.59 (1.33)         2.82 (1.54)
62            107/4497        2.59 (1.33)         2.82 (1.54)
63            107/4497        2.59 (1.33)         2.82 (1.54)
64            107/4497        2.59 (1.33)         2.82 (1.54)
65            107/4497        2.59 (1.33)         2.82 (1.54)
66            117/5144                N/A                 N/A
67            117/5144                N/A                 N/A
68            117/5144                N/A                 N/A
69            117/5144                N/A                 N/A
70            117/5144                N/A                 N/A
71             13/4497        2.59 (1.33)         2.82 (1.54)
72             13/4497        2.59 (1.33)         2.82 (1.54)
73             13/4497        2.59 (1.33)         2.82 (1.54)
74             13/4497        2.59 (1.33)         2.82 (1.54)
75             13/4497        2.59 (1.33)         2.82 (1.54)
76             14/5144                N/A                 N/A
77             14/5144                N/A                 N/A
78             14/5144                N/A                 N/A
79             14/5144                N/A                 N/A
80             14/5144                N/A                 N/A
81             92/3934        2.59 (1.33)         2.85 (1.53)
82             92/3934        2.59 (1.33)         2.85 (1.53)
83             92/3934        2.59 (1.33)         2.85 (1.53)
84             92/3934        2.59 (1.33)         2.85 (1.53)
85             92/3934        2.59 (1.33)         2.85 (1.53)
86            101/4480                N/A                 N/A
87            101/4480                N/A                 N/A
88            101/4480                N/A                 N/A
89            101/4480                N/A                 N/A
90            101/4480                N/A                 N/A
                     Effect_Estimate P_Value
1                   0.45 (0.23-0.85)   0.015
2                   0.61 (0.16-2.31)   0.466
3                   0.42 (0.20-0.88)   0.021
4                   0.72 (0.46-1.13)   0.154
5                   1.09 (0.75-1.59)   0.657
6   OR: 0.49 (0.26-0.94); RD: -9.700   0.008
7   OR: 0.69 (0.20-2.34); RD: -0.800   0.543
8   OR: 0.46 (0.23-0.96); RD: -9.900   0.009
9  OR: 0.64 (0.39-1.02); RD: -10.800   0.032
10   OR: 1.10 (0.72-1.66); RD: 3.100   0.671
11                  0.45 (0.23-0.85)   0.015
12                  0.61 (0.16-2.31)   0.466
13                  0.42 (0.20-0.88)   0.021
14                  0.72 (0.46-1.13)   0.154
15                  1.09 (0.75-1.59)   0.657
16  OR: 0.49 (0.26-0.94); RD: -9.700   0.008
17  OR: 0.69 (0.20-2.34); RD: -0.800   0.543
18  OR: 0.46 (0.23-0.96); RD: -9.900   0.009
19 OR: 0.64 (0.39-1.02); RD: -10.800   0.032
20   OR: 1.10 (0.72-1.66); RD: 3.100   0.671
21                  0.45 (0.23-0.85)   0.015
22                  0.61 (0.16-2.31)   0.466
23                  0.42 (0.20-0.88)   0.021
24                  0.72 (0.46-1.13)   0.154
25                  1.09 (0.75-1.59)   0.657
26  OR: 0.49 (0.26-0.94); RD: -9.700   0.008
27  OR: 0.69 (0.20-2.34); RD: -0.800   0.543
28  OR: 0.46 (0.23-0.96); RD: -9.900   0.009
29 OR: 0.64 (0.39-1.02); RD: -10.800   0.032
30   OR: 1.10 (0.72-1.66); RD: 3.100   0.671
31                  0.51 (0.31-0.82)   0.006
32                  1.24 (0.43-3.59)   0.697
33                  0.40 (0.24-0.68)  <0.001
34                  0.60 (0.40-0.90)   0.014
35                  0.78 (0.54-1.14)   0.204
36 OR: 0.56 (0.35-0.90); RD: -10.200   0.005
37  OR: 0.97 (0.33-2.86); RD: -0.100   0.960
38 OR: 0.48 (0.27-0.85); RD: -12.000   0.001
39  OR: 0.70 (0.48-1.01); RD: -9.500   0.032
40  OR: 0.85 (0.59-1.22); RD: -6.300   0.351
41                  0.51 (0.31-0.82)   0.006
42                  1.24 (0.43-3.59)   0.697
43                  0.40 (0.24-0.68)  <0.001
44                  0.60 (0.40-0.90)   0.014
45                  0.78 (0.54-1.14)   0.204
46 OR: 0.56 (0.35-0.90); RD: -10.200   0.005
47  OR: 0.97 (0.33-2.86); RD: -0.100   0.960
48 OR: 0.48 (0.27-0.85); RD: -12.000   0.001
49  OR: 0.70 (0.48-1.01); RD: -9.500   0.032
50  OR: 0.85 (0.59-1.22); RD: -6.300   0.351
51                  0.51 (0.31-0.82)   0.006
52                  1.24 (0.43-3.59)   0.697
53                  0.40 (0.24-0.68)  <0.001
54                  0.60 (0.40-0.90)   0.014
55                  0.78 (0.54-1.14)   0.204
56 OR: 0.56 (0.35-0.90); RD: -10.200   0.005
57  OR: 0.97 (0.33-2.86); RD: -0.100   0.960
58 OR: 0.48 (0.27-0.85); RD: -12.000   0.001
59  OR: 0.70 (0.48-1.01); RD: -9.500   0.032
60  OR: 0.85 (0.59-1.22); RD: -6.300   0.351
61                  0.75 (0.53-1.06)   0.100
62                  0.93 (0.34-2.56)   0.891
63                  0.72 (0.50-1.05)   0.087
64                  0.82 (0.64-1.06)   0.125
65                  0.69 (0.53-0.88)   0.003
66  OR: 0.84 (0.61-1.17); RD: -3.500   0.306
67   OR: 1.07 (0.44-2.58); RD: 0.200   0.884
68  OR: 0.81 (0.57-1.16); RD: -4.300   0.236
69  OR: 0.97 (0.76-1.24); RD: -1.000   0.822
70 OR: 0.75 (0.59-0.96); RD: -11.600   0.019
71                  0.75 (0.53-1.06)   0.100
72                  0.93 (0.34-2.56)   0.891
73                  0.72 (0.50-1.05)   0.087
74                  0.82 (0.64-1.06)   0.125
75                  0.69 (0.53-0.88)   0.003
76  OR: 0.84 (0.61-1.17); RD: -3.500   0.306
77   OR: 1.07 (0.44-2.58); RD: 0.200   0.884
78  OR: 0.81 (0.57-1.16); RD: -4.300   0.236
79  OR: 0.97 (0.76-1.24); RD: -1.000   0.822
80 OR: 0.75 (0.59-0.96); RD: -11.600   0.019
81                  0.75 (0.53-1.06)   0.100
82                  0.93 (0.34-2.56)   0.891
83                  0.72 (0.50-1.05)   0.087
84                  0.82 (0.64-1.06)   0.125
85                  0.69 (0.53-0.88)   0.003
86  OR: 0.84 (0.61-1.17); RD: -3.500   0.306
87   OR: 1.07 (0.44-2.58); RD: 0.200   0.884
88  OR: 0.81 (0.57-1.16); RD: -4.300   0.236
89  OR: 0.97 (0.76-1.24); RD: -1.000   0.822
90 OR: 0.75 (0.59-0.96); RD: -11.600   0.019

Table saved as: publication_summary_table.csv

>>> RUNNING DIAGNOSTIC TO IDENTIFY NUMBER DISCREPANCIES <<<

 ================================================================================ 
DIAGNOSING NUMBER DISCREPANCIES BETWEEN FLOWCHART AND PUBLICATION TABLE
================================================================================ 

=== FLOWCHART NUMBERS (from stepwise analysis) ===
ORIGINAL FLOWCHART NUMBERS (before final exclusions):
GLP1 vs SGLT2:
  Total final cohort: 6,384 
  - Semaglutide: 1,973 
  - SGLT2i: 4,558 
  - Sum check: 6,531 (should equal 6,384 )

GLP1 vs SU/DPP4:
  Total final cohort: 8,911 
  - Semaglutide: 2,321 
  - SU/DPP4i: 6,711 
  - Sum check: 9,032 (should equal 8,911 )

CORRECTED FINAL ANALYSIS NUMBERS (matching CSV files):
GLP1 vs SGLT2:
  Total final cohort: 5,375 
  - Semaglutide: 1,650 
  - SGLT2i: 3,725 

GLP1 vs SU/DPP4:
  Total final cohort: 7,326 
  - Semaglutide: 1,964 
  - SU/DPP4i: 5,362 

ADDITIONAL EXCLUSIONS APPLIED:
  GLP1 vs SGLT2: 1,009 patients excluded
  GLP1 vs SU/DPP4: 1,585 patients excluded

=== PUBLICATION TABLE NUMBERS (from cohort CSV files) ===

 GLP1 vs SGLT2 :
   Epilepsy Seizure :
    IPTW cohort ( ipwt_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1650 
      - Comparator (treatment=0): 3725 
      - Total: 5375 
    TMLE cohort ( tmle_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1773 
      - Comparator (treatment=0): 4066 
      - Total: 5839 
   Early-onset Epilepsy Seizure :
    IPTW cohort ( ipwt_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1650 
      - Comparator (treatment=0): 3725 
      - Total: 5375 
    TMLE cohort ( tmle_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1773 
      - Comparator (treatment=0): 4066 
      - Total: 5839 
   Late-onset Epilepsy Seizure :
    IPTW cohort ( ipwt_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1367 
      - Comparator (treatment=0): 3351 
      - Total: 4718 
    TMLE cohort ( tmle_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1468 
      - Comparator (treatment=0): 3646 
      - Total: 5114 

 GLP1 vs SU DPP4 :
   Epilepsy Seizure :
    IPTW cohort ( ipwt_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1964 
      - Comparator (treatment=0): 5362 
      - Total: 7326 
    TMLE cohort ( tmle_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 2098 
      - Comparator (treatment=0): 6118 
      - Total: 8216 
   Early-onset Epilepsy Seizure :
    IPTW cohort ( ipwt_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1964 
      - Comparator (treatment=0): 5362 
      - Total: 7326 
    TMLE cohort ( tmle_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 2098 
      - Comparator (treatment=0): 6118 
      - Total: 8216 
   Late-onset Epilepsy Seizure :
    IPTW cohort ( ipwt_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1657 
      - Comparator (treatment=0): 4730 
      - Total: 6387 
    TMLE cohort ( tmle_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv ):
      - Semaglutide (treatment=1): 1764 
      - Comparator (treatment=0): 5377 
      - Total: 7141 

 SGLT2 vs SU DPP4 :
   Epilepsy Seizure :
    IPTW cohort ( ipwt_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv ):
      - SGLT2i (treatment=1): 3220 
      - SU/DPP4i (treatment=0): 4497 
      - Total: 7717 
    TMLE cohort ( tmle_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv ):
      - SGLT2i (treatment=1): 3471 
      - SU/DPP4i (treatment=0): 5144 
      - Total: 8615 
   Early-onset Epilepsy Seizure :
    IPTW cohort ( ipwt_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv ):
      - SGLT2i (treatment=1): 3220 
      - SU/DPP4i (treatment=0): 4497 
      - Total: 7717 
    TMLE cohort ( tmle_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv ):
      - SGLT2i (treatment=1): 3471 
      - SU/DPP4i (treatment=0): 5144 
      - Total: 8615 
   Late-onset Epilepsy Seizure :
    IPTW cohort ( ipwt_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv ):
      - SGLT2i (treatment=1): 2889 
      - SU/DPP4i (treatment=0): 3934 
      - Total: 6823 
    TMLE cohort ( tmle_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv ):
      - SGLT2i (treatment=1): 3097 
      - SU/DPP4i (treatment=0): 4480 
      - Total: 7577 

=== DISCREPANCY ANALYSIS ===

GLP1 vs SGLT2 Discrepancies:
  Using CORRECTED flowchart numbers:
  Flowchart: Sema= 1650 , SGLT2= 3725 , Total= 5375 
  CSV file:  Sema= 1650 , SGLT2= 3725 , Total= 5375 
  Difference: Sema= 0 , SGLT2= 0 , Total= 0 
  % Change:   Sema= 0 %, SGLT2= 0 %, Total= 0 %

GLP1 vs SU/DPP4 Discrepancies:
  Using CORRECTED flowchart numbers:
  Flowchart: Sema= 1964 , SU/DPP4= 5362 , Total= 7326 
  CSV file:  Sema= 1964 , SU/DPP4= 5362 , Total= 7326 
  Difference: Sema= 0 , SU/DPP4= 0 , Total= 0 
  % Change:   Sema= 0 %, SU/DPP4= 0 %, Total= 0 %

SGLT2 vs SU/DPP4 Analysis (if available):
  CSV file numbers:
  SGLT2i (treatment=1): 3220 
  SU/DPP4i (treatment=0): 4497 
  Total: 7717 
  Note: This comparison was not tracked in the original flowchart
        as it was added later for neurologic outcomes.

=== POTENTIAL CAUSES OF DISCREPANCY ===
1. Additional exclusions applied during outcome-specific cohort creation
2. Different time windows or follow-up requirements
3. Outcome-specific exclusions (e.g., prevalent cases)
4. Propensity score matching/trimming exclusions
5. Missing data exclusions during final analysis

=== RECOMMENDATIONS ===
1. ✓ COMPLETED: Added detailed exclusion tracking for each analysis stage
2. ✓ COMPLETED: Created corrected flowchart using final CSV numbers
3. ✓ COMPLETED: Added arithmetic verification to ensure sums are correct
4. ✓ COMPLETED: Identified specific additional exclusions between stages

=== ENHANCED FLOWCHART ANALYSIS FEATURES ===
The updated analysis now provides:
• Original flowchart numbers (intermediate stage)
• Corrected flowchart numbers (final analysis stage)
• Detailed tracking of additional exclusions:
  - Patients filtered out due to event_time < 0
  - Patients with missing values in covariates
  - Patients with insufficient follow-up time
  - Patients excluded during propensity score analysis
  - Patients with missing outcome data
• Arithmetic verification to ensure correct sums
• Publication table consistency verification

=== HOW TO USE THE RESULTS ===
FOR PUBLICATION FLOWCHART: Use the 'CORRECTED FINAL ANALYSIS NUMBERS'
FOR INTERNAL TRACKING: Use the detailed exclusion breakdown
FOR VERIFICATION: Check that arithmetic verification shows ✓ CORRECT

 ================================================================================ 
PUBLICATION TABLE EXTRACTION COMPLETE
Check the printed output above for values to fill in your table
================================================================================ 

>>> GENERATING ALL BASELINE CHARACTERISTICS TABLES (CONSOLIDATED) <<<

 ==================================================================================================== 
GENERATING COMPREHENSIVE UNWEIGHTED BASELINE CHARACTERISTICS TABLES
ALL THREE COMPARISONS INCLUDING SGLT2i vs SU/DPP4i
==================================================================================================== 

 -------------------------------------------------------------------------------- 
COMPARISON: GLP1 vs SGLT2 
-------------------------------------------------------------------------------- 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
  Cohort size: 5375 patients
  Treatment distribution: 0 = 3725, 1 = 1650 
  Event distribution: 0 = 5286, 1 = 89 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - Epilepsy/Seizure 
================================================================================ 
Characteristic                      Semaglutide (n=1650) SGLT2i (n=3725)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 61.3 (12.2)          64.6 (11.1)         
  Sex, n (%):
    Male                            623 (37.8)           1934 (51.9)         
    Female                          1010 (61.2)          1743 (46.8)         
    Not specified/Other             17 (1.0)             48 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              948 (57.5)           1818 (48.8)         
    Non-Hispanic Black              353 (21.4)           755 (20.3)          
    Hispanic                        191 (11.6)           739 (19.8)          
    Non-Hispanic Asian/Other        116 (7.0)            272 (7.3)           
    Unknown/Not specified           42 (2.5)             141 (3.8)           
  Income, n (%):
    <$10k                           157 (9.5)            439 (11.8)          
    $10k-25k                        249 (15.1)           595 (16.0)          
    $25k-35k                        145 (8.8)            308 (8.3)           
    $35k-50k                        166 (10.1)           326 (8.8)           
    $50k-75k                        227 (13.8)           436 (11.7)          
    $75k-100k                       155 (9.4)            287 (7.7)           
    $100k-150k                      167 (10.1)           317 (8.5)           
    $150k-200k                      64 (3.9)             105 (2.8)           
    >$200k                          70 (4.2)             114 (3.1)           
    Others/Not specified            250 (15.2)           798 (21.4)          
  Education, n (%):
    Less than high school           100 (6.1)            477 (12.8)          
    High school/GED                 288 (17.5)           787 (21.1)          
    Some college                    573 (34.7)           1131 (30.4)         
    College graduate                347 (21.0)           684 (18.4)          
    Advanced degree                 308 (18.7)           558 (15.0)          
    Not specified/Other             34 (2.1)             88 (2.4)            
  Calendar Year (Index Date), n (%):
    2018                            90 (5.5)             571 (15.3)          
    2019                            334 (20.2)           839 (22.5)          
    2020                            381 (23.1)           966 (25.9)          
    2021                            845 (51.2)           1349 (36.2)         
  BMI (kg/m2), mean (SD)            37.7 (8.3)           34.4 (7.7)          
  BMI Category, n (%):
    Underweight                     0 (0.0)              12 (0.3)            
    Normal                          40 (2.4)             270 (7.2)           
    Overweight                      230 (13.9)           847 (22.7)          
    Obese I                         415 (25.2)           1049 (28.2)         
    Obese II                        425 (25.8)           818 (22.0)          
    Obese III                       540 (32.7)           729 (19.6)          

COMORBIDITIES, n (%):
  Myocardial infarction             190 (11.5)           723 (19.4)          
  Congestive heart failure          339 (20.5)           1169 (31.4)         
  Peripheral vascular disease       382 (23.2)           1042 (28.0)         
  Cerebrovascular disease           252 (15.3)           745 (20.0)          
  Dementia                          20 (1.2)             31 (0.8)            
  Chronic pulmonary disease         712 (43.2)           1568 (42.1)         
  Connective tissue disease         166 (10.1)           328 (8.8)           
  Peptic ulcer disease              109 (6.6)            318 (8.5)           
  Mild liver disease                528 (32.0)           1261 (33.9)         
  Paraplegia and hemiplegia         26 (1.6)             86 (2.3)            
  Renal disease                     443 (26.8)           1301 (34.9)         
  Cancer                            308 (18.7)           829 (22.3)          
  Moderate/severe liver disease     50 (3.0)             127 (3.4)           
  Metastatic cancer                 21 (1.3)             86 (2.3)            
  HIV/AIDS                          30 (1.8)             82 (2.2)            

MEDICATIONS, n (%):
  Anticoagulant                     38 (2.3)             127 (3.4)           
  Antiplatelet                      34 (2.1)             125 (3.4)           
  Beta-blocker                      250 (15.2)           739 (19.8)          
  Biguanide                         515 (31.2)           1300 (34.9)         
  Calcium channel blocker           165 (10.0)           433 (11.6)          
  Diuretic                          223 (13.5)           623 (16.7)          
  Ezetimibe                         12 (0.7)             34 (0.9)            
  Mineralocorticoid receptor antagonist 29 (1.8)             74 (2.0)            
  Other antihypertensive            75 (4.5)             146 (3.9)           
  RAAS inhibitor                    479 (29.0)           1343 (36.1)         
  Statin                            461 (27.9)           1324 (35.5)         
  Thiazolidinedione                 16 (1.0)             57 (1.5)            
  Insulin                           1038 (62.9)          2543 (68.3)         
  Sulfonylurea                      164 (9.9)            491 (13.2)          
  DPP-4 inhibitor                   61 (3.7)             172 (4.6)           
  SGLT-2 inhibitor                  19 (1.2)             204 (5.5)           
  GLP-1 agonist                     117 (7.1)            125 (3.4)           
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Semaglutide = 14, SGLT2i = 75
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - prop_treat: 0.02424242 , prop_comp: 0.07248322 
DEBUG: BMI level Normal - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Normal - var_treat: 0.02365473 , var_comp: 0.0672294 , pooled_sd: 0.2131714 , level_smd: -0.2263005 
DEBUG: BMI level Obese I - prop_treat: 0.2515152 , prop_comp: 0.2816107 
DEBUG: BMI level Obese I - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese I - var_treat: 0.1882553 , var_comp: 0.2023061 , pooled_sd: 0.4419058 , level_smd: -0.06810408 
DEBUG: BMI level Obese II - prop_treat: 0.2575758 , prop_comp: 0.2195973 
DEBUG: BMI level Obese II - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese II - var_treat: 0.1912305 , var_comp: 0.1713743 , pooled_sd: 0.4257962 , level_smd: 0.08919394 
DEBUG: BMI level Obese III - prop_treat: 0.3272727 , prop_comp: 0.1957047 
DEBUG: BMI level Obese III - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese III - var_treat: 0.2201653 , var_comp: 0.1574044 , pooled_sd: 0.4344938 , level_smd: 0.3028076 
DEBUG: BMI level Overweight - prop_treat: 0.1393939 , prop_comp: 0.2273826 
DEBUG: BMI level Overweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Overweight - var_treat: 0.1199633 , var_comp: 0.1756797 , pooled_sd: 0.3844756 , level_smd: -0.2288536 
DEBUG: BMI level Underweight - prop_treat: 0 , prop_comp: 0.003221477 
DEBUG: BMI level Underweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.003211099 , pooled_sd: 0.04006931 , level_smd: -0.08039761 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
    - Binary/continuous variables: 33
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    baseline_bmi = 0.408
    index_year: Year 2018 = -0.328
    index_year: Overall (max from level: 2018) = -0.328
    index_year: Year 2021 = 0.306
    bmi_category: Obese III = 0.303
    bmi_category: Overall (max from level: Obese III) = 0.303
    baseline_hba1c = -0.299
    sex_cat: Female = 0.292
    sex_cat: Overall (max from level: 1) = 0.292
    sex_cat: Male = -0.288
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - var_treat: 0.03266786 , var_comp: 0.05805631 , pooled_sd: 0.2129838 , level_smd: -0.1318183 
DEBUG: BMI level Obese I - var_treat: 0.2037256 , var_comp: 0.194883 , pooled_sd: 0.4464351 , level_smd: 0.04402716 
DEBUG: BMI level Obese II - var_treat: 0.1930396 , var_comp: 0.1728529 , pooled_sd: 0.4277222 , level_smd: 0.09139064 
DEBUG: BMI level Obese III - var_treat: 0.1823952 , var_comp: 0.1840541 , pooled_sd: 0.4280475 , level_smd: -0.007499049 
DEBUG: BMI level Overweight - var_treat: 0.1475853 , var_comp: 0.1628711 , pooled_sd: 0.3939901 , level_smd: -0.06306503 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.002606136 , pooled_sd: 0.03609803 , level_smd: -0.0723852 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SGLT2_Epilepsy_Seizure.csv 
  Top 10 largest absolute SMDs (after IPTW):
    raceethnicity_cat: Hispanic = -0.176
    raceethnicity_cat: Overall (max from level: 2) = -0.176
    education: Less than high school = -0.163
    education: Overall (max from level: 0) = -0.163
    sex_cat: Male = -0.156
    sex_cat: Overall (max from level: 0) = -0.156
    sex_cat: Female = 0.155
    bmi_category: Normal = -0.132
    bmi_category: Overall (max from level: Normal) = -0.132
    raceethnicity_cat: Non-Hispanic White = 0.110
  Balance improvement summary:
    - Total variables/levels: 66/70 improved (94.3%)
    - Individual multilevel categories: 30/34 improved (88.2%)
    - Largest remaining |SMD| (any level): 0.176
    - Individual levels with |SMD| > 0.1: 10

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - Epilepsy/Seizure 
================================================================================ 
Characteristic                      Semaglutide (eff_n=2651) SGLT2i (eff_n=2724)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 63.5 (11.6)          63.6 (11.5)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1113 (42.0)          1355 (49.7)         
  Female , n (%)                    1505 (56.8)          1336 (49.0)         
  Not specified/Other , n (%)       33 (1.2)             33 (1.2)            
  BMI (kg/m2), mean (SD)            35.9 (7.5)           35.5 (8.4)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Semaglutide = 23.5, SGLT2i = 53.5
================================================================================ 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
  Cohort size: 5375 patients
  Treatment distribution: 0 = 3725, 1 = 1650 
  Event distribution: 0 = 5362, 1 = 13 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - Early-onset/Epilepsy/Seizure 
================================================================================ 
Characteristic                      Semaglutide (n=1650) SGLT2i (n=3725)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 61.3 (12.2)          64.6 (11.1)         
  Sex, n (%):
    Male                            623 (37.8)           1934 (51.9)         
    Female                          1010 (61.2)          1743 (46.8)         
    Not specified/Other             17 (1.0)             48 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              948 (57.5)           1818 (48.8)         
    Non-Hispanic Black              353 (21.4)           755 (20.3)          
    Hispanic                        191 (11.6)           739 (19.8)          
    Non-Hispanic Asian/Other        116 (7.0)            272 (7.3)           
    Unknown/Not specified           42 (2.5)             141 (3.8)           
  Income, n (%):
    <$10k                           157 (9.5)            439 (11.8)          
    $10k-25k                        249 (15.1)           595 (16.0)          
    $25k-35k                        145 (8.8)            308 (8.3)           
    $35k-50k                        166 (10.1)           326 (8.8)           
    $50k-75k                        227 (13.8)           436 (11.7)          
    $75k-100k                       155 (9.4)            287 (7.7)           
    $100k-150k                      167 (10.1)           317 (8.5)           
    $150k-200k                      64 (3.9)             105 (2.8)           
    >$200k                          70 (4.2)             114 (3.1)           
    Others/Not specified            250 (15.2)           798 (21.4)          
  Education, n (%):
    Less than high school           100 (6.1)            477 (12.8)          
    High school/GED                 288 (17.5)           787 (21.1)          
    Some college                    573 (34.7)           1131 (30.4)         
    College graduate                347 (21.0)           684 (18.4)          
    Advanced degree                 308 (18.7)           558 (15.0)          
    Not specified/Other             34 (2.1)             88 (2.4)            
  Calendar Year (Index Date), n (%):
    2018                            90 (5.5)             571 (15.3)          
    2019                            334 (20.2)           839 (22.5)          
    2020                            381 (23.1)           966 (25.9)          
    2021                            845 (51.2)           1349 (36.2)         
  BMI (kg/m2), mean (SD)            37.7 (8.3)           34.4 (7.7)          
  BMI Category, n (%):
    Underweight                     0 (0.0)              12 (0.3)            
    Normal                          40 (2.4)             270 (7.2)           
    Overweight                      230 (13.9)           847 (22.7)          
    Obese I                         415 (25.2)           1049 (28.2)         
    Obese II                        425 (25.8)           818 (22.0)          
    Obese III                       540 (32.7)           729 (19.6)          

COMORBIDITIES, n (%):
  Myocardial infarction             190 (11.5)           723 (19.4)          
  Congestive heart failure          339 (20.5)           1169 (31.4)         
  Peripheral vascular disease       382 (23.2)           1042 (28.0)         
  Cerebrovascular disease           252 (15.3)           745 (20.0)          
  Dementia                          20 (1.2)             31 (0.8)            
  Chronic pulmonary disease         712 (43.2)           1568 (42.1)         
  Connective tissue disease         166 (10.1)           328 (8.8)           
  Peptic ulcer disease              109 (6.6)            318 (8.5)           
  Mild liver disease                528 (32.0)           1261 (33.9)         
  Paraplegia and hemiplegia         26 (1.6)             86 (2.3)            
  Renal disease                     443 (26.8)           1301 (34.9)         
  Cancer                            308 (18.7)           829 (22.3)          
  Moderate/severe liver disease     50 (3.0)             127 (3.4)           
  Metastatic cancer                 21 (1.3)             86 (2.3)            
  HIV/AIDS                          30 (1.8)             82 (2.2)            

MEDICATIONS, n (%):
  Anticoagulant                     38 (2.3)             127 (3.4)           
  Antiplatelet                      34 (2.1)             125 (3.4)           
  Beta-blocker                      250 (15.2)           739 (19.8)          
  Biguanide                         515 (31.2)           1300 (34.9)         
  Calcium channel blocker           165 (10.0)           433 (11.6)          
  Diuretic                          223 (13.5)           623 (16.7)          
  Ezetimibe                         12 (0.7)             34 (0.9)            
  Mineralocorticoid receptor antagonist 29 (1.8)             74 (2.0)            
  Other antihypertensive            75 (4.5)             146 (3.9)           
  RAAS inhibitor                    479 (29.0)           1343 (36.1)         
  Statin                            461 (27.9)           1324 (35.5)         
  Thiazolidinedione                 16 (1.0)             57 (1.5)            
  Insulin                           1038 (62.9)          2543 (68.3)         
  Sulfonylurea                      164 (9.9)            491 (13.2)          
  DPP-4 inhibitor                   61 (3.7)             172 (4.6)           
  SGLT-2 inhibitor                  19 (1.2)             204 (5.5)           
  GLP-1 agonist                     117 (7.1)            125 (3.4)           
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Semaglutide = 4, SGLT2i = 9
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - prop_treat: 0.02424242 , prop_comp: 0.07248322 
DEBUG: BMI level Normal - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Normal - var_treat: 0.02365473 , var_comp: 0.0672294 , pooled_sd: 0.2131714 , level_smd: -0.2263005 
DEBUG: BMI level Obese I - prop_treat: 0.2515152 , prop_comp: 0.2816107 
DEBUG: BMI level Obese I - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese I - var_treat: 0.1882553 , var_comp: 0.2023061 , pooled_sd: 0.4419058 , level_smd: -0.06810408 
DEBUG: BMI level Obese II - prop_treat: 0.2575758 , prop_comp: 0.2195973 
DEBUG: BMI level Obese II - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese II - var_treat: 0.1912305 , var_comp: 0.1713743 , pooled_sd: 0.4257962 , level_smd: 0.08919394 
DEBUG: BMI level Obese III - prop_treat: 0.3272727 , prop_comp: 0.1957047 
DEBUG: BMI level Obese III - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese III - var_treat: 0.2201653 , var_comp: 0.1574044 , pooled_sd: 0.4344938 , level_smd: 0.3028076 
DEBUG: BMI level Overweight - prop_treat: 0.1393939 , prop_comp: 0.2273826 
DEBUG: BMI level Overweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Overweight - var_treat: 0.1199633 , var_comp: 0.1756797 , pooled_sd: 0.3844756 , level_smd: -0.2288536 
DEBUG: BMI level Underweight - prop_treat: 0 , prop_comp: 0.003221477 
DEBUG: BMI level Underweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.003211099 , pooled_sd: 0.04006931 , level_smd: -0.08039761 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
    - Binary/continuous variables: 33
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    baseline_bmi = 0.408
    index_year: Year 2018 = -0.328
    index_year: Overall (max from level: 2018) = -0.328
    index_year: Year 2021 = 0.306
    bmi_category: Obese III = 0.303
    bmi_category: Overall (max from level: Obese III) = 0.303
    baseline_hba1c = -0.299
    sex_cat: Female = 0.292
    sex_cat: Overall (max from level: 1) = 0.292
    sex_cat: Male = -0.288
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - var_treat: 0.03266786 , var_comp: 0.05805631 , pooled_sd: 0.2129838 , level_smd: -0.1318183 
DEBUG: BMI level Obese I - var_treat: 0.2037256 , var_comp: 0.194883 , pooled_sd: 0.4464351 , level_smd: 0.04402716 
DEBUG: BMI level Obese II - var_treat: 0.1930396 , var_comp: 0.1728529 , pooled_sd: 0.4277222 , level_smd: 0.09139064 
DEBUG: BMI level Obese III - var_treat: 0.1823952 , var_comp: 0.1840541 , pooled_sd: 0.4280475 , level_smd: -0.007499049 
DEBUG: BMI level Overweight - var_treat: 0.1475853 , var_comp: 0.1628711 , pooled_sd: 0.3939901 , level_smd: -0.06306503 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.002606136 , pooled_sd: 0.03609803 , level_smd: -0.0723852 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SGLT2_Early-onset_Epilepsy_Seizure.csv 
  Top 10 largest absolute SMDs (after IPTW):
    raceethnicity_cat: Hispanic = -0.176
    raceethnicity_cat: Overall (max from level: 2) = -0.176
    education: Less than high school = -0.163
    education: Overall (max from level: 0) = -0.163
    sex_cat: Male = -0.156
    sex_cat: Overall (max from level: 0) = -0.156
    sex_cat: Female = 0.155
    bmi_category: Normal = -0.132
    bmi_category: Overall (max from level: Normal) = -0.132
    raceethnicity_cat: Non-Hispanic White = 0.110
  Balance improvement summary:
    - Total variables/levels: 66/70 improved (94.3%)
    - Individual multilevel categories: 30/34 improved (88.2%)
    - Largest remaining |SMD| (any level): 0.176
    - Individual levels with |SMD| > 0.1: 10

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - Early-onset/Epilepsy/Seizure 
================================================================================ 
Characteristic                      Semaglutide (eff_n=2651) SGLT2i (eff_n=2724)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 63.5 (11.6)          63.6 (11.5)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1113 (42.0)          1355 (49.7)         
  Female , n (%)                    1505 (56.8)          1336 (49.0)         
  Not specified/Other , n (%)       33 (1.2)             33 (1.2)            
  BMI (kg/m2), mean (SD)            35.9 (7.5)           35.5 (8.4)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Semaglutide = 4.9, SGLT2i = 8.3
================================================================================ 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
  Cohort size: 4718 patients
  Treatment distribution: 0 = 3351, 1 = 1367 
  Event distribution: 0 = 4643, 1 = 75 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - Late-onset Epilepsy/Seizure 
================================================================================ 
Characteristic                      Semaglutide (n=1367) SGLT2i (n=3351)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 65.4 (8.6)           67.0 (8.7)          
  Sex, n (%):
    Male                            560 (41.0)           1792 (53.5)         
    Female                          790 (57.8)           1516 (45.2)         
    Not specified/Other             17 (1.2)             43 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              819 (59.9)           1683 (50.2)         
    Non-Hispanic Black              276 (20.2)           678 (20.2)          
    Hispanic                        151 (11.0)           633 (18.9)          
    Non-Hispanic Asian/Other        83 (6.1)             230 (6.9)           
    Unknown/Not specified           38 (2.8)             127 (3.8)           
  Income, n (%):
    <$10k                           119 (8.7)            378 (11.3)          
    $10k-25k                        215 (15.7)           542 (16.2)          
    $25k-35k                        110 (8.0)            269 (8.0)           
    $35k-50k                        133 (9.7)            295 (8.8)           
    $50k-75k                        190 (13.9)           391 (11.7)          
    $75k-100k                       123 (9.0)            262 (7.8)           
    $100k-150k                      139 (10.2)           286 (8.5)           
    $150k-200k                      56 (4.1)             97 (2.9)            
    >$200k                          62 (4.5)             102 (3.0)           
    Others/Not specified            220 (16.1)           729 (21.8)          
  Education, n (%):
    Less than high school           90 (6.6)             428 (12.8)          
    High school/GED                 234 (17.1)           707 (21.1)          
    Some college                    462 (33.8)           1009 (30.1)         
    College graduate                289 (21.1)           613 (18.3)          
    Advanced degree                 262 (19.2)           513 (15.3)          
    Not specified/Other             30 (2.2)             81 (2.4)            
  Calendar Year (Index Date), n (%):
    2018                            72 (5.3)             502 (15.0)          
    2019                            289 (21.1)           754 (22.5)          
    2020                            315 (23.0)           858 (25.6)          
    2021                            691 (50.5)           1237 (36.9)         
  BMI (kg/m2), mean (SD)            36.8 (7.7)           34.0 (7.4)          
  BMI Category, n (%):
    Underweight                     0 (0.0)              12 (0.4)            
    Normal                          38 (2.8)             253 (7.5)           
    Overweight                      210 (15.4)           794 (23.7)          
    Obese I                         367 (26.8)           960 (28.6)          
    Obese II                        361 (26.4)           734 (21.9)          
    Obese III                       391 (28.6)           598 (17.8)          

COMORBIDITIES, n (%):
  Myocardial infarction             176 (12.9)           700 (20.9)          
  Congestive heart failure          311 (22.8)           1106 (33.0)         
  Peripheral vascular disease       362 (26.5)           1012 (30.2)         
  Cerebrovascular disease           244 (17.8)           713 (21.3)          
  Dementia                          19 (1.4)             31 (0.9)            
  Chronic pulmonary disease         617 (45.1)           1458 (43.5)         
  Connective tissue disease         148 (10.8)           307 (9.2)           
  Peptic ulcer disease              101 (7.4)            303 (9.0)           
  Mild liver disease                442 (32.3)           1112 (33.2)         
  Paraplegia and hemiplegia         22 (1.6)             81 (2.4)            
  Renal disease                     417 (30.5)           1245 (37.2)         
  Cancer                            288 (21.1)           805 (24.0)          
  Moderate/severe liver disease     46 (3.4)             123 (3.7)           
  Metastatic cancer                 21 (1.5)             83 (2.5)            
  HIV/AIDS                          27 (2.0)             74 (2.2)            

MEDICATIONS, n (%):
  Anticoagulant                     33 (2.4)             123 (3.7)           
  Antiplatelet                      32 (2.3)             123 (3.7)           
  Beta-blocker                      222 (16.2)           681 (20.3)          
  Biguanide                         396 (29.0)           1141 (34.0)         
  Calcium channel blocker           149 (10.9)           416 (12.4)          
  Diuretic                          188 (13.8)           580 (17.3)          
  Ezetimibe                         11 (0.8)             34 (1.0)            
  Mineralocorticoid receptor antagonist 20 (1.5)             63 (1.9)            
  Other antihypertensive            66 (4.8)             124 (3.7)           
  RAAS inhibitor                    419 (30.7)           1248 (37.2)         
  Statin                            409 (29.9)           1243 (37.1)         
  Thiazolidinedione                 14 (1.0)             55 (1.6)            
  Insulin                           881 (64.4)           2293 (68.4)         
  Sulfonylurea                      143 (10.5)           444 (13.2)          
  DPP-4 inhibitor                   55 (4.0)             161 (4.8)           
  SGLT-2 inhibitor                  15 (1.1)             176 (5.3)           
  GLP-1 agonist                     85 (6.2)             109 (3.3)           
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Semaglutide = 10, SGLT2i = 65
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight, Obese II 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 291, Obese I = 1327, Obese II = 1095, Obese III = 989, Overweight = 1004, Underweight = 12 
DEBUG: BMI level Normal - prop_treat: 0.0277981 , prop_comp: 0.07549985 
DEBUG: BMI level Normal - treat_data size: 1367 , comp_data size: 3351 
DEBUG: BMI level Normal - var_treat: 0.02702536 , var_comp: 0.06979962 , pooled_sd: 0.2200284 , level_smd: -0.2167982 
DEBUG: BMI level Obese I - prop_treat: 0.2684711 , prop_comp: 0.2864816 
DEBUG: BMI level Obese I - treat_data size: 1367 , comp_data size: 3351 
DEBUG: BMI level Obese I - var_treat: 0.1963944 , var_comp: 0.2044099 , pooled_sd: 0.447663 , level_smd: -0.04023237 
DEBUG: BMI level Obese II - prop_treat: 0.2640819 , prop_comp: 0.2190391 
DEBUG: BMI level Obese II - treat_data size: 1367 , comp_data size: 3351 
DEBUG: BMI level Obese II - var_treat: 0.1943427 , var_comp: 0.171061 , pooled_sd: 0.4274363 , level_smd: 0.1053791 
DEBUG: BMI level Obese III - prop_treat: 0.2860278 , prop_comp: 0.1784542 
DEBUG: BMI level Obese III - treat_data size: 1367 , comp_data size: 3351 
DEBUG: BMI level Obese III - var_treat: 0.2042159 , var_comp: 0.1466083 , pooled_sd: 0.4188223 , level_smd: 0.2568479 
DEBUG: BMI level Overweight - prop_treat: 0.1536211 , prop_comp: 0.2369442 
DEBUG: BMI level Overweight - treat_data size: 1367 , comp_data size: 3351 
DEBUG: BMI level Overweight - var_treat: 0.1300216 , var_comp: 0.1808016 , pooled_sd: 0.3942228 , level_smd: -0.2113605 
DEBUG: BMI level Underweight - prop_treat: 0 , prop_comp: 0.003581021 
DEBUG: BMI level Underweight - treat_data size: 1367 , comp_data size: 3351 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.003568197 , pooled_sd: 0.04223859 , level_smd: -0.08478078 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
    - Binary/continuous variables: 33
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    baseline_bmi = 0.363
    index_year: Year 2018 = -0.326
    index_year: Overall (max from level: 2018) = -0.326
    baseline_hba1c = -0.295
    index_year: Year 2021 = 0.277
    bmi_category: Obese III = 0.257
    bmi_category: Overall (max from level: Obese III) = 0.257
    sex_cat: Female = 0.253
    sex_cat: Overall (max from level: 1) = 0.253
    sex_cat: Male = -0.253
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight, Obese II 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 291, Obese I = 1327, Obese II = 1095, Obese III = 989, Overweight = 1004, Underweight = 12 
DEBUG: BMI level Normal - var_treat: 0.03561671 , var_comp: 0.0612797 , pooled_sd: 0.2201095 , level_smd: -0.1299168 
DEBUG: BMI level Obese I - var_treat: 0.2083664 , var_comp: 0.1987407 , pooled_sd: 0.4511691 , level_smd: 0.04956458 
DEBUG: BMI level Obese II - var_treat: 0.1951061 , var_comp: 0.1741756 , pooled_sd: 0.4296985 , level_smd: 0.09557391 
DEBUG: BMI level Obese III - var_treat: 0.1655984 , var_comp: 0.1691259 , pooled_sd: 0.4090992 , level_smd: -0.01499823 
DEBUG: BMI level Overweight - var_treat: 0.1550574 , var_comp: 0.1702468 , pooled_sd: 0.4033014 , level_smd: -0.06377722 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.002967978 , pooled_sd: 0.03852258 , level_smd: -0.07727519 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SGLT2_Late-onset_Epilepsy_Seizure.csv 
  Top 10 largest absolute SMDs (after IPTW):
    raceethnicity_cat: Hispanic = -0.159
    raceethnicity_cat: Overall (max from level: 2) = -0.159
    education: Less than high school = -0.150
    education: Overall (max from level: 0) = -0.150
    sex_cat: Male = -0.147
    sex_cat: Overall (max from level: 0) = -0.147
    sex_cat: Female = 0.143
    bmi_category: Normal = -0.130
    bmi_category: Overall (max from level: Normal) = -0.130
    raceethnicity_cat: Non-Hispanic White = 0.121
  Balance improvement summary:
    - Total variables/levels: 62/70 improved (88.6%)
    - Individual multilevel categories: 28/34 improved (82.4%)
    - Largest remaining |SMD| (any level): 0.159
    - Individual levels with |SMD| > 0.1: 10

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - Late-onset Epilepsy/Seizure 
================================================================================ 
Characteristic                      Semaglutide (eff_n=2327) SGLT2i (eff_n=2391)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 66.5 (8.7)           66.5 (8.7)          
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1035 (44.5)          1238 (51.8)         
  Female , n (%)                    1259 (54.1)          1123 (47.0)         
  Not specified/Other , n (%)       33 (1.4)             30 (1.2)            
  BMI (kg/m2), mean (SD)            35.2 (7.0)           34.9 (8.0)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Semaglutide = 18.5, SGLT2i = 44.7
================================================================================ 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SGLT2_ADRD.csv 
  Cohort size: 5478 patients
  Treatment distribution: 0 = 3790, 1 = 1688 
  Event distribution: 0 = 5320, 1 = 158 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - ADRD 
================================================================================ 
Characteristic                      Semaglutide (n=1688) SGLT2i (n=3790)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 60.9 (12.1)          64.3 (11.2)         
  Sex, n (%):
    Male                            616 (36.5)           1956 (51.6)         
    Female                          1052 (62.3)          1789 (47.2)         
    Not specified/Other             20 (1.2)             45 (1.2)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              955 (56.6)           1851 (48.8)         
    Non-Hispanic Black              372 (22.0)           777 (20.5)          
    Hispanic                        193 (11.4)           748 (19.7)          
    Non-Hispanic Asian/Other        121 (7.2)            274 (7.2)           
    Unknown/Not specified           47 (2.8)             140 (3.7)           
  Income, n (%):
    <$10k                           168 (10.0)           450 (11.9)          
    $10k-25k                        267 (15.8)           612 (16.1)          
    $25k-35k                        149 (8.8)            317 (8.4)           
    $35k-50k                        159 (9.4)            334 (8.8)           
    $50k-75k                        229 (13.6)           428 (11.3)          
    $75k-100k                       157 (9.3)            289 (7.6)           
    $100k-150k                      166 (9.8)            321 (8.5)           
    $150k-200k                      65 (3.9)             105 (2.8)           
    >$200k                          69 (4.1)             111 (2.9)           
    Others/Not specified            259 (15.3)           823 (21.7)          
  Education, n (%):
    Less than high school           102 (6.0)            492 (13.0)          
    High school/GED                 293 (17.4)           806 (21.3)          
    Some college                    593 (35.1)           1151 (30.4)         
    College graduate                353 (20.9)           690 (18.2)          
    Advanced degree                 310 (18.4)           559 (14.7)          
    Not specified/Other             37 (2.2)             92 (2.4)            
  Calendar Year (Index Date), n (%):
    2018                            91 (5.4)             590 (15.6)          
    2019                            346 (20.5)           870 (23.0)          
    2020                            391 (23.2)           959 (25.3)          
    2021                            860 (50.9)           1371 (36.2)         
  BMI (kg/m2), mean (SD)            37.8 (8.4)           34.4 (7.7)          
  BMI Category, n (%):
    Underweight                     1 (0.1)              12 (0.3)            
    Normal                          39 (2.3)             281 (7.4)           
    Overweight                      234 (13.9)           854 (22.5)          
    Obese I                         414 (24.5)           1067 (28.2)         
    Obese II                        437 (25.9)           830 (21.9)          
    Obese III                       563 (33.4)           746 (19.7)          

COMORBIDITIES, n (%):
  Myocardial infarction             194 (11.5)           737 (19.4)          
  Congestive heart failure          348 (20.6)           1186 (31.3)         
  Peripheral vascular disease       377 (22.3)           1057 (27.9)         
  Cerebrovascular disease           272 (16.1)           787 (20.8)          
  Dementia                          6 (0.4)              12 (0.3)            
  Chronic pulmonary disease         742 (44.0)           1613 (42.6)         
  Connective tissue disease         174 (10.3)           332 (8.8)           
  Peptic ulcer disease              111 (6.6)            314 (8.3)           
  Mild liver disease                548 (32.5)           1300 (34.3)         
  Paraplegia and hemiplegia         31 (1.8)             96 (2.5)            
  Renal disease                     450 (26.7)           1317 (34.7)         
  Cancer                            320 (19.0)           835 (22.0)          
  Moderate/severe liver disease     49 (2.9)             122 (3.2)           
  Metastatic cancer                 22 (1.3)             87 (2.3)            
  HIV/AIDS                          32 (1.9)             85 (2.2)            

MEDICATIONS, n (%):
  Anticoagulant                     36 (2.1)             125 (3.3)           
  Antiplatelet                      33 (2.0)             122 (3.2)           
  Beta-blocker                      250 (14.8)           754 (19.9)          
  Biguanide                         524 (31.0)           1319 (34.8)         
  Calcium channel blocker           166 (9.8)            435 (11.5)          
  Diuretic                          226 (13.4)           633 (16.7)          
  Ezetimibe                         12 (0.7)             36 (0.9)            
  Mineralocorticoid receptor antagonist 28 (1.7)             77 (2.0)            
  Other antihypertensive            75 (4.4)             153 (4.0)           
  RAAS inhibitor                    491 (29.1)           1355 (35.8)         
  Statin                            471 (27.9)           1349 (35.6)         
  Thiazolidinedione                 15 (0.9)             55 (1.5)            
  Insulin                           1068 (63.3)          2593 (68.4)         
  Sulfonylurea                      167 (9.9)            493 (13.0)          
  DPP-4 inhibitor                   61 (3.6)             168 (4.4)           
  SGLT-2 inhibitor                  19 (1.1)             206 (5.4)           
  GLP-1 agonist                     121 (7.2)            127 (3.4)           
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Semaglutide = 29, SGLT2i = 129
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SGLT2_ADRD.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 320, Obese I = 1481, Obese II = 1267, Obese III = 1309, Overweight = 1088, Underweight = 13 
DEBUG: BMI level Normal - prop_treat: 0.02310427 , prop_comp: 0.07414248 
DEBUG: BMI level Normal - treat_data size: 1688 , comp_data size: 3790 
DEBUG: BMI level Normal - var_treat: 0.02257046 , var_comp: 0.06864537 , pooled_sd: 0.2135601 , level_smd: -0.2389876 
DEBUG: BMI level Obese I - prop_treat: 0.2452607 , prop_comp: 0.2815303 
DEBUG: BMI level Obese I - treat_data size: 1688 , comp_data size: 3790 
DEBUG: BMI level Obese I - var_treat: 0.1851079 , var_comp: 0.202271 , pooled_sd: 0.4401016 , level_smd: -0.08241206 
DEBUG: BMI level Obese II - prop_treat: 0.2588863 , prop_comp: 0.2189974 
DEBUG: BMI level Obese II - treat_data size: 1688 , comp_data size: 3790 
DEBUG: BMI level Obese II - var_treat: 0.1918642 , var_comp: 0.1710375 , pooled_sd: 0.4259705 , level_smd: 0.09364239 
DEBUG: BMI level Obese III - prop_treat: 0.3335308 , prop_comp: 0.1968338 
DEBUG: BMI level Obese III - treat_data size: 1688 , comp_data size: 3790 
DEBUG: BMI level Obese III - var_treat: 0.222288 , var_comp: 0.1580902 , pooled_sd: 0.4361068 , level_smd: 0.3134485 
DEBUG: BMI level Overweight - prop_treat: 0.1386256 , prop_comp: 0.2253298 
DEBUG: BMI level Overweight - treat_data size: 1688 , comp_data size: 3790 
DEBUG: BMI level Overweight - var_treat: 0.1194085 , var_comp: 0.1745563 , pooled_sd: 0.3833829 , level_smd: -0.2261557 
DEBUG: BMI level Underweight - prop_treat: 0.0005924171 , prop_comp: 0.003166227 
DEBUG: BMI level Underweight - treat_data size: 1688 , comp_data size: 3790 
DEBUG: BMI level Underweight - var_treat: 0.0005920661 , var_comp: 0.003156202 , pooled_sd: 0.04329127 , level_smd: -0.05945332 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SGLT2_ADRD.csv 
    - Binary/continuous variables: 33
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    baseline_bmi = 0.423
    index_year: Year 2018 = -0.337
    index_year: Overall (max from level: 2018) = -0.337
    bmi_category: Obese III = 0.313
    bmi_category: Overall (max from level: Obese III) = 0.313
    sex_cat: Male = -0.308
    sex_cat: Overall (max from level: 0) = -0.308
    sex_cat: Female = 0.307
    index_year: Year 2021 = 0.301
    baseline_hba1c = -0.300
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 320, Obese I = 1481, Obese II = 1267, Obese III = 1309, Overweight = 1088, Underweight = 13 
DEBUG: BMI level Normal - var_treat: 0.03164488 , var_comp: 0.05908134 , pooled_sd: 0.2129862 , level_smd: -0.142462 
DEBUG: BMI level Obese I - var_treat: 0.2009184 , var_comp: 0.1947327 , pooled_sd: 0.4447759 , level_smd: 0.03045676 
DEBUG: BMI level Obese II - var_treat: 0.1940667 , var_comp: 0.1724037 , pooled_sd: 0.4280599 , level_smd: 0.09825483 
DEBUG: BMI level Obese III - var_treat: 0.1833751 , var_comp: 0.1853269 , pooled_sd: 0.4293611 , level_smd: -0.008871274 
DEBUG: BMI level Overweight - var_treat: 0.1493912 , var_comp: 0.1614258 , pooled_sd: 0.3942188 , level_smd: -0.04965451 
DEBUG: BMI level Underweight - var_treat: 0.0006371068 , var_comp: 0.002510408 , pooled_sd: 0.03967061 , level_smd: -0.0473708 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SGLT2_ADRD.csv 
  Top 10 largest absolute SMDs (after IPTW):
    raceethnicity_cat: Hispanic = -0.178
    raceethnicity_cat: Overall (max from level: 2) = -0.178
    education: Less than high school = -0.174
    education: Overall (max from level: 0) = -0.174
    sex_cat: Male = -0.170
    sex_cat: Overall (max from level: 0) = -0.170
    sex_cat: Female = 0.169
    bmi_category: Normal = -0.142
    bmi_category: Overall (max from level: Normal) = -0.142
    bmi_category: Obese II = 0.098
  Balance improvement summary:
    - Total variables/levels: 64/71 improved (90.1%)
    - Individual multilevel categories: 28/34 improved (82.4%)
    - Largest remaining |SMD| (any level): 0.178
    - Individual levels with |SMD| > 0.1: 9

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - ADRD 
================================================================================ 
Characteristic                      Semaglutide (eff_n=2700) SGLT2i (eff_n=2778)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 63.2 (11.6)          63.2 (11.6)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1109 (41.1)          1376 (49.5)         
  Female , n (%)                    1557 (57.7)          1370 (49.3)         
  Not specified/Other , n (%)       33 (1.2)             33 (1.2)            
  BMI (kg/m2), mean (SD)            35.9 (7.6)           35.6 (8.5)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Semaglutide = 58.7, SGLT2i = 83.1
================================================================================ 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SGLT2_stroke.csv 
  Cohort size: 5121 patients
  Treatment distribution: 0 = 3514, 1 = 1607 
  Event distribution: 0 = 4950, 1 = 171 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - Stroke 
================================================================================ 
Characteristic                      Semaglutide (n=1607) SGLT2i (n=3514)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 60.6 (12.2)          64.0 (11.3)         
  Sex, n (%):
    Male                            591 (36.8)           1790 (50.9)         
    Female                          999 (62.2)           1685 (48.0)         
    Not specified/Other             17 (1.1)             39 (1.1)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              915 (56.9)           1730 (49.2)         
    Non-Hispanic Black              351 (21.8)           702 (20.0)          
    Hispanic                        186 (11.6)           692 (19.7)          
    Non-Hispanic Asian/Other        114 (7.1)            260 (7.4)           
    Unknown/Not specified           41 (2.6)             130 (3.7)           
  Income, n (%):
    <$10k                           160 (10.0)           415 (11.8)          
    $10k-25k                        239 (14.9)           564 (16.1)          
    $25k-35k                        140 (8.7)            295 (8.4)           
    $35k-50k                        155 (9.6)            310 (8.8)           
    $50k-75k                        222 (13.8)           397 (11.3)          
    $75k-100k                       147 (9.1)            277 (7.9)           
    $100k-150k                      164 (10.2)           301 (8.6)           
    $150k-200k                      61 (3.8)             103 (2.9)           
    >$200k                          67 (4.2)             107 (3.0)           
    Others/Not specified            252 (15.7)           745 (21.2)          
  Education, n (%):
    Less than high school           98 (6.1)             453 (12.9)          
    High school/GED                 273 (17.0)           726 (20.7)          
    Some college                    549 (34.2)           1078 (30.7)         
    College graduate                348 (21.7)           649 (18.5)          
    Advanced degree                 303 (18.9)           521 (14.8)          
    Not specified/Other             36 (2.2)             87 (2.5)            
  Calendar Year (Index Date), n (%):
    2018                            87 (5.4)             549 (15.6)          
    2019                            330 (20.5)           806 (22.9)          
    2020                            363 (22.6)           891 (25.4)          
    2021                            827 (51.5)           1268 (36.1)         
  BMI (kg/m2), mean (SD)            37.9 (8.4)           34.5 (7.7)          
  BMI Category, n (%):
    Underweight                     0 (0.0)              13 (0.4)            
    Normal                          39 (2.4)             253 (7.2)           
    Overweight                      215 (13.4)           793 (22.6)          
    Obese I                         386 (24.0)           973 (27.7)          
    Obese II                        420 (26.1)           775 (22.1)          
    Obese III                       547 (34.0)           707 (20.1)          

COMORBIDITIES, n (%):
  Myocardial infarction             163 (10.1)           609 (17.3)          
  Congestive heart failure          317 (19.7)           1018 (29.0)         
  Peripheral vascular disease       335 (20.8)           907 (25.8)          
  Cerebrovascular disease           162 (10.1)           442 (12.6)          
  Dementia                          17 (1.1)             24 (0.7)            
  Chronic pulmonary disease         694 (43.2)           1461 (41.6)         
  Connective tissue disease         166 (10.3)           307 (8.7)           
  Peptic ulcer disease              110 (6.8)            277 (7.9)           
  Mild liver disease                520 (32.4)           1206 (34.3)         
  Paraplegia and hemiplegia         25 (1.6)             50 (1.4)            
  Renal disease                     414 (25.8)           1167 (33.2)         
  Cancer                            291 (18.1)           763 (21.7)          
  Moderate/severe liver disease     50 (3.1)             114 (3.2)           
  Metastatic cancer                 23 (1.4)             79 (2.2)            
  HIV/AIDS                          32 (2.0)             83 (2.4)            

MEDICATIONS, n (%):
  Anticoagulant                     33 (2.1)             109 (3.1)           
  Antiplatelet                      28 (1.7)             99 (2.8)            
  Beta-blocker                      234 (14.6)           669 (19.0)          
  Biguanide                         526 (32.7)           1244 (35.4)         
  Calcium channel blocker           156 (9.7)            384 (10.9)          
  Diuretic                          216 (13.4)           591 (16.8)          
  Ezetimibe                         10 (0.6)             32 (0.9)            
  Mineralocorticoid receptor antagonist 27 (1.7)             67 (1.9)            
  Other antihypertensive            71 (4.4)             143 (4.1)           
  RAAS inhibitor                    472 (29.4)           1268 (36.1)         
  Statin                            445 (27.7)           1229 (35.0)         
  Thiazolidinedione                 13 (0.8)             53 (1.5)            
  Insulin                           1000 (62.2)          2368 (67.4)         
  Sulfonylurea                      159 (9.9)            464 (13.2)          
  DPP-4 inhibitor                   57 (3.5)             163 (4.6)           
  SGLT-2 inhibitor                  18 (1.1)             203 (5.8)           
  GLP-1 agonist                     118 (7.3)            120 (3.4)           
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Semaglutide = 46, SGLT2i = 125
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SGLT2_stroke.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 292, Obese I = 1359, Obese II = 1195, Obese III = 1254, Overweight = 1008, Underweight = 13 
DEBUG: BMI level Normal - prop_treat: 0.02426882 , prop_comp: 0.07199772 
DEBUG: BMI level Normal - treat_data size: 1607 , comp_data size: 3514 
DEBUG: BMI level Normal - var_treat: 0.02367985 , var_comp: 0.06681405 , pooled_sd: 0.2127133 , level_smd: -0.2243814 
DEBUG: BMI level Obese I - prop_treat: 0.2401991 , prop_comp: 0.2768924 
DEBUG: BMI level Obese I - treat_data size: 1607 , comp_data size: 3514 
DEBUG: BMI level Obese I - var_treat: 0.1825035 , var_comp: 0.200223 , pooled_sd: 0.4374509 , level_smd: -0.08387982 
DEBUG: BMI level Obese II - prop_treat: 0.2613566 , prop_comp: 0.2205464 
DEBUG: BMI level Obese II - treat_data size: 1607 , comp_data size: 3514 
DEBUG: BMI level Obese II - var_treat: 0.1930493 , var_comp: 0.1719057 , pooled_sd: 0.4271738 , level_smd: 0.09553529 
DEBUG: BMI level Obese III - prop_treat: 0.3403858 , prop_comp: 0.2011952 
DEBUG: BMI level Obese III - treat_data size: 1607 , comp_data size: 3514 
DEBUG: BMI level Obese III - var_treat: 0.2245233 , var_comp: 0.1607157 , pooled_sd: 0.4388844 , level_smd: 0.3171464 
DEBUG: BMI level Overweight - prop_treat: 0.1337897 , prop_comp: 0.2256688 
DEBUG: BMI level Overweight - treat_data size: 1607 , comp_data size: 3514 
DEBUG: BMI level Overweight - var_treat: 0.11589 , var_comp: 0.1747424 , pooled_sd: 0.3812036 , level_smd: -0.2410237 
DEBUG: BMI level Underweight - prop_treat: 0 , prop_comp: 0.003699488 
DEBUG: BMI level Underweight - treat_data size: 1607 , comp_data size: 3514 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.003685802 , pooled_sd: 0.04292902 , level_smd: -0.08617685 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SGLT2_stroke.csv 
    - Binary/continuous variables: 33
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    baseline_bmi = 0.428
    index_year: Year 2018 = -0.337
    index_year: Overall (max from level: 2018) = -0.337
    bmi_category: Obese III = 0.317
    bmi_category: Overall (max from level: Obese III) = 0.317
    index_year: Year 2021 = 0.314
    baseline_hba1c = -0.313
    sex_cat: Female = 0.289
    sex_cat: Overall (max from level: 1) = 0.289
    sex_cat: Male = -0.288
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 292, Obese I = 1359, Obese II = 1195, Obese III = 1254, Overweight = 1008, Underweight = 13 
DEBUG: BMI level Normal - var_treat: 0.03407409 , var_comp: 0.05721303 , pooled_sd: 0.2136435 , level_smd: -0.1198405 
DEBUG: BMI level Obese I - var_treat: 0.1982315 , var_comp: 0.1922626 , pooled_sd: 0.4418677 , level_smd: 0.02887569 
DEBUG: BMI level Obese II - var_treat: 0.1945148 , var_comp: 0.1726634 , pooled_sd: 0.428473 , level_smd: 0.09928651 
DEBUG: BMI level Obese III - var_treat: 0.1858638 , var_comp: 0.1888401 , pooled_sd: 0.4328417 , level_smd: -0.01373725 
DEBUG: BMI level Overweight - var_treat: 0.148245 , var_comp: 0.1610855 , pooled_sd: 0.393275 , level_smd: -0.05290259 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.00293768 , pooled_sd: 0.03832545 , level_smd: -0.0768774 
DEBUG: SMD results list length: 73 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SGLT2_stroke.csv 
  Top 10 largest absolute SMDs (after IPTW):
    raceethnicity_cat: Hispanic = -0.181
    raceethnicity_cat: Overall (max from level: 2) = -0.181
    education: Less than high school = -0.165
    education: Overall (max from level: 0) = -0.165
    sex_cat: Male = -0.152
    sex_cat: Overall (max from level: 0) = -0.152
    sex_cat: Female = 0.151
    bmi_category: Normal = -0.120
    bmi_category: Overall (max from level: Normal) = -0.120
    education: Advanced degree = 0.100
  Balance improvement summary:
    - Total variables/levels: 64/70 improved (91.4%)
    - Individual multilevel categories: 29/34 improved (85.3%)
    - Largest remaining |SMD| (any level): 0.181
    - Individual levels with |SMD| > 0.1: 10

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SGLT2 - Stroke 
================================================================================ 
Characteristic                      Semaglutide (eff_n=2529) SGLT2i (eff_n=2592)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 62.9 (11.7)          62.9 (11.6)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1042 (41.2)          1264 (48.8)         
  Female , n (%)                    1459 (57.7)          1300 (50.2)         
  Not specified/Other , n (%)       28 (1.1)             28 (1.1)            
  BMI (kg/m2), mean (SD)            36.0 (7.6)           35.7 (8.6)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Semaglutide = 89.8, SGLT2i = 83.6
================================================================================ 

 -------------------------------------------------------------------------------- 
COMPARISON: GLP1 vs SU DPP4 
-------------------------------------------------------------------------------- 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
  Cohort size: 7326 patients
  Treatment distribution: 0 = 5362, 1 = 1964 
  Event distribution: 0 = 7166, 1 = 160 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (n=1964) Comparator (n=5362)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 62.1 (12.0)          63.8 (11.9)         
  Sex, n (%):
    Male                            833 (42.4)           2479 (46.2)         
    Female                          1111 (56.6)          2815 (52.5)         
    Not specified/Other             20 (1.0)             68 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              1128 (57.4)          2398 (44.7)         
    Non-Hispanic Black              381 (19.4)           1268 (23.6)         
    Hispanic                        255 (13.0)           1130 (21.1)         
    Non-Hispanic Asian/Other        140 (7.1)            396 (7.4)           
    Unknown/Not specified           60 (3.1)             170 (3.2)           
  Income, n (%):
    <$10k                           186 (9.5)            817 (15.2)          
    $10k-25k                        298 (15.2)           927 (17.3)          
    $25k-35k                        161 (8.2)            461 (8.6)           
    $35k-50k                        198 (10.1)           463 (8.6)           
    $50k-75k                        259 (13.2)           507 (9.5)           
    $75k-100k                       183 (9.3)            348 (6.5)           
    $100k-150k                      202 (10.3)           384 (7.2)           
    $150k-200k                      77 (3.9)             135 (2.5)           
    >$200k                          92 (4.7)             119 (2.2)           
    Others/Not specified            308 (15.7)           1201 (22.4)         
  Education, n (%):
    Less than high school           112 (5.7)            758 (14.1)          
    High school/GED                 350 (17.8)           1205 (22.5)         
    Some college                    665 (33.9)           1664 (31.0)         
    College graduate                421 (21.4)           923 (17.2)          
    Advanced degree                 375 (19.1)           689 (12.8)          
    Not specified/Other             41 (2.1)             123 (2.3)           
  Calendar Year (Index Date), n (%):
    2018                            128 (6.5)            1996 (37.2)         
    2019                            405 (20.6)           1634 (30.5)         
    2020                            495 (25.2)           971 (18.1)          
    2021                            936 (47.7)           761 (14.2)          
  BMI (kg/m2), mean (SD)            37.4 (8.3)           33.8 (7.9)          
  BMI Category, n (%):
    Underweight                     3 (0.2)              25 (0.5)            
    Normal                          58 (3.0)             506 (9.4)           
    Overweight                      285 (14.5)           1310 (24.4)         
    Obese I                         503 (25.6)           1496 (27.9)         
    Obese II                        478 (24.3)           1020 (19.0)         
    Obese III                       637 (32.4)           1005 (18.7)         

COMORBIDITIES, n (%):
  Myocardial infarction             266 (13.5)           756 (14.1)          
  Congestive heart failure          448 (22.8)           1313 (24.5)         
  Peripheral vascular disease       459 (23.4)           1316 (24.5)         
  Cerebrovascular disease           307 (15.6)           985 (18.4)          
  Dementia                          23 (1.2)             57 (1.1)            
  Chronic pulmonary disease         844 (43.0)           2078 (38.8)         
  Connective tissue disease         193 (9.8)            436 (8.1)           
  Peptic ulcer disease              128 (6.5)            397 (7.4)           
  Mild liver disease                621 (31.6)           1595 (29.7)         
  Paraplegia and hemiplegia         37 (1.9)             91 (1.7)            
  Renal disease                     576 (29.3)           1736 (32.4)         
  Cancer                            361 (18.4)           1026 (19.1)         
  Moderate/severe liver disease     59 (3.0)             170 (3.2)           
  Metastatic cancer                 23 (1.2)             148 (2.8)           
  HIV/AIDS                          36 (1.8)             97 (1.8)            

MEDICATIONS, n (%):
  Anticoagulant                     45 (2.3)             160 (3.0)           
  Antiplatelet                      50 (2.5)             170 (3.2)           
  Beta-blocker                      318 (16.2)           988 (18.4)          
  Biguanide                         618 (31.5)           1946 (36.3)         
  Calcium channel blocker           178 (9.1)            670 (12.5)          
  Diuretic                          260 (13.2)           863 (16.1)          
  Ezetimibe                         14 (0.7)             36 (0.7)            
  Mineralocorticoid receptor antagonist 34 (1.7)             84 (1.6)            
  Other antihypertensive            87 (4.4)             289 (5.4)           
  RAAS inhibitor                    590 (30.0)           1869 (34.9)         
  Statin                            576 (29.3)           1782 (33.2)         
  Thiazolidinedione                 17 (0.9)             87 (1.6)            
  Insulin                           1311 (66.8)          3331 (62.1)         
  Sulfonylurea                      181 (9.2)            1023 (19.1)         
  DPP-4 inhibitor                   72 (3.7)             448 (8.4)           
  SGLT-2 inhibitor                  43 (2.2)             89 (1.7)            
  GLP-1 agonist                     143 (7.3)            106 (2.0)           
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 24, Comparator = 136
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese III, Obese I, Obese II, Obese I, Overweight, Obese II, Overweight, Obese III, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 564, Obese I = 1999, Obese II = 1498, Obese III = 1642, Overweight = 1595, Underweight = 28 
DEBUG: BMI level Normal - prop_treat: 0.02953157 , prop_comp: 0.09436777 
DEBUG: BMI level Normal - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Normal - var_treat: 0.02865945 , var_comp: 0.0854625 , pooled_sd: 0.2388744 , level_smd: -0.2714238 
DEBUG: BMI level Obese I - prop_treat: 0.25611 , prop_comp: 0.2790004 
DEBUG: BMI level Obese I - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Obese I - var_treat: 0.1905177 , var_comp: 0.2011592 , pooled_sd: 0.4425363 , level_smd: -0.05172545 
DEBUG: BMI level Obese II - prop_treat: 0.2433809 , prop_comp: 0.1902275 
DEBUG: BMI level Obese II - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Obese II - var_treat: 0.1841466 , var_comp: 0.154041 , pooled_sd: 0.4112102 , level_smd: 0.1292607 
DEBUG: BMI level Obese III - prop_treat: 0.3243381 , prop_comp: 0.1874301 
DEBUG: BMI level Obese III - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Obese III - var_treat: 0.2191429 , var_comp: 0.1523 , pooled_sd: 0.4309541 , level_smd: 0.3176858 
DEBUG: BMI level Overweight - prop_treat: 0.145112 , prop_comp: 0.2443118 
DEBUG: BMI level Overweight - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Overweight - var_treat: 0.1240545 , var_comp: 0.1846236 , pooled_sd: 0.3928601 , level_smd: -0.2525067 
DEBUG: BMI level Underweight - prop_treat: 0.001527495 , prop_comp: 0.004662439 
DEBUG: BMI level Underweight - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Underweight - var_treat: 0.001525162 , var_comp: 0.004640701 , pooled_sd: 0.05552415 , level_smd: -0.05646092 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2018 = -0.800
    index_year: Overall (max from level: 2018) = -0.800
    index_year: Year 2021 = 0.777
    baseline_bmi = 0.441
    bmi_category: Obese III = 0.318
    bmi_category: Overall (max from level: Obese III) = 0.318
    education: Less than high school = -0.285
    education: Overall (max from level: 0) = -0.285
    bmi_category: Normal = -0.271
    raceethnicity_cat: Non-Hispanic White = 0.256
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese III, Obese I, Obese II, Obese I, Overweight, Obese II, Overweight, Obese III, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 564, Obese I = 1999, Obese II = 1498, Obese III = 1642, Overweight = 1595, Underweight = 28 
DEBUG: BMI level Normal - var_treat: 0.03757654 , var_comp: 0.0765969 , pooled_sd: 0.2389283 , level_smd: -0.186153 
DEBUG: BMI level Obese I - var_treat: 0.2069173 , var_comp: 0.1950764 , pooled_sd: 0.4483267 , level_smd: 0.05976445 
DEBUG: BMI level Obese II - var_treat: 0.1867204 , var_comp: 0.1573169 , pooled_sd: 0.4147513 , level_smd: 0.1275089 
DEBUG: BMI level Obese III - var_treat: 0.1804727 , var_comp: 0.1780508 , pooled_sd: 0.4233932 , level_smd: 0.01075392 
DEBUG: BMI level Overweight - var_treat: 0.1478157 , var_comp: 0.1713617 , pooled_sd: 0.3994855 , level_smd: -0.09822001 
DEBUG: BMI level Underweight - var_treat: 0.003344148 , var_comp: 0.003857327 , pooled_sd: 0.06000615 , level_smd: -0.00861436 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SU_DPP4_Epilepsy_Seizure.csv 
  Top 10 largest absolute SMDs (after IPTW):
    education: Less than high school = -0.266
    education: Overall (max from level: 0) = -0.266
    raceethnicity_cat: Non-Hispanic White = 0.225
    raceethnicity_cat: Overall (max from level: 0) = 0.225
    income: >$200k = 0.207
    income: Overall (max from level: 8) = 0.207
    bmi_category: Normal = -0.186
    bmi_category: Overall (max from level: Normal) = -0.186
    education: Advanced degree = 0.184
    income: <$10k = -0.184
  Balance improvement summary:
    - Total variables/levels: 51/69 improved (73.9%)
    - Individual multilevel categories: 22/34 improved (64.7%)
    - Largest remaining |SMD| (any level): 0.266
    - Individual levels with |SMD| > 0.1: 18

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (eff_n=3442) Comparator (eff_n=3884)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 62.7 (11.7)          63.2 (12.1)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1516 (44.1)          1730 (44.5)         
  Female , n (%)                    1874 (54.4)          2107 (54.2)         
  Not specified/Other , n (%)       52 (1.5)             47 (1.2)            
  BMI (kg/m2), mean (SD)            35.6 (7.6)           35.0 (8.8)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 42.9, Comparator = 89.2
================================================================================ 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
  Cohort size: 7326 patients
  Treatment distribution: 0 = 5362, 1 = 1964 
  Event distribution: 0 = 7303, 1 = 23 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - Early-onset/Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (n=1964) Comparator (n=5362)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 62.1 (12.0)          63.8 (11.9)         
  Sex, n (%):
    Male                            833 (42.4)           2479 (46.2)         
    Female                          1111 (56.6)          2815 (52.5)         
    Not specified/Other             20 (1.0)             68 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              1128 (57.4)          2398 (44.7)         
    Non-Hispanic Black              381 (19.4)           1268 (23.6)         
    Hispanic                        255 (13.0)           1130 (21.1)         
    Non-Hispanic Asian/Other        140 (7.1)            396 (7.4)           
    Unknown/Not specified           60 (3.1)             170 (3.2)           
  Income, n (%):
    <$10k                           186 (9.5)            817 (15.2)          
    $10k-25k                        298 (15.2)           927 (17.3)          
    $25k-35k                        161 (8.2)            461 (8.6)           
    $35k-50k                        198 (10.1)           463 (8.6)           
    $50k-75k                        259 (13.2)           507 (9.5)           
    $75k-100k                       183 (9.3)            348 (6.5)           
    $100k-150k                      202 (10.3)           384 (7.2)           
    $150k-200k                      77 (3.9)             135 (2.5)           
    >$200k                          92 (4.7)             119 (2.2)           
    Others/Not specified            308 (15.7)           1201 (22.4)         
  Education, n (%):
    Less than high school           112 (5.7)            758 (14.1)          
    High school/GED                 350 (17.8)           1205 (22.5)         
    Some college                    665 (33.9)           1664 (31.0)         
    College graduate                421 (21.4)           923 (17.2)          
    Advanced degree                 375 (19.1)           689 (12.8)          
    Not specified/Other             41 (2.1)             123 (2.3)           
  Calendar Year (Index Date), n (%):
    2018                            128 (6.5)            1996 (37.2)         
    2019                            405 (20.6)           1634 (30.5)         
    2020                            495 (25.2)           971 (18.1)          
    2021                            936 (47.7)           761 (14.2)          
  BMI (kg/m2), mean (SD)            37.4 (8.3)           33.8 (7.9)          
  BMI Category, n (%):
    Underweight                     3 (0.2)              25 (0.5)            
    Normal                          58 (3.0)             506 (9.4)           
    Overweight                      285 (14.5)           1310 (24.4)         
    Obese I                         503 (25.6)           1496 (27.9)         
    Obese II                        478 (24.3)           1020 (19.0)         
    Obese III                       637 (32.4)           1005 (18.7)         

COMORBIDITIES, n (%):
  Myocardial infarction             266 (13.5)           756 (14.1)          
  Congestive heart failure          448 (22.8)           1313 (24.5)         
  Peripheral vascular disease       459 (23.4)           1316 (24.5)         
  Cerebrovascular disease           307 (15.6)           985 (18.4)          
  Dementia                          23 (1.2)             57 (1.1)            
  Chronic pulmonary disease         844 (43.0)           2078 (38.8)         
  Connective tissue disease         193 (9.8)            436 (8.1)           
  Peptic ulcer disease              128 (6.5)            397 (7.4)           
  Mild liver disease                621 (31.6)           1595 (29.7)         
  Paraplegia and hemiplegia         37 (1.9)             91 (1.7)            
  Renal disease                     576 (29.3)           1736 (32.4)         
  Cancer                            361 (18.4)           1026 (19.1)         
  Moderate/severe liver disease     59 (3.0)             170 (3.2)           
  Metastatic cancer                 23 (1.2)             148 (2.8)           
  HIV/AIDS                          36 (1.8)             97 (1.8)            

MEDICATIONS, n (%):
  Anticoagulant                     45 (2.3)             160 (3.0)           
  Antiplatelet                      50 (2.5)             170 (3.2)           
  Beta-blocker                      318 (16.2)           988 (18.4)          
  Biguanide                         618 (31.5)           1946 (36.3)         
  Calcium channel blocker           178 (9.1)            670 (12.5)          
  Diuretic                          260 (13.2)           863 (16.1)          
  Ezetimibe                         14 (0.7)             36 (0.7)            
  Mineralocorticoid receptor antagonist 34 (1.7)             84 (1.6)            
  Other antihypertensive            87 (4.4)             289 (5.4)           
  RAAS inhibitor                    590 (30.0)           1869 (34.9)         
  Statin                            576 (29.3)           1782 (33.2)         
  Thiazolidinedione                 17 (0.9)             87 (1.6)            
  Insulin                           1311 (66.8)          3331 (62.1)         
  Sulfonylurea                      181 (9.2)            1023 (19.1)         
  DPP-4 inhibitor                   72 (3.7)             448 (8.4)           
  SGLT-2 inhibitor                  43 (2.2)             89 (1.7)            
  GLP-1 agonist                     143 (7.3)            106 (2.0)           
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 6, Comparator = 17
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese III, Obese I, Obese II, Obese I, Overweight, Obese II, Overweight, Obese III, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 564, Obese I = 1999, Obese II = 1498, Obese III = 1642, Overweight = 1595, Underweight = 28 
DEBUG: BMI level Normal - prop_treat: 0.02953157 , prop_comp: 0.09436777 
DEBUG: BMI level Normal - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Normal - var_treat: 0.02865945 , var_comp: 0.0854625 , pooled_sd: 0.2388744 , level_smd: -0.2714238 
DEBUG: BMI level Obese I - prop_treat: 0.25611 , prop_comp: 0.2790004 
DEBUG: BMI level Obese I - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Obese I - var_treat: 0.1905177 , var_comp: 0.2011592 , pooled_sd: 0.4425363 , level_smd: -0.05172545 
DEBUG: BMI level Obese II - prop_treat: 0.2433809 , prop_comp: 0.1902275 
DEBUG: BMI level Obese II - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Obese II - var_treat: 0.1841466 , var_comp: 0.154041 , pooled_sd: 0.4112102 , level_smd: 0.1292607 
DEBUG: BMI level Obese III - prop_treat: 0.3243381 , prop_comp: 0.1874301 
DEBUG: BMI level Obese III - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Obese III - var_treat: 0.2191429 , var_comp: 0.1523 , pooled_sd: 0.4309541 , level_smd: 0.3176858 
DEBUG: BMI level Overweight - prop_treat: 0.145112 , prop_comp: 0.2443118 
DEBUG: BMI level Overweight - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Overweight - var_treat: 0.1240545 , var_comp: 0.1846236 , pooled_sd: 0.3928601 , level_smd: -0.2525067 
DEBUG: BMI level Underweight - prop_treat: 0.001527495 , prop_comp: 0.004662439 
DEBUG: BMI level Underweight - treat_data size: 1964 , comp_data size: 5362 
DEBUG: BMI level Underweight - var_treat: 0.001525162 , var_comp: 0.004640701 , pooled_sd: 0.05552415 , level_smd: -0.05646092 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2018 = -0.800
    index_year: Overall (max from level: 2018) = -0.800
    index_year: Year 2021 = 0.777
    baseline_bmi = 0.441
    bmi_category: Obese III = 0.318
    bmi_category: Overall (max from level: Obese III) = 0.318
    education: Less than high school = -0.285
    education: Overall (max from level: 0) = -0.285
    bmi_category: Normal = -0.271
    raceethnicity_cat: Non-Hispanic White = 0.256
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese III, Obese I, Obese II, Obese I, Overweight, Obese II, Overweight, Obese III, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 564, Obese I = 1999, Obese II = 1498, Obese III = 1642, Overweight = 1595, Underweight = 28 
DEBUG: BMI level Normal - var_treat: 0.03757654 , var_comp: 0.0765969 , pooled_sd: 0.2389283 , level_smd: -0.186153 
DEBUG: BMI level Obese I - var_treat: 0.2069173 , var_comp: 0.1950764 , pooled_sd: 0.4483267 , level_smd: 0.05976445 
DEBUG: BMI level Obese II - var_treat: 0.1867204 , var_comp: 0.1573169 , pooled_sd: 0.4147513 , level_smd: 0.1275089 
DEBUG: BMI level Obese III - var_treat: 0.1804727 , var_comp: 0.1780508 , pooled_sd: 0.4233932 , level_smd: 0.01075392 
DEBUG: BMI level Overweight - var_treat: 0.1478157 , var_comp: 0.1713617 , pooled_sd: 0.3994855 , level_smd: -0.09822001 
DEBUG: BMI level Underweight - var_treat: 0.003344148 , var_comp: 0.003857327 , pooled_sd: 0.06000615 , level_smd: -0.00861436 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
  Top 10 largest absolute SMDs (after IPTW):
    education: Less than high school = -0.266
    education: Overall (max from level: 0) = -0.266
    raceethnicity_cat: Non-Hispanic White = 0.225
    raceethnicity_cat: Overall (max from level: 0) = 0.225
    income: >$200k = 0.207
    income: Overall (max from level: 8) = 0.207
    bmi_category: Normal = -0.186
    bmi_category: Overall (max from level: Normal) = -0.186
    education: Advanced degree = 0.184
    income: <$10k = -0.184
  Balance improvement summary:
    - Total variables/levels: 51/69 improved (73.9%)
    - Individual multilevel categories: 22/34 improved (64.7%)
    - Largest remaining |SMD| (any level): 0.266
    - Individual levels with |SMD| > 0.1: 18

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - Early-onset/Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (eff_n=3442) Comparator (eff_n=3884)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 62.7 (11.7)          63.2 (12.1)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1516 (44.1)          1730 (44.5)         
  Female , n (%)                    1874 (54.4)          2107 (54.2)         
  Not specified/Other , n (%)       52 (1.5)             47 (1.2)            
  BMI (kg/m2), mean (SD)            35.6 (7.6)           35.0 (8.8)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 13.5, Comparator = 11.4
================================================================================ 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
  Cohort size: 6387 patients
  Treatment distribution: 0 = 4730, 1 = 1657 
  Event distribution: 0 = 6252, 1 = 135 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - Late-onset Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (n=1657) Comparator (n=4730)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 65.8 (8.6)           66.7 (9.2)          
  Sex, n (%):
    Male                            754 (45.5)           2249 (47.5)         
    Female                          883 (53.3)           2421 (51.2)         
    Not specified/Other             20 (1.2)             60 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              988 (59.6)           2178 (46.0)         
    Non-Hispanic Black              305 (18.4)           1111 (23.5)         
    Hispanic                        207 (12.5)           949 (20.1)          
    Non-Hispanic Asian/Other        105 (6.3)            337 (7.1)           
    Unknown/Not specified           52 (3.1)             155 (3.3)           
  Income, n (%):
    <$10k                           142 (8.6)            691 (14.6)          
    $10k-25k                        260 (15.7)           831 (17.6)          
    $25k-35k                        126 (7.6)            396 (8.4)           
    $35k-50k                        165 (10.0)           399 (8.4)           
    $50k-75k                        217 (13.1)           443 (9.4)           
    $75k-100k                       153 (9.2)            318 (6.7)           
    $100k-150k                      167 (10.1)           359 (7.6)           
    $150k-200k                      67 (4.0)             115 (2.4)           
    >$200k                          83 (5.0)             109 (2.3)           
    Others/Not specified            277 (16.7)           1069 (22.6)         
  Education, n (%):
    Less than high school           102 (6.2)            672 (14.2)          
    High school/GED                 297 (17.9)           1051 (22.2)         
    Some college                    543 (32.8)           1458 (30.8)         
    College graduate                353 (21.3)           813 (17.2)          
    Advanced degree                 325 (19.6)           628 (13.3)          
    Not specified/Other             37 (2.2)             108 (2.3)           
  Calendar Year (Index Date), n (%):
    2018                            104 (6.3)            1795 (37.9)         
    2019                            351 (21.2)           1435 (30.3)         
    2020                            416 (25.1)           842 (17.8)          
    2021                            786 (47.4)           658 (13.9)          
  BMI (kg/m2), mean (SD)            36.6 (7.7)           33.4 (7.5)          
  BMI Category, n (%):
    Underweight                     3 (0.2)              20 (0.4)            
    Normal                          54 (3.3)             465 (9.8)           
    Overweight                      259 (15.6)           1197 (25.3)         
    Obese I                         447 (27.0)           1359 (28.7)         
    Obese II                        412 (24.9)           896 (18.9)          
    Obese III                       482 (29.1)           793 (16.8)          

COMORBIDITIES, n (%):
  Myocardial infarction             253 (15.3)           733 (15.5)          
  Congestive heart failure          420 (25.3)           1246 (26.3)         
  Peripheral vascular disease       438 (26.4)           1271 (26.9)         
  Cerebrovascular disease           298 (18.0)           926 (19.6)          
  Dementia                          23 (1.4)             57 (1.2)            
  Chronic pulmonary disease         741 (44.7)           1893 (40.0)         
  Connective tissue disease         176 (10.6)           405 (8.6)           
  Peptic ulcer disease              117 (7.1)            372 (7.9)           
  Mild liver disease                529 (31.9)           1398 (29.6)         
  Paraplegia and hemiplegia         33 (2.0)             81 (1.7)            
  Renal disease                     549 (33.1)           1648 (34.8)         
  Cancer                            339 (20.5)           987 (20.9)          
  Moderate/severe liver disease     56 (3.4)             165 (3.5)           
  Metastatic cancer                 23 (1.4)             146 (3.1)           
  HIV/AIDS                          32 (1.9)             91 (1.9)            

MEDICATIONS, n (%):
  Anticoagulant                     40 (2.4)             148 (3.1)           
  Antiplatelet                      48 (2.9)             167 (3.5)           
  Beta-blocker                      285 (17.2)           916 (19.4)          
  Biguanide                         485 (29.3)           1647 (34.8)         
  Calcium channel blocker           163 (9.8)            608 (12.9)          
  Diuretic                          224 (13.5)           807 (17.1)          
  Ezetimibe                         12 (0.7)             36 (0.8)            
  Mineralocorticoid receptor antagonist 24 (1.4)             73 (1.5)            
  Other antihypertensive            77 (4.6)             250 (5.3)           
  RAAS inhibitor                    525 (31.7)           1695 (35.8)         
  Statin                            519 (31.3)           1653 (34.9)         
  Thiazolidinedione                 16 (1.0)             79 (1.7)            
  Insulin                           1133 (68.4)          2946 (62.3)         
  Sulfonylurea                      167 (10.1)           886 (18.7)          
  DPP-4 inhibitor                   65 (3.9)             404 (8.5)           
  SGLT-2 inhibitor                  34 (2.1)             80 (1.7)            
  GLP-1 agonist                     107 (6.5)            97 (2.1)            
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 18, Comparator = 117
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese III, Obese II, Obese I, Overweight, Obese II, Overweight, Obese I, Obese I, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 519, Obese I = 1806, Obese II = 1308, Obese III = 1275, Overweight = 1456, Underweight = 23 
DEBUG: BMI level Normal - prop_treat: 0.03258902 , prop_comp: 0.09830867 
DEBUG: BMI level Normal - treat_data size: 1657 , comp_data size: 4730 
DEBUG: BMI level Normal - var_treat: 0.03152697 , var_comp: 0.08864407 , pooled_sd: 0.2451235 , level_smd: -0.2681083 
DEBUG: BMI level Obese I - prop_treat: 0.2697646 , prop_comp: 0.287315 
DEBUG: BMI level Obese I - treat_data size: 1657 , comp_data size: 4730 
DEBUG: BMI level Obese I - var_treat: 0.1969917 , var_comp: 0.2047651 , pooled_sd: 0.4481946 , level_smd: -0.03915794 
DEBUG: BMI level Obese II - prop_treat: 0.2486421 , prop_comp: 0.1894292 
DEBUG: BMI level Obese II - treat_data size: 1657 , comp_data size: 4730 
DEBUG: BMI level Obese II - var_treat: 0.1868192 , var_comp: 0.1535458 , pooled_sd: 0.4125318 , level_smd: 0.1435355 
DEBUG: BMI level Obese III - prop_treat: 0.2908871 , prop_comp: 0.1676533 
DEBUG: BMI level Obese III - treat_data size: 1657 , comp_data size: 4730 
DEBUG: BMI level Obese III - var_treat: 0.2062718 , var_comp: 0.1395457 , pooled_sd: 0.415823 , level_smd: 0.2963614 
DEBUG: BMI level Overweight - prop_treat: 0.1563066 , prop_comp: 0.2530655 
DEBUG: BMI level Overweight - treat_data size: 1657 , comp_data size: 4730 
DEBUG: BMI level Overweight - var_treat: 0.1318748 , var_comp: 0.1890234 , pooled_sd: 0.400561 , level_smd: -0.2415586 
DEBUG: BMI level Underweight - prop_treat: 0.001810501 , prop_comp: 0.00422833 
DEBUG: BMI level Underweight - treat_data size: 1657 , comp_data size: 4730 
DEBUG: BMI level Underweight - var_treat: 0.001807223 , var_comp: 0.004210451 , pooled_sd: 0.05485287 , level_smd: -0.04407844 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2018 = -0.826
    index_year: Overall (max from level: 2018) = -0.826
    index_year: Year 2021 = 0.780
    baseline_bmi = 0.424
    bmi_category: Obese III = 0.296
    bmi_category: Overall (max from level: Obese III) = 0.296
    raceethnicity_cat: Non-Hispanic White = 0.275
    raceethnicity_cat: Overall (max from level: 0) = 0.275
    education: Less than high school = -0.269
    education: Overall (max from level: 0) = -0.269
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese III, Obese II, Obese I, Overweight, Obese II, Overweight, Obese I, Obese I, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 519, Obese I = 1806, Obese II = 1308, Obese III = 1275, Overweight = 1456, Underweight = 23 
DEBUG: BMI level Normal - var_treat: 0.0400849 , var_comp: 0.08023625 , pooled_sd: 0.2452765 , level_smd: -0.1881181 
DEBUG: BMI level Obese I - var_treat: 0.2104133 , var_comp: 0.2003109 , pooled_sd: 0.453169 , level_smd: 0.05284211 
DEBUG: BMI level Obese II - var_treat: 0.1876809 , var_comp: 0.1586399 , pooled_sd: 0.4161255 , level_smd: 0.1264532 
DEBUG: BMI level Obese III - var_treat: 0.1670263 , var_comp: 0.1619189 , pooled_sd: 0.4055522 , level_smd: 0.02153404 
DEBUG: BMI level Overweight - var_treat: 0.1544811 , var_comp: 0.1773655 , pooled_sd: 0.4073368 , level_smd: -0.0971026 
DEBUG: BMI level Underweight - var_treat: 0.003864676 , var_comp: 0.003473122 , pooled_sd: 0.06057144 , level_smd: 0.006512297 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
  Top 10 largest absolute SMDs (after IPTW):
    raceethnicity_cat: Non-Hispanic White = 0.258
    raceethnicity_cat: Overall (max from level: 0) = 0.258
    education: Less than high school = -0.248
    education: Overall (max from level: 0) = -0.248
    income: >$200k = 0.221
    income: Overall (max from level: 8) = 0.221
    index_year: Year 2018 = -0.206
    index_year: Overall (max from level: 2018) = -0.206
    education: Advanced degree = 0.194
    bmi_category: Normal = -0.188
  Balance improvement summary:
    - Total variables/levels: 50/69 improved (72.5%)
    - Individual multilevel categories: 24/34 improved (70.6%)
    - Largest remaining |SMD| (any level): 0.258
    - Individual levels with |SMD| > 0.1: 18

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - Late-onset Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (eff_n=2977) Comparator (eff_n=3374)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 66.0 (8.7)           66.4 (9.2)          
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1386 (46.6)          1561 (46.3)         
  Female , n (%)                    1539 (51.7)          1771 (52.5)         
  Not specified/Other , n (%)       52 (1.7)             41 (1.2)            
  BMI (kg/m2), mean (SD)            35.0 (7.1)           34.3 (8.1)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 29.4, Comparator = 76.6
================================================================================ 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_ADRD.csv 
  Cohort size: 7487 patients
  Treatment distribution: 0 = 5494, 1 = 1993 
  Event distribution: 0 = 7258, 1 = 229 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - ADRD 
================================================================================ 
Characteristic                      Treatment (n=1993) Comparator (n=5494)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 61.7 (11.9)          63.5 (11.9)         
  Sex, n (%):
    Male                            826 (41.4)           2530 (46.1)         
    Female                          1145 (57.5)          2895 (52.7)         
    Not specified/Other             22 (1.1)             69 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              1133 (56.8)          2456 (44.7)         
    Non-Hispanic Black              398 (20.0)           1324 (24.1)         
    Hispanic                        256 (12.8)           1132 (20.6)         
    Non-Hispanic Asian/Other        144 (7.2)            411 (7.5)           
    Unknown/Not specified           62 (3.1)             171 (3.1)           
  Income, n (%):
    <$10k                           189 (9.5)            842 (15.3)          
    $10k-25k                        315 (15.8)           961 (17.5)          
    $25k-35k                        163 (8.2)            468 (8.5)           
    $35k-50k                        192 (9.6)            475 (8.6)           
    $50k-75k                        264 (13.2)           519 (9.4)           
    $75k-100k                       184 (9.2)            350 (6.4)           
    $100k-150k                      200 (10.0)           385 (7.0)           
    $150k-200k                      77 (3.9)             137 (2.5)           
    >$200k                          91 (4.6)             124 (2.3)           
    Others/Not specified            318 (16.0)           1233 (22.4)         
  Education, n (%):
    Less than high school           114 (5.7)            770 (14.0)          
    High school/GED                 349 (17.5)           1253 (22.8)         
    Some college                    686 (34.4)           1699 (30.9)         
    College graduate                427 (21.4)           955 (17.4)          
    Advanced degree                 375 (18.8)           698 (12.7)          
    Not specified/Other             42 (2.1)             119 (2.2)           
  Calendar Year (Index Date), n (%):
    2018                            130 (6.5)            2054 (37.4)         
    2019                            415 (20.8)           1660 (30.2)         
    2020                            505 (25.3)           1011 (18.4)         
    2021                            943 (47.3)           769 (14.0)          
  BMI (kg/m2), mean (SD)            37.5 (8.4)           33.9 (8.0)          
  BMI Category, n (%):
    Underweight                     4 (0.2)              26 (0.5)            
    Normal                          57 (2.9)             518 (9.4)           
    Overweight                      290 (14.6)           1331 (24.2)         
    Obese I                         501 (25.1)           1530 (27.8)         
    Obese II                        486 (24.4)           1046 (19.0)         
    Obese III                       655 (32.9)           1043 (19.0)         

COMORBIDITIES, n (%):
  Myocardial infarction             269 (13.5)           782 (14.2)          
  Congestive heart failure          454 (22.8)           1359 (24.7)         
  Peripheral vascular disease       456 (22.9)           1366 (24.9)         
  Cerebrovascular disease           326 (16.4)           1044 (19.0)         
  Dementia                          8 (0.4)              28 (0.5)            
  Chronic pulmonary disease         859 (43.1)           2161 (39.3)         
  Connective tissue disease         195 (9.8)            447 (8.1)           
  Peptic ulcer disease              130 (6.5)            408 (7.4)           
  Mild liver disease                639 (32.1)           1644 (29.9)         
  Paraplegia and hemiplegia         43 (2.2)             106 (1.9)           
  Renal disease                     579 (29.1)           1786 (32.5)         
  Cancer                            373 (18.7)           1040 (18.9)         
  Moderate/severe liver disease     57 (2.9)             174 (3.2)           
  Metastatic cancer                 25 (1.3)             151 (2.7)           
  HIV/AIDS                          38 (1.9)             105 (1.9)           

MEDICATIONS, n (%):
  Anticoagulant                     44 (2.2)             164 (3.0)           
  Antiplatelet                      51 (2.6)             173 (3.1)           
  Beta-blocker                      320 (16.1)           1025 (18.7)         
  Biguanide                         618 (31.0)           1976 (36.0)         
  Calcium channel blocker           181 (9.1)            693 (12.6)          
  Diuretic                          264 (13.2)           886 (16.1)          
  Ezetimibe                         14 (0.7)             37 (0.7)            
  Mineralocorticoid receptor antagonist 32 (1.6)             87 (1.6)            
  Other antihypertensive            90 (4.5)             303 (5.5)           
  RAAS inhibitor                    597 (30.0)           1900 (34.6)         
  Statin                            587 (29.5)           1819 (33.1)         
  Thiazolidinedione                 16 (0.8)             91 (1.7)            
  Insulin                           1335 (67.0)          3425 (62.3)         
  Sulfonylurea                      180 (9.0)            1031 (18.8)         
  DPP-4 inhibitor                   73 (3.7)             454 (8.3)           
  SGLT-2 inhibitor                  43 (2.2)             89 (1.6)            
  GLP-1 agonist                     145 (7.3)            105 (1.9)           
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 39, Comparator = 190
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SU_DPP4_ADRD.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Overweight, Obese III, Obese III, Obese I, Obese II, Obese I, Overweight, Obese II, Overweight, Obese III 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 575, Obese I = 2031, Obese II = 1532, Obese III = 1698, Overweight = 1621, Underweight = 30 
DEBUG: BMI level Normal - prop_treat: 0.0286001 , prop_comp: 0.09428467 
DEBUG: BMI level Normal - treat_data size: 1993 , comp_data size: 5494 
DEBUG: BMI level Normal - var_treat: 0.02778213 , var_comp: 0.08539507 , pooled_sd: 0.2378836 , level_smd: -0.2761207 
DEBUG: BMI level Obese I - prop_treat: 0.2513798 , prop_comp: 0.2784856 
DEBUG: BMI level Obese I - treat_data size: 1993 , comp_data size: 5494 
DEBUG: BMI level Obese I - var_treat: 0.188188 , var_comp: 0.2009314 , pooled_sd: 0.4410892 , level_smd: -0.06145195 
DEBUG: BMI level Obese II - prop_treat: 0.2438535 , prop_comp: 0.1903895 
DEBUG: BMI level Obese II - treat_data size: 1993 , comp_data size: 5494 
DEBUG: BMI level Obese II - var_treat: 0.184389 , var_comp: 0.1541413 , pooled_sd: 0.4114185 , level_smd: 0.1299503 
DEBUG: BMI level Obese III - prop_treat: 0.3286503 , prop_comp: 0.1898435 
DEBUG: BMI level Obese III - treat_data size: 1993 , comp_data size: 5494 
DEBUG: BMI level Obese III - var_treat: 0.2206393 , var_comp: 0.1538029 , pooled_sd: 0.4326905 , level_smd: 0.3207993 
DEBUG: BMI level Overweight - prop_treat: 0.1455093 , prop_comp: 0.2422643 
DEBUG: BMI level Overweight - treat_data size: 1993 , comp_data size: 5494 
DEBUG: BMI level Overweight - var_treat: 0.1243363 , var_comp: 0.1835723 , pooled_sd: 0.3923701 , level_smd: -0.2465912 
DEBUG: BMI level Underweight - prop_treat: 0.002007025 , prop_comp: 0.004732435 
DEBUG: BMI level Underweight - treat_data size: 1993 , comp_data size: 5494 
DEBUG: BMI level Underweight - var_treat: 0.002002996 , var_comp: 0.004710039 , pooled_sd: 0.05793546 , level_smd: -0.04704219 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SU_DPP4_ADRD.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2018 = -0.804
    index_year: Overall (max from level: 2018) = -0.804
    index_year: Year 2021 = 0.775
    baseline_bmi = 0.438
    bmi_category: Obese III = 0.321
    bmi_category: Overall (max from level: Obese III) = 0.321
    education: Less than high school = -0.281
    education: Overall (max from level: 0) = -0.281
    bmi_category: Normal = -0.276
    bmi_category: Overweight = -0.247
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Overweight, Obese III, Obese III, Obese I, Obese II, Obese I, Overweight, Obese II, Overweight, Obese III 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 575, Obese I = 2031, Obese II = 1532, Obese III = 1698, Overweight = 1621, Underweight = 30 
DEBUG: BMI level Normal - var_treat: 0.03638106 , var_comp: 0.07647918 , pooled_sd: 0.2375503 , level_smd: -0.1920898 
DEBUG: BMI level Obese I - var_treat: 0.2047912 , var_comp: 0.1951161 , pooled_sd: 0.4471618 , level_smd: 0.04841553 
DEBUG: BMI level Obese II - var_treat: 0.1872456 , var_comp: 0.1573443 , pooled_sd: 0.4150843 , level_smd: 0.1298188 
DEBUG: BMI level Obese III - var_treat: 0.1835371 , var_comp: 0.1789263 , pooled_sd: 0.4257131 , level_smd: 0.02065359 
DEBUG: BMI level Overweight - var_treat: 0.1471905 , var_comp: 0.1704113 , pooled_sd: 0.3984983 , level_smd: -0.09667452 
DEBUG: BMI level Underweight - var_treat: 0.003750169 , var_comp: 0.003921032 , pooled_sd: 0.06193223 , level_smd: -0.002780279 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SU_DPP4_ADRD.csv 
  Top 10 largest absolute SMDs (after IPTW):
    education: Less than high school = -0.264
    education: Overall (max from level: 0) = -0.264
    raceethnicity_cat: Non-Hispanic White = 0.219
    raceethnicity_cat: Overall (max from level: 0) = 0.219
    income: >$200k = 0.198
    income: Overall (max from level: 8) = 0.198
    bmi_category: Normal = -0.192
    bmi_category: Overall (max from level: Normal) = -0.192
    income: <$10k = -0.192
    education: Advanced degree = 0.182
  Balance improvement summary:
    - Total variables/levels: 52/69 improved (75.4%)
    - Individual multilevel categories: 23/34 improved (67.6%)
    - Largest remaining |SMD| (any level): 0.264
    - Individual levels with |SMD| > 0.1: 17

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - ADRD 
================================================================================ 
Characteristic                      Treatment (eff_n=3508) Comparator (eff_n=3979)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 62.4 (11.7)          62.9 (12.1)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1525 (43.5)          1764 (44.3)         
  Female , n (%)                    1931 (55.1)          2167 (54.5)         
  Not specified/Other , n (%)       52 (1.5)             49 (1.2)            
  BMI (kg/m2), mean (SD)            35.8 (7.7)           35.1 (8.9)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 70.8, Comparator = 126.4
================================================================================ 

✓ Found cohort file: ipwt_cohort_GLP1_vs_SU_DPP4_stroke.csv 
  Cohort size: 7082 patients
  Treatment distribution: 0 = 5194, 1 = 1888 
  Event distribution: 0 = 6786, 1 = 296 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - Stroke 
================================================================================ 
Characteristic                      Treatment (n=1888) Comparator (n=5194)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 61.4 (12.0)          63.2 (11.9)         
  Sex, n (%):
    Male                            783 (41.5)           2394 (46.1)         
    Female                          1087 (57.6)          2736 (52.7)         
    Not specified/Other             18 (1.0)             64 (1.2)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              1086 (57.5)          2338 (45.0)         
    Non-Hispanic Black              372 (19.7)           1227 (23.6)         
    Hispanic                        236 (12.5)           1084 (20.9)         
    Non-Hispanic Asian/Other        138 (7.3)            386 (7.4)           
    Unknown/Not specified           56 (3.0)             159 (3.1)           
  Income, n (%):
    <$10k                           181 (9.6)            805 (15.5)          
    $10k-25k                        275 (14.6)           894 (17.2)          
    $25k-35k                        154 (8.2)            444 (8.5)           
    $35k-50k                        189 (10.0)           454 (8.7)           
    $50k-75k                        260 (13.8)           486 (9.4)           
    $75k-100k                       172 (9.1)            338 (6.5)           
    $100k-150k                      198 (10.5)           375 (7.2)           
    $150k-200k                      73 (3.9)             133 (2.6)           
    >$200k                          88 (4.7)             116 (2.2)           
    Others/Not specified            298 (15.8)           1149 (22.1)         
  Education, n (%):
    Less than high school           103 (5.5)            728 (14.0)          
    High school/GED                 325 (17.2)           1172 (22.6)         
    Some college                    641 (34.0)           1602 (30.8)         
    College graduate                413 (21.9)           905 (17.4)          
    Advanced degree                 367 (19.4)           664 (12.8)          
    Not specified/Other             39 (2.1)             123 (2.4)           
  Calendar Year (Index Date), n (%):
    2018                            125 (6.6)            1960 (37.7)         
    2019                            394 (20.9)           1559 (30.0)         
    2020                            469 (24.8)           947 (18.2)          
    2021                            900 (47.7)           728 (14.0)          
  BMI (kg/m2), mean (SD)            37.7 (8.4)           33.9 (8.0)          
  BMI Category, n (%):
    Underweight                     3 (0.2)              24 (0.5)            
    Normal                          53 (2.8)             493 (9.5)           
    Overweight                      262 (13.9)           1247 (24.0)         
    Obese I                         464 (24.6)           1441 (27.7)         
    Obese II                        474 (25.1)           991 (19.1)          
    Obese III                       632 (33.5)           998 (19.2)          

COMORBIDITIES, n (%):
  Myocardial infarction             225 (11.9)           679 (13.1)          
  Congestive heart failure          408 (21.6)           1221 (23.5)         
  Peripheral vascular disease       399 (21.1)           1210 (23.3)         
  Cerebrovascular disease           185 (9.8)            667 (12.8)          
  Dementia                          21 (1.1)             49 (0.9)            
  Chronic pulmonary disease         801 (42.4)           2008 (38.7)         
  Connective tissue disease         189 (10.0)           415 (8.0)           
  Peptic ulcer disease              125 (6.6)            382 (7.4)           
  Mild liver disease                600 (31.8)           1560 (30.0)         
  Paraplegia and hemiplegia         28 (1.5)             79 (1.5)            
  Renal disease                     524 (27.8)           1632 (31.4)         
  Cancer                            340 (18.0)           957 (18.4)          
  Moderate/severe liver disease     56 (3.0)             172 (3.3)           
  Metastatic cancer                 26 (1.4)             140 (2.7)           
  HIV/AIDS                          36 (1.9)             102 (2.0)           

MEDICATIONS, n (%):
  Anticoagulant                     38 (2.0)             149 (2.9)           
  Antiplatelet                      42 (2.2)             141 (2.7)           
  Beta-blocker                      295 (15.6)           935 (18.0)          
  Biguanide                         616 (32.6)           1910 (36.8)         
  Calcium channel blocker           167 (8.8)            622 (12.0)          
  Diuretic                          252 (13.3)           821 (15.8)          
  Ezetimibe                         11 (0.6)             33 (0.6)            
  Mineralocorticoid receptor antagonist 32 (1.7)             81 (1.6)            
  Other antihypertensive            82 (4.3)             277 (5.3)           
  RAAS inhibitor                    575 (30.5)           1813 (34.9)         
  Statin                            547 (29.0)           1713 (33.0)         
  Thiazolidinedione                 15 (0.8)             91 (1.8)            
  Insulin                           1246 (66.0)          3210 (61.8)         
  Sulfonylurea                      168 (8.9)            1004 (19.3)         
  DPP-4 inhibitor                   66 (3.5)             439 (8.5)           
  SGLT-2 inhibitor                  40 (2.1)             87 (1.7)            
  GLP-1 agonist                     142 (7.5)            103 (2.0)           
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 54, Comparator = 242
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_GLP1_vs_SU_DPP4_stroke.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Overweight, Obese III, Obese III, Obese I, Obese II, Obese I, Overweight, Obese II, Overweight, Obese III 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 546, Obese I = 1905, Obese II = 1465, Obese III = 1630, Overweight = 1509, Underweight = 27 
DEBUG: BMI level Normal - prop_treat: 0.02807203 , prop_comp: 0.09491721 
DEBUG: BMI level Normal - treat_data size: 1888 , comp_data size: 5194 
DEBUG: BMI level Normal - var_treat: 0.02728399 , var_comp: 0.08590794 , pooled_sd: 0.2378991 , level_smd: -0.2809813 
DEBUG: BMI level Obese I - prop_treat: 0.2457627 , prop_comp: 0.2774355 
DEBUG: BMI level Obese I - treat_data size: 1888 , comp_data size: 5194 
DEBUG: BMI level Obese I - var_treat: 0.1853634 , var_comp: 0.200465 , pooled_sd: 0.43922 , level_smd: -0.07211145 
DEBUG: BMI level Obese II - prop_treat: 0.2510593 , prop_comp: 0.1907971 
DEBUG: BMI level Obese II - treat_data size: 1888 , comp_data size: 5194 
DEBUG: BMI level Obese II - var_treat: 0.1880285 , var_comp: 0.1543936 , pooled_sd: 0.4137766 , level_smd: 0.1456396 
DEBUG: BMI level Obese III - prop_treat: 0.3347458 , prop_comp: 0.1921448 
DEBUG: BMI level Obese III - treat_data size: 1888 , comp_data size: 5194 
DEBUG: BMI level Obese III - var_treat: 0.222691 , var_comp: 0.1552252 , pooled_sd: 0.4346931 , level_smd: 0.3280498 
DEBUG: BMI level Overweight - prop_treat: 0.1387712 , prop_comp: 0.2400847 
DEBUG: BMI level Overweight - treat_data size: 1888 , comp_data size: 5194 
DEBUG: BMI level Overweight - var_treat: 0.1195137 , var_comp: 0.182444 , pooled_sd: 0.38856 , level_smd: -0.260741 
DEBUG: BMI level Underweight - prop_treat: 0.001588983 , prop_comp: 0.004620716 
DEBUG: BMI level Underweight - treat_data size: 1888 , comp_data size: 5194 
DEBUG: BMI level Underweight - var_treat: 0.001586458 , var_comp: 0.004599365 , pooled_sd: 0.05561395 , level_smd: -0.0545139 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_GLP1_vs_SU_DPP4_stroke.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2018 = -0.808
    index_year: Overall (max from level: 2018) = -0.808
    index_year: Year 2021 = 0.782
    baseline_bmi = 0.458
    bmi_category: Obese III = 0.328
    bmi_category: Overall (max from level: Obese III) = 0.328
    education: Less than high school = -0.292
    education: Overall (max from level: 0) = -0.292
    bmi_category: Normal = -0.281
    baseline_hba1c = -0.265
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Overweight, Obese III, Obese III, Obese I, Obese II, Obese I, Overweight, Obese II, Overweight, Obese III 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 546, Obese I = 1905, Obese II = 1465, Obese III = 1630, Overweight = 1509, Underweight = 27 
DEBUG: BMI level Normal - var_treat: 0.03638879 , var_comp: 0.0768641 , pooled_sd: 0.2379631 , level_smd: -0.1936641 
DEBUG: BMI level Obese I - var_treat: 0.2038532 , var_comp: 0.1944328 , pooled_sd: 0.4462544 , level_smd: 0.0468542 
DEBUG: BMI level Obese II - var_treat: 0.1899334 , var_comp: 0.1572843 , pooled_sd: 0.416664 , level_smd: 0.1425791 
DEBUG: BMI level Obese III - var_treat: 0.1830252 , var_comp: 0.1811029 , pooled_sd: 0.4266896 , level_smd: 0.008642429 
DEBUG: BMI level Overweight - var_treat: 0.1458693 , var_comp: 0.1687868 , pooled_sd: 0.396646 , level_smd: -0.09508107 
DEBUG: BMI level Underweight - var_treat: 0.003558983 , var_comp: 0.003763147 , pooled_sd: 0.06050674 , level_smd: -0.003399209 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_GLP1_vs_SU_DPP4_stroke.csv 
  Top 10 largest absolute SMDs (after IPTW):
    education: Less than high school = -0.274
    education: Overall (max from level: 0) = -0.274
    raceethnicity_cat: Non-Hispanic White = 0.229
    raceethnicity_cat: Overall (max from level: 0) = 0.229
    income: >$200k = 0.209
    income: Overall (max from level: 8) = 0.209
    education: Advanced degree = 0.194
    income: <$10k = -0.194
    bmi_category: Normal = -0.194
    bmi_category: Overall (max from level: Normal) = -0.194
  Balance improvement summary:
    - Total variables/levels: 56/69 improved (81.2%)
    - Individual multilevel categories: 25/34 improved (73.5%)
    - Largest remaining |SMD| (any level): 0.274
    - Individual levels with |SMD| > 0.1: 18

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: GLP1 vs SU DPP4 - Stroke 
================================================================================ 
Characteristic                      Treatment (eff_n=3328) Comparator (eff_n=3754)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 62.3 (11.7)          62.7 (12.1)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1465 (44.0)          1661 (44.3)         
  Female , n (%)                    1816 (54.6)          2049 (54.6)         
  Not specified/Other , n (%)       47 (1.4)             44 (1.2)            
  BMI (kg/m2), mean (SD)            35.8 (7.6)           35.2 (9.0)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 116.8, Comparator = 160.0
================================================================================ 

 -------------------------------------------------------------------------------- 
COMPARISON: SGLT2 vs SU DPP4 
-------------------------------------------------------------------------------- 

✓ Found cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
  Cohort size: 7717 patients
  Treatment distribution: 0 = 4497, 1 = 3220 
  Event distribution: 0 = 7552, 1 = 165 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (n=3220) Comparator (n=4497)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 64.6 (11.3)          63.5 (12.2)         
  Sex, n (%):
    Male                            1725 (53.6)          2035 (45.3)         
    Female                          1452 (45.1)          2403 (53.4)         
    Not specified/Other             43 (1.3)             59 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              1627 (50.5)          2016 (44.8)         
    Non-Hispanic Black              641 (19.9)           1110 (24.7)         
    Hispanic                        601 (18.7)           914 (20.3)          
    Non-Hispanic Asian/Other        233 (7.2)            331 (7.4)           
    Unknown/Not specified           118 (3.7)            126 (2.8)           
  Income, n (%):
    <$10k                           358 (11.1)           705 (15.7)          
    $10k-25k                        492 (15.3)           766 (17.0)          
    $25k-35k                        256 (8.0)            383 (8.5)           
    $35k-50k                        296 (9.2)            400 (8.9)           
    $50k-75k                        409 (12.7)           442 (9.8)           
    $75k-100k                       253 (7.9)            282 (6.3)           
    $100k-150k                      272 (8.4)            301 (6.7)           
    $150k-200k                      101 (3.1)            117 (2.6)           
    >$200k                          117 (3.6)            99 (2.2)            
    Others/Not specified            666 (20.7)           1002 (22.3)         
  Education, n (%):
    Less than high school           353 (11.0)           614 (13.7)          
    High school/GED                 671 (20.8)           1014 (22.5)         
    Some college                    989 (30.7)           1415 (31.5)         
    College graduate                643 (20.0)           804 (17.9)          
    Advanced degree                 489 (15.2)           548 (12.2)          
    Not specified/Other             75 (2.3)             102 (2.3)           
  Calendar Year (Index Date), n (%):
    2018                            528 (16.4)           1646 (36.6)         
    2019                            727 (22.6)           1359 (30.2)         
    2020                            833 (25.9)           820 (18.2)          
    2021                            1132 (35.2)          672 (14.9)          
  BMI (kg/m2), mean (SD)            34.9 (7.7)           33.9 (8.0)          
  BMI Category, n (%):
    Underweight                     13 (0.4)             22 (0.5)            
    Normal                          189 (5.9)            419 (9.3)           
    Overweight                      682 (21.2)           1072 (23.8)         
    Obese I                         896 (27.8)           1252 (27.8)         
    Obese II                        740 (23.0)           867 (19.3)          
    Obese III                       700 (21.7)           865 (19.2)          

COMORBIDITIES, n (%):
  Myocardial infarction             651 (20.2)           601 (13.4)          
  Congestive heart failure          1055 (32.8)          1066 (23.7)         
  Peripheral vascular disease       931 (28.9)           1106 (24.6)         
  Cerebrovascular disease           657 (20.4)           825 (18.3)          
  Dementia                          33 (1.0)             56 (1.2)            
  Chronic pulmonary disease         1384 (43.0)          1740 (38.7)         
  Connective tissue disease         280 (8.7)            362 (8.0)           
  Peptic ulcer disease              258 (8.0)            310 (6.9)           
  Mild liver disease                1093 (33.9)          1317 (29.3)         
  Paraplegia and hemiplegia         83 (2.6)             75 (1.7)            
  Renal disease                     1182 (36.7)          1464 (32.6)         
  Cancer                            711 (22.1)           842 (18.7)          
  Moderate/severe liver disease     123 (3.8)            153 (3.4)           
  Metastatic cancer                 71 (2.2)             129 (2.9)           
  HIV/AIDS                          68 (2.1)             79 (1.8)            

MEDICATIONS, n (%):
  Anticoagulant                     102 (3.2)            126 (2.8)           
  Antiplatelet                      112 (3.5)            141 (3.1)           
  Beta-blocker                      653 (20.3)           828 (18.4)          
  Biguanide                         1088 (33.8)          1623 (36.1)         
  Calcium channel blocker           368 (11.4)           584 (13.0)          
  Diuretic                          533 (16.6)           730 (16.2)          
  Ezetimibe                         28 (0.9)             28 (0.6)            
  Mineralocorticoid receptor antagonist 63 (2.0)             68 (1.5)            
  Other antihypertensive            128 (4.0)            259 (5.8)           
  RAAS inhibitor                    1151 (35.7)          1551 (34.5)         
  Statin                            1153 (35.8)          1478 (32.9)         
  Thiazolidinedione                 47 (1.5)             76 (1.7)            
  Insulin                           2303 (71.5)          2789 (62.0)         
  Sulfonylurea                      372 (11.6)           878 (19.5)          
  DPP-4 inhibitor                   116 (3.6)            380 (8.5)           
  SGLT-2 inhibitor                  176 (5.5)            32 (0.7)            
  GLP-1 agonist                     129 (4.0)            80 (1.8)            
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 58, Comparator = 107
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese II, Obese I, Overweight, Obese II, Overweight, Overweight, Normal, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 608, Obese I = 2148, Obese II = 1607, Obese III = 1565, Overweight = 1754, Underweight = 35 
DEBUG: BMI level Normal - prop_treat: 0.05869565 , prop_comp: 0.09317323 
DEBUG: BMI level Normal - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Normal - var_treat: 0.05525047 , var_comp: 0.08449198 , pooled_sd: 0.2643317 , level_smd: -0.130433 
DEBUG: BMI level Obese I - prop_treat: 0.2782609 , prop_comp: 0.2784078 
DEBUG: BMI level Obese I - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Obese I - var_treat: 0.2008318 , var_comp: 0.2008969 , pooled_sd: 0.4481789 , level_smd: -0.0003279 
DEBUG: BMI level Obese II - prop_treat: 0.2298137 , prop_comp: 0.1927952 
DEBUG: BMI level Obese II - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Obese II - var_treat: 0.1769993 , var_comp: 0.1556252 , pooled_sd: 0.407814 , level_smd: 0.09077292 
DEBUG: BMI level Obese III - prop_treat: 0.2173913 , prop_comp: 0.1923505 
DEBUG: BMI level Obese III - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Obese III - var_treat: 0.1701323 , var_comp: 0.1553518 , pooled_sd: 0.403413 , level_smd: 0.06207249 
DEBUG: BMI level Overweight - prop_treat: 0.2118012 , prop_comp: 0.2383811 
DEBUG: BMI level Overweight - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Overweight - var_treat: 0.1669415 , var_comp: 0.1815556 , pooled_sd: 0.4174309 , level_smd: -0.06367498 
DEBUG: BMI level Underweight - prop_treat: 0.004037267 , prop_comp: 0.00489215 
DEBUG: BMI level Underweight - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Underweight - var_treat: 0.004020968 , var_comp: 0.004868217 , pooled_sd: 0.06666778 , level_smd: -0.01282304 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2021 = 0.480
    index_year: Overall (max from level: 2021) = 0.480
    index_year: Year 2018 = -0.470
    Insulin: 1 = 0.203
    chf: 1 = 0.202
    index_year: Year 2020 = 0.185
    mi: 1 = 0.184
    index_year: Year 2019 = -0.174
    sex_cat: Female = -0.167
    sex_cat: Overall (max from level: 1) = -0.167
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese II, Obese I, Overweight, Obese II, Overweight, Overweight, Normal, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 608, Obese I = 2148, Obese II = 1607, Obese III = 1565, Overweight = 1754, Underweight = 35 
DEBUG: BMI level Normal - var_treat: 0.05925478 , var_comp: 0.08155112 , pooled_sd: 0.2653355 , level_smd: -0.09919001 
DEBUG: BMI level Obese I - var_treat: 0.2054644 , var_comp: 0.1990272 , pooled_sd: 0.4497175 , level_smd: 0.03276902 
DEBUG: BMI level Obese II - var_treat: 0.1721647 , var_comp: 0.1590559 , pooled_sd: 0.4069525 , level_smd: 0.05548449 
DEBUG: BMI level Obese III - var_treat: 0.1589809 , var_comp: 0.1649009 , pooled_sd: 0.4024188 , level_smd: -0.02479072 
DEBUG: BMI level Overweight - var_treat: 0.1741379 , var_comp: 0.1744682 , pooled_sd: 0.4174962 , level_smd: -0.001437576 
DEBUG: BMI level Underweight - var_treat: 0.0038777 , var_comp: 0.004295525 , pooled_sd: 0.06392662 , level_smd: -0.006590098 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_SGLT2_vs_SU_DPP4_Epilepsy_Seizure.csv 
  Top 10 largest absolute SMDs (after IPTW):
    sex_cat: Female = -0.149
    sex_cat: Overall (max from level: 1) = -0.149
    sex_cat: Male = 0.147
    income: <$10k = -0.133
    income: Overall (max from level: 0) = -0.133
    income: >$200k = 0.120
    bmi_category: Normal = -0.099
    bmi_category: Overall (max from level: Normal) = -0.099
    education: Advanced degree = 0.096
    education: Overall (max from level: 4) = 0.096
  Balance improvement summary:
    - Total variables/levels: 59/71 improved (83.1%)
    - Individual multilevel categories: 23/34 improved (67.6%)
    - Largest remaining |SMD| (any level): 0.149
    - Individual levels with |SMD| > 0.1: 6

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (eff_n=3853) Comparator (eff_n=3864)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 63.8 (11.5)          63.9 (12.1)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      2007 (52.1)          1731 (44.8)         
  Female , n (%)                    1792 (46.5)          2085 (53.9)         
  Not specified/Other , n (%)       53 (1.4)             49 (1.3)            
  BMI (kg/m2), mean (SD)            34.5 (7.5)           34.4 (8.3)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 73.0, Comparator = 89.0
================================================================================ 

✓ Found cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
  Cohort size: 7717 patients
  Treatment distribution: 0 = 4497, 1 = 3220 
  Event distribution: 0 = 7697, 1 = 20 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - Early-onset/Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (n=3220) Comparator (n=4497)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 64.6 (11.3)          63.5 (12.2)         
  Sex, n (%):
    Male                            1725 (53.6)          2035 (45.3)         
    Female                          1452 (45.1)          2403 (53.4)         
    Not specified/Other             43 (1.3)             59 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              1627 (50.5)          2016 (44.8)         
    Non-Hispanic Black              641 (19.9)           1110 (24.7)         
    Hispanic                        601 (18.7)           914 (20.3)          
    Non-Hispanic Asian/Other        233 (7.2)            331 (7.4)           
    Unknown/Not specified           118 (3.7)            126 (2.8)           
  Income, n (%):
    <$10k                           358 (11.1)           705 (15.7)          
    $10k-25k                        492 (15.3)           766 (17.0)          
    $25k-35k                        256 (8.0)            383 (8.5)           
    $35k-50k                        296 (9.2)            400 (8.9)           
    $50k-75k                        409 (12.7)           442 (9.8)           
    $75k-100k                       253 (7.9)            282 (6.3)           
    $100k-150k                      272 (8.4)            301 (6.7)           
    $150k-200k                      101 (3.1)            117 (2.6)           
    >$200k                          117 (3.6)            99 (2.2)            
    Others/Not specified            666 (20.7)           1002 (22.3)         
  Education, n (%):
    Less than high school           353 (11.0)           614 (13.7)          
    High school/GED                 671 (20.8)           1014 (22.5)         
    Some college                    989 (30.7)           1415 (31.5)         
    College graduate                643 (20.0)           804 (17.9)          
    Advanced degree                 489 (15.2)           548 (12.2)          
    Not specified/Other             75 (2.3)             102 (2.3)           
  Calendar Year (Index Date), n (%):
    2018                            528 (16.4)           1646 (36.6)         
    2019                            727 (22.6)           1359 (30.2)         
    2020                            833 (25.9)           820 (18.2)          
    2021                            1132 (35.2)          672 (14.9)          
  BMI (kg/m2), mean (SD)            34.9 (7.7)           33.9 (8.0)          
  BMI Category, n (%):
    Underweight                     13 (0.4)             22 (0.5)            
    Normal                          189 (5.9)            419 (9.3)           
    Overweight                      682 (21.2)           1072 (23.8)         
    Obese I                         896 (27.8)           1252 (27.8)         
    Obese II                        740 (23.0)           867 (19.3)          
    Obese III                       700 (21.7)           865 (19.2)          

COMORBIDITIES, n (%):
  Myocardial infarction             651 (20.2)           601 (13.4)          
  Congestive heart failure          1055 (32.8)          1066 (23.7)         
  Peripheral vascular disease       931 (28.9)           1106 (24.6)         
  Cerebrovascular disease           657 (20.4)           825 (18.3)          
  Dementia                          33 (1.0)             56 (1.2)            
  Chronic pulmonary disease         1384 (43.0)          1740 (38.7)         
  Connective tissue disease         280 (8.7)            362 (8.0)           
  Peptic ulcer disease              258 (8.0)            310 (6.9)           
  Mild liver disease                1093 (33.9)          1317 (29.3)         
  Paraplegia and hemiplegia         83 (2.6)             75 (1.7)            
  Renal disease                     1182 (36.7)          1464 (32.6)         
  Cancer                            711 (22.1)           842 (18.7)          
  Moderate/severe liver disease     123 (3.8)            153 (3.4)           
  Metastatic cancer                 71 (2.2)             129 (2.9)           
  HIV/AIDS                          68 (2.1)             79 (1.8)            

MEDICATIONS, n (%):
  Anticoagulant                     102 (3.2)            126 (2.8)           
  Antiplatelet                      112 (3.5)            141 (3.1)           
  Beta-blocker                      653 (20.3)           828 (18.4)          
  Biguanide                         1088 (33.8)          1623 (36.1)         
  Calcium channel blocker           368 (11.4)           584 (13.0)          
  Diuretic                          533 (16.6)           730 (16.2)          
  Ezetimibe                         28 (0.9)             28 (0.6)            
  Mineralocorticoid receptor antagonist 63 (2.0)             68 (1.5)            
  Other antihypertensive            128 (4.0)            259 (5.8)           
  RAAS inhibitor                    1151 (35.7)          1551 (34.5)         
  Statin                            1153 (35.8)          1478 (32.9)         
  Thiazolidinedione                 47 (1.5)             76 (1.7)            
  Insulin                           2303 (71.5)          2789 (62.0)         
  Sulfonylurea                      372 (11.6)           878 (19.5)          
  DPP-4 inhibitor                   116 (3.6)            380 (8.5)           
  SGLT-2 inhibitor                  176 (5.5)            32 (0.7)            
  GLP-1 agonist                     129 (4.0)            80 (1.8)            
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 7, Comparator = 13
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese II, Obese I, Overweight, Obese II, Overweight, Overweight, Normal, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 608, Obese I = 2148, Obese II = 1607, Obese III = 1565, Overweight = 1754, Underweight = 35 
DEBUG: BMI level Normal - prop_treat: 0.05869565 , prop_comp: 0.09317323 
DEBUG: BMI level Normal - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Normal - var_treat: 0.05525047 , var_comp: 0.08449198 , pooled_sd: 0.2643317 , level_smd: -0.130433 
DEBUG: BMI level Obese I - prop_treat: 0.2782609 , prop_comp: 0.2784078 
DEBUG: BMI level Obese I - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Obese I - var_treat: 0.2008318 , var_comp: 0.2008969 , pooled_sd: 0.4481789 , level_smd: -0.0003279 
DEBUG: BMI level Obese II - prop_treat: 0.2298137 , prop_comp: 0.1927952 
DEBUG: BMI level Obese II - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Obese II - var_treat: 0.1769993 , var_comp: 0.1556252 , pooled_sd: 0.407814 , level_smd: 0.09077292 
DEBUG: BMI level Obese III - prop_treat: 0.2173913 , prop_comp: 0.1923505 
DEBUG: BMI level Obese III - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Obese III - var_treat: 0.1701323 , var_comp: 0.1553518 , pooled_sd: 0.403413 , level_smd: 0.06207249 
DEBUG: BMI level Overweight - prop_treat: 0.2118012 , prop_comp: 0.2383811 
DEBUG: BMI level Overweight - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Overweight - var_treat: 0.1669415 , var_comp: 0.1815556 , pooled_sd: 0.4174309 , level_smd: -0.06367498 
DEBUG: BMI level Underweight - prop_treat: 0.004037267 , prop_comp: 0.00489215 
DEBUG: BMI level Underweight - treat_data size: 3220 , comp_data size: 4497 
DEBUG: BMI level Underweight - var_treat: 0.004020968 , var_comp: 0.004868217 , pooled_sd: 0.06666778 , level_smd: -0.01282304 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2021 = 0.480
    index_year: Overall (max from level: 2021) = 0.480
    index_year: Year 2018 = -0.470
    Insulin: 1 = 0.203
    chf: 1 = 0.202
    index_year: Year 2020 = 0.185
    mi: 1 = 0.184
    index_year: Year 2019 = -0.174
    sex_cat: Female = -0.167
    sex_cat: Overall (max from level: 1) = -0.167
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese II, Obese I, Overweight, Obese II, Overweight, Overweight, Normal, Obese I 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 608, Obese I = 2148, Obese II = 1607, Obese III = 1565, Overweight = 1754, Underweight = 35 
DEBUG: BMI level Normal - var_treat: 0.05925478 , var_comp: 0.08155112 , pooled_sd: 0.2653355 , level_smd: -0.09919001 
DEBUG: BMI level Obese I - var_treat: 0.2054644 , var_comp: 0.1990272 , pooled_sd: 0.4497175 , level_smd: 0.03276902 
DEBUG: BMI level Obese II - var_treat: 0.1721647 , var_comp: 0.1590559 , pooled_sd: 0.4069525 , level_smd: 0.05548449 
DEBUG: BMI level Obese III - var_treat: 0.1589809 , var_comp: 0.1649009 , pooled_sd: 0.4024188 , level_smd: -0.02479072 
DEBUG: BMI level Overweight - var_treat: 0.1741379 , var_comp: 0.1744682 , pooled_sd: 0.4174962 , level_smd: -0.001437576 
DEBUG: BMI level Underweight - var_treat: 0.0038777 , var_comp: 0.004295525 , pooled_sd: 0.06392662 , level_smd: -0.006590098 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_SGLT2_vs_SU_DPP4_Early-onset_Epilepsy_Seizure.csv 
  Top 10 largest absolute SMDs (after IPTW):
    sex_cat: Female = -0.149
    sex_cat: Overall (max from level: 1) = -0.149
    sex_cat: Male = 0.147
    income: <$10k = -0.133
    income: Overall (max from level: 0) = -0.133
    income: >$200k = 0.120
    bmi_category: Normal = -0.099
    bmi_category: Overall (max from level: Normal) = -0.099
    education: Advanced degree = 0.096
    education: Overall (max from level: 4) = 0.096
  Balance improvement summary:
    - Total variables/levels: 59/71 improved (83.1%)
    - Individual multilevel categories: 23/34 improved (67.6%)
    - Largest remaining |SMD| (any level): 0.149
    - Individual levels with |SMD| > 0.1: 6

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - Early-onset/Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (eff_n=3853) Comparator (eff_n=3864)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 63.8 (11.5)          63.9 (12.1)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      2007 (52.1)          1731 (44.8)         
  Female , n (%)                    1792 (46.5)          2085 (53.9)         
  Not specified/Other , n (%)       53 (1.4)             49 (1.3)            
  BMI (kg/m2), mean (SD)            34.5 (7.5)           34.4 (8.3)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 10.0, Comparator = 9.9
================================================================================ 

✓ Found cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
  Cohort size: 6823 patients
  Treatment distribution: 0 = 3934, 1 = 2889 
  Event distribution: 0 = 6681, 1 = 142 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - Late-onset Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (n=2889) Comparator (n=3934)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 67.1 (8.7)           66.6 (9.3)          
  Sex, n (%):
    Male                            1600 (55.4)          1839 (46.7)         
    Female                          1249 (43.2)          2042 (51.9)         
    Not specified/Other             40 (1.4)             53 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              1508 (52.2)          1823 (46.3)         
    Non-Hispanic Black              573 (19.8)           960 (24.4)          
    Hispanic                        507 (17.5)           755 (19.2)          
    Non-Hispanic Asian/Other        195 (6.7)            278 (7.1)           
    Unknown/Not specified           106 (3.7)            118 (3.0)           
  Income, n (%):
    <$10k                           302 (10.5)           589 (15.0)          
    $10k-25k                        445 (15.4)           679 (17.3)          
    $25k-35k                        222 (7.7)            325 (8.3)           
    $35k-50k                        265 (9.2)            335 (8.5)           
    $50k-75k                        365 (12.6)           386 (9.8)           
    $75k-100k                       231 (8.0)            254 (6.5)           
    $100k-150k                      243 (8.4)            284 (7.2)           
    $150k-200k                      95 (3.3)             101 (2.6)           
    >$200k                          106 (3.7)            90 (2.3)            
    Others/Not specified            615 (21.3)           891 (22.6)          
  Education, n (%):
    Less than high school           315 (10.9)           539 (13.7)          
    High school/GED                 605 (20.9)           877 (22.3)          
    Some college                    874 (30.3)           1226 (31.2)         
    College graduate                577 (20.0)           708 (18.0)          
    Advanced degree                 448 (15.5)           495 (12.6)          
    Not specified/Other             70 (2.4)             89 (2.3)            
  Calendar Year (Index Date), n (%):
    2018                            468 (16.2)           1475 (37.5)         
    2019                            661 (22.9)           1192 (30.3)         
    2020                            733 (25.4)           697 (17.7)          
    2021                            1027 (35.5)          570 (14.5)          
  BMI (kg/m2), mean (SD)            34.5 (7.4)           33.5 (7.5)          
  BMI Category, n (%):
    Underweight                     13 (0.4)             18 (0.5)            
    Normal                          172 (6.0)            381 (9.7)           
    Overweight                      640 (22.2)           975 (24.8)          
    Obese I                         833 (28.8)           1139 (29.0)         
    Obese II                        654 (22.6)           753 (19.1)          
    Obese III                       577 (20.0)           668 (17.0)          

COMORBIDITIES, n (%):
  Myocardial infarction             631 (21.8)           580 (14.7)          
  Congestive heart failure          996 (34.5)           1005 (25.5)         
  Peripheral vascular disease       902 (31.2)           1064 (27.0)         
  Cerebrovascular disease           631 (21.8)           774 (19.7)          
  Dementia                          33 (1.1)             55 (1.4)            
  Chronic pulmonary disease         1283 (44.4)          1574 (40.0)         
  Connective tissue disease         265 (9.2)            336 (8.5)           
  Peptic ulcer disease              245 (8.5)            289 (7.3)           
  Mild liver disease                969 (33.5)           1156 (29.4)         
  Paraplegia and hemiplegia         77 (2.7)             64 (1.6)            
  Renal disease                     1136 (39.3)          1387 (35.3)         
  Cancer                            690 (23.9)           809 (20.6)          
  Moderate/severe liver disease     120 (4.2)            148 (3.8)           
  Metastatic cancer                 68 (2.4)             127 (3.2)           
  HIV/AIDS                          60 (2.1)             74 (1.9)            

MEDICATIONS, n (%):
  Anticoagulant                     97 (3.4)             113 (2.9)           
  Antiplatelet                      109 (3.8)            137 (3.5)           
  Beta-blocker                      608 (21.0)           771 (19.6)          
  Biguanide                         955 (33.1)           1364 (34.7)         
  Calcium channel blocker           354 (12.3)           524 (13.3)          
  Diuretic                          492 (17.0)           677 (17.2)          
  Ezetimibe                         27 (0.9)             28 (0.7)            
  Mineralocorticoid receptor antagonist 55 (1.9)             61 (1.6)            
  Other antihypertensive            111 (3.8)            226 (5.7)           
  RAAS inhibitor                    1073 (37.1)          1399 (35.6)         
  Statin                            1079 (37.3)          1361 (34.6)         
  Thiazolidinedione                 46 (1.6)             68 (1.7)            
  Insulin                           2069 (71.6)          2441 (62.0)         
  Sulfonylurea                      347 (12.0)           755 (19.2)          
  DPP-4 inhibitor                   108 (3.7)            341 (8.7)           
  SGLT-2 inhibitor                  146 (5.1)            28 (0.7)            
  GLP-1 agonist                     110 (3.8)            72 (1.8)            
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 50, Comparator = 92
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese II, Obese I, Obese II, Overweight, Overweight, Obese I, Obese III, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 553, Obese I = 1972, Obese II = 1407, Obese III = 1245, Overweight = 1615, Underweight = 31 
DEBUG: BMI level Normal - prop_treat: 0.05953617 , prop_comp: 0.09684799 
DEBUG: BMI level Normal - treat_data size: 2889 , comp_data size: 3934 
DEBUG: BMI level Normal - var_treat: 0.05599162 , var_comp: 0.08746846 , pooled_sd: 0.2678246 , level_smd: -0.1393144 
DEBUG: BMI level Obese I - prop_treat: 0.2883351 , prop_comp: 0.2895272 
DEBUG: BMI level Obese I - treat_data size: 2889 , comp_data size: 3934 
DEBUG: BMI level Obese I - var_treat: 0.205198 , var_comp: 0.2057012 , pooled_sd: 0.4532655 , level_smd: -0.002630103 
DEBUG: BMI level Obese II - prop_treat: 0.2263759 , prop_comp: 0.1914082 
DEBUG: BMI level Obese II - treat_data size: 2889 , comp_data size: 3934 
DEBUG: BMI level Obese II - var_treat: 0.1751299 , var_comp: 0.1547711 , pooled_sd: 0.406141 , level_smd: 0.08609738 
DEBUG: BMI level Obese III - prop_treat: 0.1997231 , prop_comp: 0.1698017 
DEBUG: BMI level Obese III - treat_data size: 2889 , comp_data size: 3934 
DEBUG: BMI level Obese III - var_treat: 0.1598338 , var_comp: 0.1409691 , pooled_sd: 0.3878162 , level_smd: 0.07715344 
DEBUG: BMI level Overweight - prop_treat: 0.2215299 , prop_comp: 0.2478393 
DEBUG: BMI level Overweight - treat_data size: 2889 , comp_data size: 3934 
DEBUG: BMI level Overweight - var_treat: 0.1724544 , var_comp: 0.186415 , pooled_sd: 0.4235974 , level_smd: -0.06210947 
DEBUG: BMI level Underweight - prop_treat: 0.004499827 , prop_comp: 0.004575496 
DEBUG: BMI level Underweight - treat_data size: 2889 , comp_data size: 3934 
DEBUG: BMI level Underweight - var_treat: 0.004479578 , var_comp: 0.004554561 , pooled_sd: 0.06720915 , level_smd: -0.00112587 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2021 = 0.501
    index_year: Overall (max from level: 2021) = 0.501
    index_year: Year 2018 = -0.495
    Insulin: 1 = 0.204
    chf: 1 = 0.196
    index_year: Year 2020 = 0.187
    mi: 1 = 0.184
    sex_cat: Female = -0.174
    sex_cat: Overall (max from level: 1) = -0.174
    sex_cat: Male = 0.173
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese II, Obese I, Obese II, Overweight, Overweight, Obese I, Obese III, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 553, Obese I = 1972, Obese II = 1407, Obese III = 1245, Overweight = 1615, Underweight = 31 
DEBUG: BMI level Normal - var_treat: 0.05925028 , var_comp: 0.08454573 , pooled_sd: 0.268138 , level_smd: -0.1118391 
DEBUG: BMI level Obese I - var_treat: 0.20983 , var_comp: 0.2038457 , pooled_sd: 0.4547943 , level_smd: 0.0316867 
DEBUG: BMI level Obese II - var_treat: 0.1695888 , var_comp: 0.1591292 , pooled_sd: 0.4054121 , level_smd: 0.04410109 
DEBUG: BMI level Obese III - var_treat: 0.1484614 , var_comp: 0.1506896 , pooled_sd: 0.3867499 , level_smd: -0.009090312 
DEBUG: BMI level Overweight - var_treat: 0.1797717 , var_comp: 0.1793571 , pooled_sd: 0.4237504 , level_smd: 0.001842863 
DEBUG: BMI level Underweight - var_treat: 0.004380541 , var_comp: 0.003951122 , pooled_sd: 0.06454325 , level_smd: 0.006709335 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_SGLT2_vs_SU_DPP4_Late-onset_Epilepsy_Seizure.csv 
  Top 10 largest absolute SMDs (after IPTW):
    sex_cat: Female = -0.157
    sex_cat: Overall (max from level: 1) = -0.157
    sex_cat: Male = 0.154
    income: <$10k = -0.135
    income: Overall (max from level: 0) = -0.135
    income: >$200k = 0.114
    bmi_category: Normal = -0.112
    bmi_category: Overall (max from level: Normal) = -0.112
    education: Advanced degree = 0.090
    education: Overall (max from level: 4) = 0.090
  Balance improvement summary:
    - Total variables/levels: 57/70 improved (81.4%)
    - Individual multilevel categories: 24/34 improved (70.6%)
    - Largest remaining |SMD| (any level): 0.157
    - Individual levels with |SMD| > 0.1: 8

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - Late-onset Epilepsy/Seizure 
================================================================================ 
Characteristic                      Treatment (eff_n=3409) Comparator (eff_n=3404)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 66.6 (8.7)           66.9 (9.3)          
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1839 (54.0)          1576 (46.3)         
  Female , n (%)                    1520 (44.6)          1785 (52.4)         
  Not specified/Other , n (%)       49 (1.4)             44 (1.3)            
  BMI (kg/m2), mean (SD)            34.1 (7.2)           33.9 (7.8)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 60.2, Comparator = 77.7
================================================================================ 

✓ Found cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_ADRD.csv 
  Cohort size: 7909 patients
  Treatment distribution: 0 = 4627, 1 = 3282 
  Event distribution: 0 = 7634, 1 = 275 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - ADRD 
================================================================================ 
Characteristic                      Treatment (n=3282) Comparator (n=4627)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 64.2 (11.4)          63.2 (12.2)         
  Sex, n (%):
    Male                            1740 (53.0)          2075 (44.8)         
    Female                          1502 (45.8)          2491 (53.8)         
    Not specified/Other             40 (1.2)             61 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              1663 (50.7)          2073 (44.8)         
    Non-Hispanic Black              659 (20.1)           1161 (25.1)         
    Hispanic                        611 (18.6)           918 (19.8)          
    Non-Hispanic Asian/Other        234 (7.1)            346 (7.5)           
    Unknown/Not specified           115 (3.5)            129 (2.8)           
  Income, n (%):
    <$10k                           371 (11.3)           736 (15.9)          
    $10k-25k                        508 (15.5)           798 (17.2)          
    $25k-35k                        261 (8.0)            388 (8.4)           
    $35k-50k                        299 (9.1)            408 (8.8)           
    $50k-75k                        404 (12.3)           452 (9.8)           
    $75k-100k                       255 (7.8)            285 (6.2)           
    $100k-150k                      276 (8.4)            302 (6.5)           
    $150k-200k                      101 (3.1)            120 (2.6)           
    >$200k                          114 (3.5)            104 (2.2)           
    Others/Not specified            693 (21.1)           1034 (22.3)         
  Education, n (%):
    Less than high school           369 (11.2)           627 (13.6)          
    High school/GED                 690 (21.0)           1062 (23.0)         
    Some college                    1009 (30.7)          1453 (31.4)         
    College graduate                644 (19.6)           826 (17.9)          
    Advanced degree                 490 (14.9)           558 (12.1)          
    Not specified/Other             80 (2.4)             101 (2.2)           
  Calendar Year (Index Date), n (%):
    2018                            545 (16.6)           1706 (36.9)         
    2019                            753 (22.9)           1384 (29.9)         
    2020                            829 (25.3)           855 (18.5)          
    2021                            1155 (35.2)          682 (14.7)          
  BMI (kg/m2), mean (SD)            34.9 (7.7)           34.1 (8.0)          
  BMI Category, n (%):
    Underweight                     13 (0.4)             23 (0.5)            
    Normal                          199 (6.1)            428 (9.3)           
    Overweight                      691 (21.1)           1089 (23.5)         
    Obese I                         910 (27.7)           1281 (27.7)         
    Obese II                        755 (23.0)           902 (19.5)          
    Obese III                       714 (21.8)           904 (19.5)          

COMORBIDITIES, n (%):
  Myocardial infarction             668 (20.4)           624 (13.5)          
  Congestive heart failure          1066 (32.5)          1104 (23.9)         
  Peripheral vascular disease       945 (28.8)           1146 (24.8)         
  Cerebrovascular disease           693 (21.1)           878 (19.0)          
  Dementia                          16 (0.5)             29 (0.6)            
  Chronic pulmonary disease         1419 (43.2)          1819 (39.3)         
  Connective tissue disease         283 (8.6)            376 (8.1)           
  Peptic ulcer disease              257 (7.8)            324 (7.0)           
  Mild liver disease                1128 (34.4)          1363 (29.5)         
  Paraplegia and hemiplegia         96 (2.9)             91 (2.0)            
  Renal disease                     1185 (36.1)          1503 (32.5)         
  Cancer                            716 (21.8)           858 (18.5)          
  Moderate/severe liver disease     115 (3.5)            156 (3.4)           
  Metastatic cancer                 71 (2.2)             131 (2.8)           
  HIV/AIDS                          71 (2.2)             83 (1.8)            

MEDICATIONS, n (%):
  Anticoagulant                     103 (3.1)            131 (2.8)           
  Antiplatelet                      111 (3.4)            143 (3.1)           
  Beta-blocker                      665 (20.3)           857 (18.5)          
  Biguanide                         1104 (33.6)          1652 (35.7)         
  Calcium channel blocker           367 (11.2)           602 (13.0)          
  Diuretic                          539 (16.4)           747 (16.1)          
  Ezetimibe                         30 (0.9)             29 (0.6)            
  Mineralocorticoid receptor antagonist 65 (2.0)             70 (1.5)            
  Other antihypertensive            137 (4.2)            272 (5.9)           
  RAAS inhibitor                    1159 (35.3)          1578 (34.1)         
  Statin                            1176 (35.8)          1511 (32.7)         
  Thiazolidinedione                 45 (1.4)             79 (1.7)            
  Insulin                           2358 (71.8)          2887 (62.4)         
  Sulfonylurea                      372 (11.3)           887 (19.2)          
  DPP-4 inhibitor                   117 (3.6)            387 (8.4)           
  SGLT-2 inhibitor                  178 (5.4)            32 (0.7)            
  GLP-1 agonist                     134 (4.1)            83 (1.8)            
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 116, Comparator = 159
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_SGLT2_vs_SU_DPP4_ADRD.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese I, Overweight, Obese II, Overweight, Normal, Obese I, Obese III, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 627, Obese I = 2191, Obese II = 1657, Obese III = 1618, Overweight = 1780, Underweight = 36 
DEBUG: BMI level Normal - prop_treat: 0.06063376 , prop_comp: 0.09250054 
DEBUG: BMI level Normal - treat_data size: 3282 , comp_data size: 4627 
DEBUG: BMI level Normal - var_treat: 0.05695731 , var_comp: 0.08394419 , pooled_sd: 0.2654256 , level_smd: -0.1200592 
DEBUG: BMI level Obese I - prop_treat: 0.27727 , prop_comp: 0.2768533 
DEBUG: BMI level Obese I - treat_data size: 3282 , comp_data size: 4627 
DEBUG: BMI level Obese I - var_treat: 0.2003913 , var_comp: 0.2002055 , pooled_sd: 0.4475471 , level_smd: 0.0009310856 
DEBUG: BMI level Obese II - prop_treat: 0.2300427 , prop_comp: 0.1949427 
DEBUG: BMI level Obese II - treat_data size: 3282 , comp_data size: 4627 
DEBUG: BMI level Obese II - var_treat: 0.177123 , var_comp: 0.1569401 , pooled_sd: 0.4086949 , level_smd: 0.08588296 
DEBUG: BMI level Obese III - prop_treat: 0.2175503 , prop_comp: 0.195375 
DEBUG: BMI level Obese III - treat_data size: 3282 , comp_data size: 4627 
DEBUG: BMI level Obese III - var_treat: 0.1702222 , var_comp: 0.1572036 , pooled_sd: 0.4046145 , level_smd: 0.054806 
DEBUG: BMI level Overweight - prop_treat: 0.2105424 , prop_comp: 0.2353577 
DEBUG: BMI level Overweight - treat_data size: 3282 , comp_data size: 4627 
DEBUG: BMI level Overweight - var_treat: 0.1662143 , var_comp: 0.1799644 , pooled_sd: 0.4160401 , level_smd: -0.05964649 
DEBUG: BMI level Underweight - prop_treat: 0.003960999 , prop_comp: 0.004970823 
DEBUG: BMI level Underweight - treat_data size: 3282 , comp_data size: 4627 
DEBUG: BMI level Underweight - var_treat: 0.00394531 , var_comp: 0.004946114 , pooled_sd: 0.06667617 , level_smd: -0.0151452 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_SGLT2_vs_SU_DPP4_ADRD.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2021 = 0.486
    index_year: Overall (max from level: 2021) = 0.486
    index_year: Year 2018 = -0.470
    Insulin: 1 = 0.202
    chf: 1 = 0.193
    mi: 1 = 0.184
    index_year: Year 2020 = 0.165
    sex_cat: Male = 0.164
    sex_cat: Overall (max from level: 0) = 0.164
    sex_cat: Female = -0.162
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese I, Overweight, Obese II, Overweight, Normal, Obese I, Obese III, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 627, Obese I = 2191, Obese II = 1657, Obese III = 1618, Overweight = 1780, Underweight = 36 
DEBUG: BMI level Normal - var_treat: 0.0612514 , var_comp: 0.08175815 , pooled_sd: 0.2674038 , level_smd: -0.09079572 
DEBUG: BMI level Obese I - var_treat: 0.2047938 , var_comp: 0.1990494 , pooled_sd: 0.4493569 , level_smd: 0.02916363 
DEBUG: BMI level Obese II - var_treat: 0.1727765 , var_comp: 0.1601095 , pooled_sd: 0.4079743 , level_smd: 0.05374448 
DEBUG: BMI level Obese III - var_treat: 0.1605123 , var_comp: 0.16475 , pooled_sd: 0.4032755 , level_smd: -0.01777669 
DEBUG: BMI level Overweight - var_treat: 0.17152 , var_comp: 0.1734247 , pooled_sd: 0.4152979 , level_smd: -0.008236106 
DEBUG: BMI level Underweight - var_treat: 0.004230502 , var_comp: 0.004391874 , pooled_sd: 0.06565964 , level_smd: -0.002479172 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_SGLT2_vs_SU_DPP4_ADRD.csv 
  Top 10 largest absolute SMDs (after IPTW):
    sex_cat: Female = -0.143
    sex_cat: Overall (max from level: 1) = -0.143
    income: <$10k = -0.143
    income: Overall (max from level: 0) = -0.143
    sex_cat: Male = 0.141
    income: >$200k = 0.109
    raceethnicity_cat: Non-Hispanic Black = -0.097
    raceethnicity_cat: Overall (max from level: 1) = -0.097
    education: Advanced degree = 0.094
    education: Overall (max from level: 4) = 0.094
  Balance improvement summary:
    - Total variables/levels: 57/70 improved (81.4%)
    - Individual multilevel categories: 25/34 improved (73.5%)
    - Largest remaining |SMD| (any level): 0.143
    - Individual levels with |SMD| > 0.1: 6

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - ADRD 
================================================================================ 
Characteristic                      Treatment (eff_n=3945) Comparator (eff_n=3964)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 63.5 (11.5)          63.6 (12.1)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      2028 (51.4)          1760 (44.4)         
  Female , n (%)                    1864 (47.2)          2156 (54.4)         
  Not specified/Other , n (%)       53 (1.3)             49 (1.2)            
  BMI (kg/m2), mean (SD)            34.5 (7.6)           34.4 (8.3)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 126.0, Comparator = 140.2
================================================================================ 

✓ Found cohort file: ipwt_cohort_SGLT2_vs_SU_DPP4_stroke.csv 
  Cohort size: 7426 patients
  Treatment distribution: 0 = 4387, 1 = 3039 
  Event distribution: 0 = 7110, 1 = 316 

 ================================================================================ 
UNWEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - Stroke 
================================================================================ 
Characteristic                      Treatment (n=3039) Comparator (n=4387)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS:
  Age, mean (SD), y                 63.9 (11.5)          62.9 (12.2)         
  Sex, n (%):
    Male                            1597 (52.6)          1978 (45.1)         
    Female                          1407 (46.3)          2351 (53.6)         
    Not specified/Other             35 (1.2)             58 (1.3)            
  Race/Ethnicity, n (%):
    Non-Hispanic White              1547 (50.9)          1968 (44.9)         
    Non-Hispanic Black              604 (19.9)           1090 (24.8)         
    Hispanic                        556 (18.3)           885 (20.2)          
    Non-Hispanic Asian/Other        224 (7.4)            325 (7.4)           
    Unknown/Not specified           108 (3.6)            119 (2.7)           
  Income, n (%):
    <$10k                           339 (11.2)           704 (16.0)          
    $10k-25k                        459 (15.1)           744 (17.0)          
    $25k-35k                        247 (8.1)            372 (8.5)           
    $35k-50k                        281 (9.2)            391 (8.9)           
    $50k-75k                        380 (12.5)           422 (9.6)           
    $75k-100k                       245 (8.1)            276 (6.3)           
    $100k-150k                      254 (8.4)            293 (6.7)           
    $150k-200k                      99 (3.3)             116 (2.6)           
    >$200k                          109 (3.6)            96 (2.2)            
    Others/Not specified            626 (20.6)           973 (22.2)          
  Education, n (%):
    Less than high school           331 (10.9)           594 (13.5)          
    High school/GED                 621 (20.4)           999 (22.8)          
    Some college                    952 (31.3)           1370 (31.2)         
    College graduate                605 (19.9)           790 (18.0)          
    Advanced degree                 457 (15.0)           530 (12.1)          
    Not specified/Other             73 (2.4)             104 (2.4)           
  Calendar Year (Index Date), n (%):
    2018                            508 (16.7)           1634 (37.2)         
    2019                            692 (22.8)           1313 (29.9)         
    2020                            773 (25.4)           802 (18.3)          
    2021                            1066 (35.1)          638 (14.5)          
  BMI (kg/m2), mean (SD)            35.1 (7.8)           34.1 (8.0)          
  BMI Category, n (%):
    Underweight                     14 (0.5)             22 (0.5)            
    Normal                          179 (5.9)            409 (9.3)           
    Overweight                      634 (20.9)           1028 (23.4)         
    Obese I                         822 (27.0)           1211 (27.6)         
    Obese II                        713 (23.5)           851 (19.4)          
    Obese III                       677 (22.3)           866 (19.7)          

COMORBIDITIES, n (%):
  Myocardial infarction             543 (17.9)           541 (12.3)          
  Congestive heart failure          922 (30.3)           1003 (22.9)         
  Peripheral vascular disease       807 (26.6)           1027 (23.4)         
  Cerebrovascular disease           389 (12.8)           573 (13.1)          
  Dementia                          26 (0.9)             47 (1.1)            
  Chronic pulmonary disease         1287 (42.3)          1701 (38.8)         
  Connective tissue disease         265 (8.7)            351 (8.0)           
  Peptic ulcer disease              225 (7.4)            308 (7.0)           
  Mild liver disease                1044 (34.4)          1298 (29.6)         
  Paraplegia and hemiplegia         45 (1.5)             67 (1.5)            
  Renal disease                     1056 (34.7)          1387 (31.6)         
  Cancer                            657 (21.6)           790 (18.0)          
  Moderate/severe liver disease     109 (3.6)            158 (3.6)           
  Metastatic cancer                 65 (2.1)             121 (2.8)           
  HIV/AIDS                          66 (2.2)             81 (1.8)            

MEDICATIONS, n (%):
  Anticoagulant                     85 (2.8)             117 (2.7)           
  Antiplatelet                      90 (3.0)             116 (2.6)           
  Beta-blocker                      590 (19.4)           786 (17.9)          
  Biguanide                         1035 (34.1)          1600 (36.5)         
  Calcium channel blocker           322 (10.6)           540 (12.3)          
  Diuretic                          508 (16.7)           694 (15.8)          
  Ezetimibe                         26 (0.9)             26 (0.6)            
  Mineralocorticoid receptor antagonist 60 (2.0)             66 (1.5)            
  Other antihypertensive            124 (4.1)            246 (5.6)           
  RAAS inhibitor                    1081 (35.6)          1506 (34.3)         
  Statin                            1073 (35.3)          1429 (32.6)         
  Thiazolidinedione                 43 (1.4)             79 (1.8)            
  Insulin                           2150 (70.7)          2714 (61.9)         
  Sulfonylurea                      348 (11.5)           867 (19.8)          
  DPP-4 inhibitor                   111 (3.7)            375 (8.5)           
  SGLT-2 inhibitor                  173 (5.7)            31 (0.7)            
  GLP-1 agonist                     125 (4.1)            80 (1.8)            
-------------------------------------------------------------------------------- 
TOTAL EVENTS: Treatment = 109, Comparator = 207
================================================================================ 
  ✓ Saved structured data to: unweighted_baseline_characteristics_SGLT2_vs_SU_DPP4_stroke.csv 

--- SMD CALCULATIONS (INDIVIDUAL LEVELS) ---
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese II, Obese I, Overweight, Obese II, Overweight, Normal, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 588, Obese I = 2033, Obese II = 1564, Obese III = 1543, Overweight = 1662, Underweight = 36 
DEBUG: BMI level Normal - prop_treat: 0.05890095 , prop_comp: 0.09323 
DEBUG: BMI level Normal - treat_data size: 3039 , comp_data size: 4387 
DEBUG: BMI level Normal - var_treat: 0.05543163 , var_comp: 0.08453817 , pooled_sd: 0.2645466 , level_smd: -0.1297656 
DEBUG: BMI level Obese I - prop_treat: 0.2704837 , prop_comp: 0.2760429 
DEBUG: BMI level Obese I - treat_data size: 3039 , comp_data size: 4387 
DEBUG: BMI level Obese I - var_treat: 0.1973223 , var_comp: 0.1998432 , pooled_sd: 0.4456262 , level_smd: -0.0124749 
DEBUG: BMI level Obese II - prop_treat: 0.2346167 , prop_comp: 0.1939822 
DEBUG: BMI level Obese II - treat_data size: 3039 , comp_data size: 4387 
DEBUG: BMI level Obese II - var_treat: 0.1795717 , var_comp: 0.1563531 , pooled_sd: 0.4098322 , level_smd: 0.09914895 
DEBUG: BMI level Obese III - prop_treat: 0.2227706 , prop_comp: 0.1974014 
DEBUG: BMI level Obese III - treat_data size: 3039 , comp_data size: 4387 
DEBUG: BMI level Obese III - var_treat: 0.1731439 , var_comp: 0.1584341 , pooled_sd: 0.4071719 , level_smd: 0.06230595 
DEBUG: BMI level Overweight - prop_treat: 0.2086213 , prop_comp: 0.2343287 
DEBUG: BMI level Overweight - treat_data size: 3039 , comp_data size: 4387 
DEBUG: BMI level Overweight - var_treat: 0.1650984 , var_comp: 0.1794188 , pooled_sd: 0.4150405 , level_smd: -0.0619396 
DEBUG: BMI level Underweight - prop_treat: 0.004606779 , prop_comp: 0.005014817 
DEBUG: BMI level Underweight - treat_data size: 3039 , comp_data size: 4387 
DEBUG: BMI level Underweight - var_treat: 0.004585556 , var_comp: 0.004989668 , pooled_sd: 0.06919257 , level_smd: -0.005897135 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD before IPTW saved to: smd_individual_before_iptw_SGLT2_vs_SU_DPP4_stroke.csv 
    - Binary/continuous variables: 32
    - Individual multilevel categories: 34
    - Overall multilevel summaries: 6
  Top 10 largest absolute SMDs (before IPTW):
    index_year: Year 2021 = 0.489
    index_year: Overall (max from level: 2021) = 0.489
    index_year: Year 2018 = -0.475
    Insulin: 1 = 0.189
    index_year: Year 2020 = 0.174
    chf: 1 = 0.170
    index_year: Year 2019 = -0.163
    mi: 1 = 0.155
    sex_cat: Male = 0.150
    sex_cat: Overall (max from level: 0) = 0.150
DEBUG: Excluding treatment-defining variables from SMD calculation: SGLT2, SU, DPP4 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese I, Obese III, Obese II, Obese I, Overweight, Obese II, Overweight, Normal, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 588, Obese I = 2033, Obese II = 1564, Obese III = 1543, Overweight = 1662, Underweight = 36 
DEBUG: BMI level Normal - var_treat: 0.06069779 , var_comp: 0.08230703 , pooled_sd: 0.2673993 , level_smd: -0.0956824 
DEBUG: BMI level Obese I - var_treat: 0.2029742 , var_comp: 0.1979315 , pooled_sd: 0.4477196 , level_smd: 0.02530846 
DEBUG: BMI level Obese II - var_treat: 0.1733618 , var_comp: 0.1591604 , pooled_sd: 0.4077513 , level_smd: 0.0602328 
DEBUG: BMI level Obese III - var_treat: 0.1623806 , var_comp: 0.1677602 , pooled_sd: 0.4062885 , level_smd: -0.02272009 
DEBUG: BMI level Overweight - var_treat: 0.1715897 , var_comp: 0.1724323 , pooled_sd: 0.4147421 , level_smd: -0.003637429 
DEBUG: BMI level Underweight - var_treat: 0.004780147 , var_comp: 0.0043503 , pooled_sd: 0.06756644 , level_smd: 0.006420735 
DEBUG: SMD results list length: 72 
  ✓ Individual-level SMD after IPTW saved to: smd_individual_after_iptw_SGLT2_vs_SU_DPP4_stroke.csv 
  Top 10 largest absolute SMDs (after IPTW):
    income: <$10k = -0.147
    income: Overall (max from level: 0) = -0.147
    sex_cat: Female = -0.138
    sex_cat: Overall (max from level: 1) = -0.138
    sex_cat: Male = 0.137
    income: >$200k = 0.118
    bmi_category: Normal = -0.096
    bmi_category: Overall (max from level: Normal) = -0.096
    raceethnicity_cat: Non-Hispanic Black = -0.094
    raceethnicity_cat: Overall (max from level: 1) = -0.094
  Balance improvement summary:
    - Total variables/levels: 52/69 improved (75.4%)
    - Individual multilevel categories: 22/34 improved (64.7%)
    - Largest remaining |SMD| (any level): 0.147
    - Individual levels with |SMD| > 0.1: 6

--- IPTW WEIGHTED BASELINE CHARACTERISTICS ---

 ================================================================================ 
IPTW-WEIGHTED BASELINE CHARACTERISTICS: SGLT2 vs SU DPP4 - Stroke 
================================================================================ 
Characteristic                      Treatment (eff_n=3709) Comparator (eff_n=3717)
-------------------------------------------------------------------------------- 
DEMOGRAPHICS (IPTW-WEIGHTED):
  Age, mean (SD), y                 63.2 (11.6)          63.3 (12.1)         
WEIGHTED SEX DISTRIBUTION:
  Male , n (%)                      1902 (51.3)          1653 (44.5)         
  Female , n (%)                    1758 (47.4)          2018 (54.3)         
  Not specified/Other , n (%)       48 (1.3)             46 (1.2)            
  BMI (kg/m2), mean (SD)            34.6 (7.6)           34.5 (8.3)          
-------------------------------------------------------------------------------- 
WEIGHTED EVENTS: Treatment = 134.3, Comparator = 177.2
================================================================================ 

 ==================================================================================================== 
BASELINE CHARACTERISTICS SUMMARY ACROSS ALL COMPARISONS
==================================================================================================== 

Sample sizes across all analyses:
         Comparison                      Outcome Treatment_Label Treatment_N
1     GLP1 vs SGLT2             Epilepsy/Seizure     Semaglutide        1650
2     GLP1 vs SGLT2 Early-onset/Epilepsy/Seizure     Semaglutide        1650
3     GLP1 vs SGLT2  Late-onset Epilepsy/Seizure     Semaglutide        1367
4     GLP1 vs SGLT2                         ADRD     Semaglutide        1688
5     GLP1 vs SGLT2                       Stroke     Semaglutide        1607
6   GLP1 vs SU DPP4             Epilepsy/Seizure       Treatment        1964
7   GLP1 vs SU DPP4 Early-onset/Epilepsy/Seizure       Treatment        1964
8   GLP1 vs SU DPP4  Late-onset Epilepsy/Seizure       Treatment        1657
9   GLP1 vs SU DPP4                         ADRD       Treatment        1993
10  GLP1 vs SU DPP4                       Stroke       Treatment        1888
11 SGLT2 vs SU DPP4             Epilepsy/Seizure       Treatment        3220
12 SGLT2 vs SU DPP4 Early-onset/Epilepsy/Seizure       Treatment        3220
13 SGLT2 vs SU DPP4  Late-onset Epilepsy/Seizure       Treatment        2889
14 SGLT2 vs SU DPP4                         ADRD       Treatment        3282
15 SGLT2 vs SU DPP4                       Stroke       Treatment        3039
   Comparator_Label Comparator_N Treatment_Events Comparator_Events
1            SGLT2i         3725               14                75
2            SGLT2i         3725                4                 9
3            SGLT2i         3351               10                65
4            SGLT2i         3790               29               129
5            SGLT2i         3514               46               125
6        Comparator         5362               24               136
7        Comparator         5362                6                17
8        Comparator         4730               18               117
9        Comparator         5494               39               190
10       Comparator         5194               54               242
11       Comparator         4497               58               107
12       Comparator         4497                7                13
13       Comparator         3934               50                92
14       Comparator         4627              116               159
15       Comparator         4387              109               207

✓ Saved baseline characteristics summary to: baseline_characteristics_summary.csv

 ==================================================================================================== 
BASELINE CHARACTERISTICS GENERATION COMPLETE
==================================================================================================== 
✓ Successfully generated 15 baseline characteristics tables
✓ Tables available for all three comparisons:
  - Semaglutide vs SGLT2i
  - Semaglutide vs SU/DPP4i
  - SGLT2i vs SU/DPP4i ⭐ (New comparison as requested)
✓ Both outcomes analyzed: Epilepsy/Seizure and Late-onset Epilepsy/Seizure
✓ All tables show UNWEIGHTED baseline characteristics
✓ Individual CSV files saved with detailed structured data

>>> TESTING CORRECTED SMD CALCULATIONS <<<

 ================================================================================ 
DEBUGGING SMD CALCULATIONS FOR GLP1 vs SGLT2 - Epilepsy/Seizure 
================================================================================ 
Loaded cohort with 5375 patients
Treatment distribution: 3725 1650 

=== DEBUGGING SEX_CAT SMD ===
Manual calculation (before IPTW):
  Treatment group: n = 1650 , prop_female = 0.6121212 
  Comparator group: n = 3725 , prop_female = 0.4679195 
  Pooled SD = 0.493153 
  SMD = 0.2924078 

Manual calculation (after IPTW):
  Treatment group: eff_n = 2650.871 , weighted_prop_female = 0.5677668 
  Comparator group: eff_n = 2724.129 , weighted_prop_female = 0.4904738 
  Pooled SD = 0.4976529 
  SMD = 0.1553151 

Weight summary:
  Treatment weights: min = 0.5912435 , max = 4.266085 , mean = 1.606588 
  Comparator weights: min = 0.5300011 , max = 3.554838 , mean = 0.7313098 

=== TESTING CORRECTED SMD FUNCTION ===
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - prop_treat: 0.02424242 , prop_comp: 0.07248322 
DEBUG: BMI level Normal - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Normal - var_treat: 0.02365473 , var_comp: 0.0672294 , pooled_sd: 0.2131714 , level_smd: -0.2263005 
DEBUG: BMI level Obese I - prop_treat: 0.2515152 , prop_comp: 0.2816107 
DEBUG: BMI level Obese I - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese I - var_treat: 0.1882553 , var_comp: 0.2023061 , pooled_sd: 0.4419058 , level_smd: -0.06810408 
DEBUG: BMI level Obese II - prop_treat: 0.2575758 , prop_comp: 0.2195973 
DEBUG: BMI level Obese II - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese II - var_treat: 0.1912305 , var_comp: 0.1713743 , pooled_sd: 0.4257962 , level_smd: 0.08919394 
DEBUG: BMI level Obese III - prop_treat: 0.3272727 , prop_comp: 0.1957047 
DEBUG: BMI level Obese III - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese III - var_treat: 0.2201653 , var_comp: 0.1574044 , pooled_sd: 0.4344938 , level_smd: 0.3028076 
DEBUG: BMI level Overweight - prop_treat: 0.1393939 , prop_comp: 0.2273826 
DEBUG: BMI level Overweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Overweight - var_treat: 0.1199633 , var_comp: 0.1756797 , pooled_sd: 0.3844756 , level_smd: -0.2288536 
DEBUG: BMI level Underweight - prop_treat: 0 , prop_comp: 0.003221477 
DEBUG: BMI level Underweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.003211099 , pooled_sd: 0.04006931 , level_smd: -0.08039761 
DEBUG: SMD results list length: 73 
Function calculation (before IPTW):
  SMD = -0.28769 0.2924078 -0.02412916 0.2924078 
  Match with manual: FALSE TRUE FALSE TRUE 
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - var_treat: 0.03266786 , var_comp: 0.05805631 , pooled_sd: 0.2129838 , level_smd: -0.1318183 
DEBUG: BMI level Obese I - var_treat: 0.2037256 , var_comp: 0.194883 , pooled_sd: 0.4464351 , level_smd: 0.04402716 
DEBUG: BMI level Obese II - var_treat: 0.1930396 , var_comp: 0.1728529 , pooled_sd: 0.4277222 , level_smd: 0.09139064 
DEBUG: BMI level Obese III - var_treat: 0.1823952 , var_comp: 0.1840541 , pooled_sd: 0.4280475 , level_smd: -0.007499049 
DEBUG: BMI level Overweight - var_treat: 0.1475853 , var_comp: 0.1628711 , pooled_sd: 0.3939901 , level_smd: -0.06306503 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.002606136 , pooled_sd: 0.03609803 , level_smd: -0.0723852 
DEBUG: SMD results list length: 73 

Function calculation (after IPTW):
  SMD = -0.1559983 0.1553151 0.001841793 -0.1559983 
  Match with manual: FALSE TRUE FALSE FALSE 

Balance improvement:
  Before IPTW SMD = -0.28769 0.2924078 -0.02412916 0.2924078 
  After IPTW SMD = -0.1559983 0.1553151 0.001841793 -0.1559983 
  Improvement = 0.1316917 0.1370927 0.02228736 0.1364095 
  % reduction in |SMD| = 45.77556 46.88408 92.36694 46.65043 %

=== TESTING MULTILEVEL VARIABLE SMD ===
Race/ethnicity levels in data: 0 1 2 3 999 
Overall race/ethnicity SMD (before IPTW): 0.173978 0.02771702 -0.2285695 -0.01053455 -0.07085838 -0.2285695 
Overall race/ethnicity SMD (after IPTW): 0.110403 0.03941458 -0.1758559 -0.007900709 -0.02728825 -0.1758559 

>>> TESTING NEW INDIVIDUAL LEVEL SMD CALCULATIONS <<<

 ================================================================================ 
TESTING INDIVIDUAL LEVEL SMD CALCULATIONS FOR GLP1 vs SGLT2 - Epilepsy/Seizure 
================================================================================ 
Loaded cohort with 5375 patients
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - prop_treat: 0.02424242 , prop_comp: 0.07248322 
DEBUG: BMI level Normal - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Normal - var_treat: 0.02365473 , var_comp: 0.0672294 , pooled_sd: 0.2131714 , level_smd: -0.2263005 
DEBUG: BMI level Obese I - prop_treat: 0.2515152 , prop_comp: 0.2816107 
DEBUG: BMI level Obese I - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese I - var_treat: 0.1882553 , var_comp: 0.2023061 , pooled_sd: 0.4419058 , level_smd: -0.06810408 
DEBUG: BMI level Obese II - prop_treat: 0.2575758 , prop_comp: 0.2195973 
DEBUG: BMI level Obese II - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese II - var_treat: 0.1912305 , var_comp: 0.1713743 , pooled_sd: 0.4257962 , level_smd: 0.08919394 
DEBUG: BMI level Obese III - prop_treat: 0.3272727 , prop_comp: 0.1957047 
DEBUG: BMI level Obese III - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese III - var_treat: 0.2201653 , var_comp: 0.1574044 , pooled_sd: 0.4344938 , level_smd: 0.3028076 
DEBUG: BMI level Overweight - prop_treat: 0.1393939 , prop_comp: 0.2273826 
DEBUG: BMI level Overweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Overweight - var_treat: 0.1199633 , var_comp: 0.1756797 , pooled_sd: 0.3844756 , level_smd: -0.2288536 
DEBUG: BMI level Underweight - prop_treat: 0 , prop_comp: 0.003221477 
DEBUG: BMI level Underweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.003211099 , pooled_sd: 0.04006931 , level_smd: -0.08039761 
DEBUG: SMD results list length: 73 
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - var_treat: 0.03266786 , var_comp: 0.05805631 , pooled_sd: 0.2129838 , level_smd: -0.1318183 
DEBUG: BMI level Obese I - var_treat: 0.2037256 , var_comp: 0.194883 , pooled_sd: 0.4464351 , level_smd: 0.04402716 
DEBUG: BMI level Obese II - var_treat: 0.1930396 , var_comp: 0.1728529 , pooled_sd: 0.4277222 , level_smd: 0.09139064 
DEBUG: BMI level Obese III - var_treat: 0.1823952 , var_comp: 0.1840541 , pooled_sd: 0.4280475 , level_smd: -0.007499049 
DEBUG: BMI level Overweight - var_treat: 0.1475853 , var_comp: 0.1628711 , pooled_sd: 0.3939901 , level_smd: -0.06306503 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.002606136 , pooled_sd: 0.03609803 , level_smd: -0.0723852 
DEBUG: SMD results list length: 73 

=== INDIVIDUAL LEVEL SMDs (BEFORE IPTW) ===

=== INDIVIDUAL LEVEL SMDs (AFTER IPTW) ===

=== SUMMARY STATISTICS ===
Total individual levels from multilevel variables: 34 
Levels with |SMD| > 0.1: 11 
Levels with |SMD| > 0.2: 9 
Largest |SMD| among individual levels: 0.328 

After IPTW:
Levels with |SMD| > 0.1: 6 
Levels with |SMD| > 0.2: 0 
Largest |SMD| among individual levels: 0.176 
Individual levels with improved balance: 30 / 34  (88.2%)

>>> TESTING UPDATED MULTILEVEL APPROACH <<<

 ================================================================================ 
TESTING UPDATED MULTILEVEL APPROACH - ALL LEVELS INCLUDED
Comparison: GLP1 vs SGLT2 - Outcome: Epilepsy/Seizure 
================================================================================ 

=== SEX CATEGORY ANALYSIS ===
Sex categories in data:

   0    1  999 <NA> 
2557 2753   65    0 

Sex by treatment group:
      
          0    1  999 <NA>
  0    1934 1743   48    0
  1     623 1010   17    0
  <NA>    0    0    0    0

=== BMI CATEGORY ANALYSIS ===
BMI categories in data:

     Normal     Obese I    Obese II   Obese III  Overweight Underweight 
        310        1464        1243        1269        1077          12 
       <NA> 
          0 

BMI categories by treatment group:
      
       Normal Obese I Obese II Obese III Overweight Underweight <NA>
  0       270    1049      818       729        847          12    0
  1        40     415      425       540        230           0    0
  <NA>      0       0        0         0          0           0    0

=== UPDATED SMD CALCULATION TEST ===
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - prop_treat: 0.02424242 , prop_comp: 0.07248322 
DEBUG: BMI level Normal - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Normal - var_treat: 0.02365473 , var_comp: 0.0672294 , pooled_sd: 0.2131714 , level_smd: -0.2263005 
DEBUG: BMI level Obese I - prop_treat: 0.2515152 , prop_comp: 0.2816107 
DEBUG: BMI level Obese I - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese I - var_treat: 0.1882553 , var_comp: 0.2023061 , pooled_sd: 0.4419058 , level_smd: -0.06810408 
DEBUG: BMI level Obese II - prop_treat: 0.2575758 , prop_comp: 0.2195973 
DEBUG: BMI level Obese II - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese II - var_treat: 0.1912305 , var_comp: 0.1713743 , pooled_sd: 0.4257962 , level_smd: 0.08919394 
DEBUG: BMI level Obese III - prop_treat: 0.3272727 , prop_comp: 0.1957047 
DEBUG: BMI level Obese III - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese III - var_treat: 0.2201653 , var_comp: 0.1574044 , pooled_sd: 0.4344938 , level_smd: 0.3028076 
DEBUG: BMI level Overweight - prop_treat: 0.1393939 , prop_comp: 0.2273826 
DEBUG: BMI level Overweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Overweight - var_treat: 0.1199633 , var_comp: 0.1756797 , pooled_sd: 0.3844756 , level_smd: -0.2288536 
DEBUG: BMI level Underweight - prop_treat: 0 , prop_comp: 0.003221477 
DEBUG: BMI level Underweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.003211099 , pooled_sd: 0.04006931 , level_smd: -0.08039761 
DEBUG: SMD results list length: 73 

SEX_CAT SMDs (should include Male, Female, and potentially Not specified/Other):
  Male                      SMD = -0.288 (treat=0.378, comp=0.519)
  Female                    SMD =  0.292 (treat=0.612, comp=0.468)
  Not specified/Other       SMD = -0.024 (treat=0.010, comp=0.013)
  Overall (max from level: 1) SMD =  0.292 (treat=NA, comp=NA)

RACEETHNICITY_CAT SMDs (should include ALL levels including Non-Hispanic White):
  Non-Hispanic White             SMD =  0.174 (treat=0.575, comp=0.488)
  Non-Hispanic Black             SMD =  0.028 (treat=0.214, comp=0.203)
  Hispanic                       SMD = -0.229 (treat=0.116, comp=0.198)
  Non-Hispanic Asian/Other       SMD = -0.011 (treat=0.070, comp=0.073)
  Unknown/Not specified          SMD = -0.071 (treat=0.025, comp=0.038)
  Overall (max from level: 2)    SMD = -0.229 (treat=NA, comp=NA)

INCOME SMDs (should include ALL levels including <$10K):
  <$10k                SMD = -0.074 (treat=0.095, comp=0.118)
  $10k-25k             SMD = -0.024 (treat=0.151, comp=0.160)
  $25k-35k             SMD =  0.019 (treat=0.088, comp=0.083)
  $35k-50k             SMD =  0.045 (treat=0.101, comp=0.088)
  $50k-75k             SMD =  0.062 (treat=0.138, comp=0.117)
  $75k-100k            SMD =  0.060 (treat=0.094, comp=0.077)
  $100k-150k           SMD =  0.055 (treat=0.101, comp=0.085)
  $150k-200k           SMD =  0.059 (treat=0.039, comp=0.028)
  >$200k               SMD =  0.063 (treat=0.042, comp=0.031)
  Others/Not specified SMD = -0.163 (treat=0.152, comp=0.214)
  Overall (max from level: 999) SMD = -0.163 (treat=NA, comp=NA)

BMI_CATEGORY SMDs (should include Underweight, Normal, Overweight, Obese I-III):
  Normal          SMD = -0.226 (treat=0.024, comp=0.072)
  Obese I         SMD = -0.068 (treat=0.252, comp=0.282)
  Obese II        SMD =  0.089 (treat=0.258, comp=0.220)
  Obese III       SMD =  0.303 (treat=0.327, comp=0.196)
  Overweight      SMD = -0.229 (treat=0.139, comp=0.227)
  Underweight     SMD = -0.080 (treat=0.000, comp=0.003)
  Overall (max from level: Obese III) SMD =  0.303 (treat=NA, comp=NA)

=== SUMMARY ===
Number of individual levels calculated per multilevel variable:
# A tibble: 5 × 2
  variable          levels_calculated
  <chr>                         <int>
1 bmi_category                      6
2 education                         6
3 income                           10
4 raceethnicity_cat                 5
5 sex_cat                           3

Expected vs actual:
           variable                 expected_levels levels_calculated
1      bmi_category varies (BMI categories present)                 6
2         education  up to 5 (all education levels)                 6
3            income     up to 9 (all income levels)                10
4 raceethnicity_cat             4 (all race groups)                 5
5           sex_cat        2-3 (Male, Female, +999)                 3

>>> DIAGNOSING TREATMENT ASSIGNMENT ISSUES <<<

 ================================================================================ 
DIAGNOSING TREATMENT ASSIGNMENT ISSUES FOR GLP1 vs SGLT2 - Epilepsy/Seizure 
================================================================================ 
Loaded cohort with 5375 patients

=== GLP1 vs SGLT2 TREATMENT ASSIGNMENT CHECK ===
Treatment assignment summary:
# A tibble: 2 × 8
  treatment     n glp1_users sglt2_users glp1_pct sglt2_pct both_drugs
      <dbl> <int>      <int>       <int>    <dbl>     <dbl>      <int>
1         0  3725        125         204     3.36      5.48         24
2         1  1650        117          19     7.09      1.15          0
# ℹ 1 more variable: neither_drug <int>

EXPECTED vs ACTUAL:
Treatment = 1 (should be Semaglutide group):
  Expected: GLP1 = ~100%, SGLT2 = 0%
  Actual:   GLP1 = 7.1% , SGLT2 = 1.2% 
Treatment = 0 (should be SGLT2 group):
  Expected: GLP1 = 0%, SGLT2 = ~100%
  Actual:   GLP1 = 3.4% , SGLT2 = 5.5% 

Problematic cases found: 5078 

  Sema group but no GLP1 SGLT2 group but has GLP1 SGLT2 group but no SGLT2 
                    1533                      125                     3420 

This suggests issues with:
1. Treatment assignment logic
2. Medication variable definitions
3. Possible inclusion of baseline medications vs index medications

=== MEDICATION VARIABLE INTERPRETATION ===
The medication variables (GLP1, SGLT2, etc.) appear to represent:
- Baseline medication use (period before/around index date)
- NOT just the index medication that defines treatment
- This includes:
  * Index drug
  * Other drugs in same class used during baseline period
  * Possibly concurrent therapy

=== RECOMMENDATIONS ===
1. ✅ FIXED: Exclude treatment-defining variables from SMD calculation
2. Consider creating 'index_drug' variables that are 100%/0% by design
3. Keep existing medication variables for clinical context
4. Document that medication variables represent baseline use, not treatment assignment

>>> GENERATING CORRECTED SMD TABLE (EXCLUDING TREATMENT-DEFINING VARIABLES) <<<

=== COMPARISON: Original vs Corrected SMD Tables ===
Comparison: GLP1 vs SGLT2 - Outcome: Epilepsy/Seizure 
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - prop_treat: 0.02424242 , prop_comp: 0.07248322 
DEBUG: BMI level Normal - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Normal - var_treat: 0.02365473 , var_comp: 0.0672294 , pooled_sd: 0.2131714 , level_smd: -0.2263005 
DEBUG: BMI level Obese I - prop_treat: 0.2515152 , prop_comp: 0.2816107 
DEBUG: BMI level Obese I - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese I - var_treat: 0.1882553 , var_comp: 0.2023061 , pooled_sd: 0.4419058 , level_smd: -0.06810408 
DEBUG: BMI level Obese II - prop_treat: 0.2575758 , prop_comp: 0.2195973 
DEBUG: BMI level Obese II - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese II - var_treat: 0.1912305 , var_comp: 0.1713743 , pooled_sd: 0.4257962 , level_smd: 0.08919394 
DEBUG: BMI level Obese III - prop_treat: 0.3272727 , prop_comp: 0.1957047 
DEBUG: BMI level Obese III - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Obese III - var_treat: 0.2201653 , var_comp: 0.1574044 , pooled_sd: 0.4344938 , level_smd: 0.3028076 
DEBUG: BMI level Overweight - prop_treat: 0.1393939 , prop_comp: 0.2273826 
DEBUG: BMI level Overweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Overweight - var_treat: 0.1199633 , var_comp: 0.1756797 , pooled_sd: 0.3844756 , level_smd: -0.2288536 
DEBUG: BMI level Underweight - prop_treat: 0 , prop_comp: 0.003221477 
DEBUG: BMI level Underweight - treat_data size: 1650 , comp_data size: 3725 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.003211099 , pooled_sd: 0.04006931 , level_smd: -0.08039761 
DEBUG: SMD results list length: 73 
DEBUG: Excluding treatment-defining variables from SMD calculation: GLP1, SGLT2 
DEBUG: BMI category levels found: Normal, Obese I, Obese II, Obese III, Overweight, Underweight 
DEBUG: BMI category sample values: Obese III, Obese I, Obese II, Obese I, Obese II, Overweight, Obese I, Overweight, Obese I, Overweight 
DEBUG: BMI category data type: character 
DEBUG: BMI category table: Normal = 310, Obese I = 1464, Obese II = 1243, Obese III = 1269, Overweight = 1077, Underweight = 12 
DEBUG: BMI level Normal - var_treat: 0.03266786 , var_comp: 0.05805631 , pooled_sd: 0.2129838 , level_smd: -0.1318183 
DEBUG: BMI level Obese I - var_treat: 0.2037256 , var_comp: 0.194883 , pooled_sd: 0.4464351 , level_smd: 0.04402716 
DEBUG: BMI level Obese II - var_treat: 0.1930396 , var_comp: 0.1728529 , pooled_sd: 0.4277222 , level_smd: 0.09139064 
DEBUG: BMI level Obese III - var_treat: 0.1823952 , var_comp: 0.1840541 , pooled_sd: 0.4280475 , level_smd: -0.007499049 
DEBUG: BMI level Overweight - var_treat: 0.1475853 , var_comp: 0.1628711 , pooled_sd: 0.3939901 , level_smd: -0.06306503 
DEBUG: BMI level Underweight - var_treat: 0 , var_comp: 0.002606136 , pooled_sd: 0.03609803 , level_smd: -0.0723852 
DEBUG: SMD results list length: 73 

Top 10 largest absolute SMDs (CORRECTED - after IPTW):
  raceethnicity_cat: Hispanic = -0.176
  raceethnicity_cat: Overall (max from level: 2) = -0.176
  education: Less than high school = -0.163
  education: Overall (max from level: 0) = -0.163
  sex_cat: Male = -0.156
  sex_cat: Overall (max from level: 0) = -0.156
  sex_cat: Female = 0.155
  bmi_category: Normal = -0.132
  bmi_category: Overall (max from level: Normal) = -0.132
  raceethnicity_cat: Non-Hispanic White = 0.110

Balance improvement summary:
- Variables with improved balance: 69/73 (94.5%)
- Largest remaining |SMD|: 0.176
- Variables with |SMD| > 0.1: 10
- Variables with |SMD| > 0.2: 0

✓ Saved corrected SMD tables:
  - smd_before_iptw_CORRECTED_GLP1_vs_SGLT2_Epilepsy_Seizure.csv
  - smd_after_iptw_CORRECTED_GLP1_vs_SGLT2_Epilepsy_Seizure.csv
Error in select(., outcome, risk_glp1, risk_sglt2i): unused arguments (outcome, risk_glp1, risk_sglt2i)
Traceback:

1. tmle_data %>% filter(analysis == "Main Analysis (2-year)") %>% 
 .     select(outcome, risk_glp1, risk_sglt2i) %>% pivot_longer(cols = c(risk_glp1, 
 .     risk_sglt2i), names_to = "treatment", values_to = "risk") %>% 
 .     mutate(treatment = ifelse(treatment == "risk_glp1", "GLP1 RA", 
 .         "SGLT2i"))
2. mutate(., treatment = ifelse(treatment == "risk_glp1", "GLP1 RA", 
 .     "SGLT2i"))
3. pivot_longer(., cols = c(risk_glp1, risk_sglt2i), names_to = "treatment", 
 .     values_to = "risk")
4. .handleSimpleError(function (cnd) 
 . {
 .     watcher$capture_plot_and_output()
 .     cnd <- sanitize_call(cnd)
 .     watcher$push(cnd)
 .     switch(on_error, continue = invokeRestart("eval_continue"), 
 .         stop = invokeRestart("eval_stop"), error = NULL)
 . }, "unused arguments (outcome, risk_glp1, risk_sglt2i)", base::quote(select(., 
 .     outcome, risk_glp1, risk_sglt2i)))

